UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 orOR 15(d) ofOF THE SECURITIES EXCHANGE ACT OF 1934
For the Securities Exchange Act of 1934 for the Fiscal Year Ended fiscal year ended: December 31 2020
☐TRANSITION REPORT PURSUANT TO SECTION 13 orOR 15(d) of the Securities Exchange Act ofOF THE SECURITIES EXCHANGE ACT OF 1934 for
For the transition period from ______________________ to ________
Commission File Number: 001-38190
Panacea Life Sciences Holdings, Inc.
(Exact name of registrant as specified in its charter)
Nevada | 27-1085858 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
5910 S University Blvd, C18-193, Greenwood Village, CO80121
(Address of principal executive offices, Zip Code)
800-985-0515
(Registrant’s telephone number, including area code)
Exactus, Inc. 80 NE 4th Avenue, Suite 28, Delray Beach, FL 33483
(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Trading Symbol(s) | Name of each exchange on which registered | |||
N/A | ||||
N/A | N/A |
Securities registered pursuant to Section 12(g) of the Act:
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the precedingpast 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☑ ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☑ ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”filer”, “smaller reporting company,”company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large | Accelerated | Filer ☐ | ||
Smaller reporting company | ||||
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☑
The aggregate market value of the voting and non-voting common stockequity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 20202021, was $3.5 million.
State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 31, 2021 was 99,632,710.
shares of common stock, par value $0.0001 per share, outstanding as March
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement for its 2022 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13, and 14 of Part III of this Annual Report on Form 10-K previously filed with the United States Securities and Exchange Commission on April 15, 2021, is to include the opinion of our independent accounting firm, include certain exhibits omitted from the original filing, and to make other minor corrections.
TABLE OF CONTENTS
PART I | 1 | ||
Item 1. | Business | 1 | |
Item 1A. | Risk Factors | 6 | |
Item 1B. | Unresolved Staff Comments | 20 | |
Item 2. | Properties | 20 | |
Item 3. | Legal Proceedings | 20 | |
Item 4. | Mine Safety Disclosures | 21 | |
27 | |||
F-1 | |||
28 | |||
28 | |||
28 | |||
PART III | 28 | ||
28 | |||
28 | |||
28 | |||
28 | |||
28 | |||
PART IV | 29 | ||
SIGNATURES | 30 |
i |
Cautionary Statement Regarding Forward-Looking Statements
This annual reportAnnual Report on Form 10-K (this “Annual Report”) containsmay contain forward-looking statements which are subject towithin the safe harbor provisions created bymeaning of the Private Securities Litigation Reform Act of 1995.1995, including statements about our new and planned operations in the hemp industry through our subsidiary, Panacea Life Sciences, Inc. (“Panacea” or “PLS”), our expected revenue growth, our future plans and developments with respect to PPE products and the COVID-19 pandemic, research conducted at the Panacea Life Sciences Cannabinoid Lab at Colorado State University and plans, goals and anticipated results in connection therewith, our human resources following our acquisition of Panacea, proposed federal legislation and its potential impact on the CBD industry, our business relationship with XXII, our plans for our current and future products and our marketing and sales strategy including our intention to expand into new markets, our plans to raise capital, and our liquidity. Words such as “expects,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” “may,” “intends,” “targets” and similar expressions or variations of such words are intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements in this Annual Report. The identification of certain statements as “forward-looking” is not intended to mean that other statements not specifically identified are not forward-looking. All statements other than statements about historical facts are statements that could be deemed forward-looking statements, including, but not limited to, statements that relate to our future revenue, product development, customer demand, market acceptance, growth rate, competitiveness, gross margins, and expenditures.
Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and changes in condition, significance, value and effect, including those discussed below under the heading “Risk Factors” within Part I, Item 1A of this Annual Report, and other documents we file from time to timetime-to-time with the Securities and Exchange Commission (the “SEC”), such as our annual reports on Form 10-K, our quarterly reports on Form 10-Q and our current reports on Form 8-K.SEC. Such risks, uncertainties and changes in condition, significance, value, and effect could cause our actual results to differ materially from those expressed herein and in ways not readily foreseeable. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report and are based on information currently and reasonably known to us. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this Annual Report, other than as required by law. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.
ii |
PART I
Item 1. Business
General
Panacea Life Sciences Holdings, Inc. (the “Company”, “we”, “us”, “our”) is a seed to sale cannabinoid and nutraceutical manufacturer and research company that produces purposeful, natural pharmaceutical alternatives for consumers and pets. We aremanufacture and sell softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. The Company operates through its wholly-owned subsidiary, Panacea Life Sciences, Inc. (“PLS” or “Panacea”), which the Company acquired in a Nevada corporation organized underreverse merger in June 2021. Panacea was founded by Leslie Buttorff in 2017 as a woman-owned business. Panacea was formed to own and engage in creating disruptive healthcare and veterinary solutions with a specific focus on hemp. In 2020 PLS also expanded into the Personal Protection Equipment (“PPE”) business on a temporary basis.
Recent Developments
Effective October 25, 2021 we completed the 1-for-28 reverse stock split as well as the name Solid Solar Energy, Inc in 2008 and renamedchange from Exactus, Inc. in 2016. We have pursued opportunities in Cannabidiol, which we refer to as CBD, since 2019.
On October 25, 2021, of the 2018 Farm Bill, known as10,649,078 shares of EXDI Common Stock issued to Quintel-MC, Incorporated (an affiliate of our Chief Executive Officer) were exchanged for 100 shares of Series C-2 Convertible Preferred Stock (the “Parent C-2 Stock”) which are convertible into 7,321,429 shares of Parent Common Stock and are entitled to vote on an as-converted basis. Other than the Agriculture Improvement Act of 2018, which will remain in force through 2023. The 2018 Farm Bill authorized the production of hempconversion and removed hemp and hemp seeds from the Drug Enforcement Administration’s, or the DEA’s, schedule of Controlled Substances. It also directed the U.S. Department of Agriculture, or the USDA, to issue regulations and guidance to implement a program to create a consistent regulatory framework around production of hemp throughout the United states. On October 31, 2019, the USDA, Agricultural Marketing Services, issued an interim final rule (with request for comments). The rule outlines provisionsvoting rights, there are no other preferences for the USDAParent C-2 Stock.
On November 18, 2021, the Company and an institutional investor signed an agreement for a $1.1 million original issue discount convertible note (the “Note”) financing in which the investor is paying $1 million in gross proceeds. The one-year Note is convertible into common stock at $1.40 per share. We also issued the investor 785,715 warrants to approve plans submitted by states and Indian tribes.purchase common stock at an exercise price of $1.40 per share. The U.S. Domestic Hemp Production Program establishes federal regulatory oversight of the production of hemp in the U.S.warrants are exercisable over a five-year period beginning May 18, 2022. The program authorizes the USDA to approve plans submitted by states and Indian tribes for the domestic production of hemp and establishes a federal plan for producers in states or territories that choose not to administer a state or tribe specific plan, provide the state or tribe does not ban hemp production.
On March 3, 2022, the Company entered into an Exchange Agreement (the “Agreement”) with an institutional investor (the “Investor”) pursuant to which the Company agreed to issue a 10% original issue discount senior convertible promissory note in the principal amount of $385,000 (the “Note”) and five-year warrants to purchase 275,000 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share (the “Warrants”) in exchange for 350 shares of the Company’s 0% Series A Convertible Preferred Stock (“Series A”). The Agreement was entered into after the Investor exercised the most favored nation rights contained in Section 7(b) of the Company’s Certificate of Designation of Preferences, Rights and Limitations of the Series A in connection with the consummation of a private placement with an institutional investor (the “Purchaser”) on November 18, 2021.
Our Competitive Analysis
We believe that our competitive advantages are derived from being vertically integrated that allows for extraction, enrichment and manufacturing under a cGMP quality environment: 1) Using pharmaceutical formulation methods to optimize the delivery of various hemp products, 2) Developing both full spectrum and THC-free products, 3) Hemp supply, agreementand 4) utilize Good Manufacturing Practice to produce goods that are safe and quality products that deliver consistent dosing. The ability to produce both full spectrum products (those that contain <0.3%) and THC-free products allows us to optimize dosage and delivery to various human conditions. Removal of the THC from products is a difficult and expensive process, but we believe this is essential for specific patient populations; such as, athletes where testing positive for THC would lead to disqualification, first responders who would be terminated for testing positive for THC, and in animal products where even a small amount of THC can lead to toxicity and potential lethality. Industrial hemp extracts are found to have particular application as neuroprotectants, for example in limiting neurological damage and increasing speed of recovery with Hemptown USA, Inc.traumatic brain injury. The cannabinoids have also been reported to treat human disease conditions where currently multiple pharmacologicals are needed to address, e.g., Post Traumatic Stress Disorder (PTSD), or where there is no current cure such as Alzheimer’s, Parkinson’s Disease, and age-related dementia, to name a few.
1 |
Although numerous reports describe cannabis/hemp extract health benefits the industry lacks sufficient clinical data and quality control to provide uspatient benefit. We are combining human and pet clinical studies with industrial hemp
We believe a multitude (hundreds) of companies, large and small, have launched or intend to launch retail brands and white label products containing cannabinoids like CBD.CBD, including retail and seed-to-sale companies that are larger and better capitalized than we are and/or which offer products similar to ours with a larger geographic scope of operations and a market presence. Many of these are dependent upon third parties to provide raw material inventory for sale. We believe this makes many of the participants in the industry vulnerable to shortages, quality issues, reliability, and pricing variability. Our industry relationships may allow us to build an efficient supply chain that will put us among the few companies that maintain a competitive pricing and supply advantage.
Our Intellectual Property
We operate in every segment of the cannabinoid product value chain. From the hemp plant to finished goods, we ensure our products with stringent testing protocols employed at every stage of the supply chain. In year 2021 we obtained registration for three of our six brands and our mark. Panacea endeavors to offer pure natural remedies within product lines for every aspect of life, Our portfolio includes the following trademarks and registrations: PANA Health™, PANA Beauty®, PANA Sport™, PANA Pet®, PANA Life® and PANA Pure™ and our PANA logo mark™.
Research and Development
In October 2021, the Panacea Life Sciences Cannabinoid Lab at Colorado State University, or CSU, was opened. The cannabinoid research center is conducting numerous studies and clinical research with the goal of extending our knowledge of how cannabis extracts affect human and animal health. We will work through the center to form multiple research collaborations as well as perform our own studies in multiple therapeutic areas. The lab is housed in the Chemistry Building in the heart of the CSU campus. The objective is to develop the center into a leader in cannabinoid research nation- and world-wide as the industry continues to grow. Panacea and CSU will work collaboratively on new projects and clinical research studies.
Our Sales Strategy
As previously described, since our products contain little to no THC, we have the ability to sell our products across the United States and internationally. We have established a multi-faceted sales strategy targeting:
● | global ecommerce platform for fulfilling orders and shipping worldwide where legally permitted; | |
● | direct pharmacy placement; | |
● | direct placement in retail stores, salons, spas, athletic facilities, etc. | |
● | Intelligent vending machines | |
● | Kiosks in Denver International Airport | |
● | E-commerce based systems and social media |
2 |
In addition, we have established several other sales channels via sales representatives (“reps”), e-commerce (selling directly to customers), large bulk sales to suppliers and to dispensaries. We are working to establish a multi-tiered sales strategy focused on utilizing representatives for education and sales. The sales team is comprised of independent representatives (1099 consultants) that are compensated by commission only. We have over 20 sales reps that have signed up to be in the sales channel. The e-commerce sales platform also works with the commissioned based sales. All sales commissions are tracked and paid via our integrated systems.
We also manufacture products for several other companies for various white label and contract manufacturing deals. We specialize in bovine and vegan soft gel manufacturing. Prior to the COVID-19 pandemic, these business lines were approximately 30% of our revenue. We plan to reinitiate these product lines in 2022.
Marketing and Distribution
We distribute our products to various businesses across the United States through channels optimized to the individual needs of customers. Our business to business (B2B) as well as business to customer (B2C) approaches allow much flexibility for healthcare providers the ability to recommend specific treatment options using cannabinoids as a replacement for conventional pharmaceuticals.
We are recruiting key service providers to leverage the power of online sales and social media placement. We have placed products on various online cannabidiol (CBD) sales stores and has launched product sales on Amazon.com. As product ambassadors are secured, we intend to increase its online and social media exposure to advance a business-to-consumer and business to business distribution model.
In 2021, we engaged Karsh Hagan, an independent, multi-disciplined marketing, design and technology company in Denver, Colorado to assist with brand development and roll out strategies. Currently we sell over 60 different product SKUs of CBD and Cannabigerol (CBG) products. In addition, we offer “white label” licensing to retail businesses and contract manufacturing services to smaller CBD companies. We plan to continue to build an integrated healthcare organization by creating products and programs using emerging botanical extracts. We deliver these programs through managed agriculture, pharmaceutical production, physician education, distribution and social media networks. We use our intellectual property in extraction technology, proprietary compounds, delivery systems, and distribution to produce high-quality products in terms of control, consistency, accountability, and packaging.
All of our products are stored in a secure distribution area in preparation for delivery to various sales channels, healthcare providers and other retail locations. The laboratory and production facility have the capacity for domestic and international delivery fulfillment and for international export. All products are tracked and securely manifested for delivery to retail and medical offices for distribution.
In 2018, our operating subsidiary PLS, a Colorado corporation, entered into an agreement with Canna Software/Quintel-MC, Incorporated, a related party, to research and define Panacea Life Sciences business and manufacturing processes. The ERPCannabis system based on an SAP architecture was used to develop the base installation. All financial, human resource, payroll, procurement, production planning and materials management business processes are represented in this system. In addition, the system is linked to our e-Commerce web site. This system allows us to update product costing and determine inventory levels which will be critical as the company expands. In addition, sophisticated financial and payroll processing are inherent in the solution; thus, offering investors detailed accounting results related to company investments. (See Note 6 under related party transactions in Notes Payable.)
Our Industrial Hemp Supply
In 2019, Panacea Life Sciences acquired Needle Rock Farms (NRF) in Crawford, Colorado. Our 2020 hemp crop was grown at NeedleRock Farms. Also, in December, 2019 Twenty Second Century Group, Inc. (Nasdaq: XXII) (“XXII”) made a $14 million investment in Panacea which consisted of $7 million in preferred stock and $7 million in convertible debt. XXII also was to provide an additional $10 million in funding at a later point in time. On June 30, 2021 Panacea and XXII agreed to dissolve the agreement and agreed on the following: the preferred stock was converted to common stock; a $4.3 million loan was secured against the laboratory space owned by J&N Real Estate, LLC (owned by Panacea’s CEO), the NRF and equipment would be transferred to XXII in exchange for a reduction of $2.2 million in convertible debt, 10 acres of the farm would be sub platted to Panacea, $500,000 in hemp would be delivered from the 2021 crop yield, and a 15-year agreement for hemp supply would be finalized after the deal was completed. In 2021 XXII was the grower at NRF and used organic practices for the crop. As of the date of this Report, XXII has not delivered the $500,000 of hemp to Panacea, nor have we closed on the 10 acres. However, we also have the 2020 crop and several hemp tolling contracts in which the output of crude and or distillate is shared with the growers to process.
Biotechnology Goals
We seek to take advantage of an emerging worldwide trend to utilize the production of cannabinoids derived from industrial hemp, such as CBD, CBDA, CBG, and other minor cannabinoids, to produce consumer products. Hemp is being used in cosmetics, nutritional supplements, and animal feed, where we also intend to focus our efforts. The market for hemp-derived products is expected to increase substantially over the next five years.
3 |
The therapeutic potential of cannabinoids is attributable to the valuable overlap between phyto-cannabinoids (i.e., plant-derived cannabinoids) and the endogenous cannabinoid system in humans, termed a “therapeutic handshake”. Clinical trials demonstrate few adverse effects from oral CBD doses of up to 1,500 mg/day. The scientific understanding of the hemp plant’s clinical effects is based mostly on studies in specific indications, like epilepsy. One company, GW Pharmaceuticals pls, a company developing pharmaceutical drugs and cannabinoid-based medicines, has sought and obtained US and foreign approvals since 2018. EPIDIOLEX®/EPIDYOLEX® (cannabidiol), the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA) for use in the U.S. and the European Commission (EC) for use in Europe, is an oral solution which contains highly purified CBD. In the U.S., EPIDIOLEX® is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or Tuberous Sclerosis Complex (TSC) in patients one year of age and older. Panacea has produced a similar product for sale.
Environmental Matters
Compliance with federal, state and local requirements regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, havehas not had, nor are theyis expected to have, any direct material effect on our capital expenditures, earnings or competitive position.
Government Regulations
On December 20, 2018, the President of the United States signed the Farm Bill into law. Among other things, this new law changed certain federal laws relating to the production and marketing of hemp, defined as cannabis (Cannabis sativa L.), and hemp products containing less than 0.3 percent delta-9-tetrahydrocannabinol (THC, including removing hemp and derivatives of hemp from the Controlled Substance Act. On January 15, 2021 the United States Department of Agriculture (USDA) issued its final rule regarding the Establishment of a Domestic Hemp Production Program which authorized hemp to be grown and processed legally in the United States and made it legal to transport in interstate commerce.
The Farm Bill recognizes hemp as distinct from its genetic cousin, marijuana, and specifically industrial hemp has been excluded from U.S. federal drug laws. The Farm Bill allows for each individual state to regulate industrial hemp and industrial hemp-based products or accept the USDA rules. Although no longer a controlled substance under federal law, cannabinoids derived from industrial hemp (other than THC) are still subject to a patchwork of state regulations. We are actively monitoring the regulations and proposed regulations in each state to ensure our operations are compliant.
In conjunction with the enactment of the Farm Bill, the FDA released a statement about the status of CBD and the agency’s actions in the short term with regards to CBD are expected to continue to influence the industry. The statement noted that the Farm Bill explicitly preserved the FDA’s authority to regulate products containing cannabis or cannabis-derived compounds under Section 351 of the Public Health Service Act. This authority allows the FDA to continue enforcing the law to protect patients and the public while also providing potential regulatory pathways for products containing cannabis and cannabis-derived compounds. The statement also noted the growing public interest in cannabis and cannabis-derived products, including CBD, and informed the public that the FDA will treat products containing cannabis or cannabis-derived compounds as it does any other FDA-regulated products — meaning the products will be subject to the same authorities and requirements as FDA-regulated products containing any other substance, regardless of the source of the substance, including whether the substance is derived from a plant that is classified as hemp under the Farm Bill.
As of the date of this Report, and based upon publicly available information, to our knowledge the FDA has not taken any enforcement actions against CBD companies. The FDA, however, has sent warning letters to companies demanding they cease and desist from the production, distribution, or advertising of CBD products, only relating to instances that such CBD companies have made misleading and unapproved label claims. We will continue to monitor the FDA’s position howeveron CBD. In December 2020, the Federal Trade Commission (FTC) announced it was going to seek penalties against companies making deceptive marketing claims and named 6 companies which it had targeted for making egregious and unsupported health claims. On March 5, 2021, the FTC approved the final administrative consent orders with all 6 companies. We are unaware of any further actions and we will continue to monitor the FTC’s position with regards to deceptive marketing claims.
4 |
We are subject to federal and state consumer protection laws, including laws protecting the privacy of customer non-public information and the handling of customer complaints and regulations prohibiting unfair and deceptive trade practices. The growth and demand for online commerce has and may continue to result in more stringent consumer protection laws that impose additional compliance burdens on online companies. These laws may cover issues such factors could indirectly affect usas user privacy, spyware and the tracking of consumer activities, marketing e-mails and communications, other advertising and promotional practices, money transfers, pricing, product safety, content and quality of products and services, taxation, electronic contracts and other communications and information security.
There is also great uncertainty over whether or how existing laws governing issues such as sales and other taxes, auctions, libel, and personal privacy apply to the internet and commercial online services. These issues may take years to resolve. For example, tax authorities in a number of states, as well as participantsa Congressional advisory commission, are currently reviewing the appropriate tax treatment of companies engaged in online commerce, and new state tax regulations may subject us to additional state sales and income taxes. New legislation or regulation, the supply chain for our products,application of laws and regulations from jurisdictions whose laws do not currently apply to our business or the application of existing laws and regulations to the internet and commercial online services or other contexts applicable to our operations vendorscould result in significant additional taxes or suppliers.
Potential Impacts of the COVID-19 Pandemic on Our Business Operations
As disclosed in Note 2 to our consolidated financial statements, the COVID-19 pandemic has had a notable impact on general economic conditions, including but not limited to the temporary closures of many businesses, “shelter in place” and other governmental regulations, reduced business and consumer spending due to both job losses and reduced investing activity, among many other effects attributable to the COVID-19 pandemic, and there continue to be many unknowns. During 2020, COVID-19 had a significant impact on our CBD operations. Recognizing the sudden need for personal protective equipment, we shifted our business to importing and selling PPE hand sanitizers and masks.
The Omicron variant which had a significant impact in the second half of 2021 and early 2022. While a new variant is replacing Omicron, the economy has substantially reopened and it is uncertain as the impact it may have. The duration and extent of the impact from the COVID-19 pandemic depends on future operating resultsdevelopments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus and its many variants, the extent and effectiveness of containment actions including vaccinations and the impact of these and other factors on our employees, customers, partners and vendors. If we are not able to respond to and manage the impact of such events effectively, our business will be harmed.
Potential Impacts of Certain Current and Proposed Regulations on Our Business and Operations
Recently, a bill titled the Cannabis Administration and Opportunity Act, put forward by Senate Majority leader Chuck Schumer, D-NY, would amend the definition of a dietary supplement to remove the prohibition on marketing CBD as a dietary supplement. Management sees the bill, if enacted, as an opportunity for the FDA to accelerate their decision to classify CBD products as a dietary supplement. This would be a significant step for hemp/CBD companies as it would open the door to new selling opportunities, such as getting into retail stores, who have largely been hesitant to welcome CBD in their doors without a clear position from the FDA.
Many people are increasingly turning to CBD products for several reasons: CBD is non-psychoactive, so it does not produce a “high” like THC, there are few known contraindications, the properties of different cannabinoids can positively affect a wide range of ailments, and cannabinoids work directly and indirectly with the body’s endocannabinoid system to create balance known as homeostasis. As demand increases, we believe the FDA must provide more clarity about CBD’s legalization, and this bill is a promising first step.
Human Capital
On December 31, 2021 we had 35 employees, including 29 full-time employees. There are no collective bargaining agreements covering any of our employees. Panacea is registered as a Woman-Owned Business as its founder, majority shareholder and CEO is female.
We believe that our success depends on our ability to attract, develop and retain key personnel. We believe that the skills, experience and industry knowledge of our key employees significantly benefit our operations and performance.
Employee health and safety in the workplace is one of our core values. The COVID-19 pandemic has underscored for us the importance of keeping our employees safe and healthy. In response to the pandemic, we have taken actions aligned with the World Health Organization and the Centers for Disease Control and Prevention in an effort to protect our workforce so they can more safely and effectively perform their work. Panacea does not have a remote workforce.
Employee levels are managed to align with the pace of business and management believes it has sufficient human capital to operate its business successfully.
Additional information
We file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers such as our company that file electronically with the SEC.
Our corporate website address is www.panacealife.com. We make available free of charge, through the Investor section of our website, annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information which appears on our corporate website is not part of this Report.
5 |
Item 1A. Risk Factors
RISK FACTORS
Investing in our common stock involves a high degree of risk. Investors should carefully consider the following Risk Factors before deciding whether to invest in us. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also impair our business operations or our financial condition. If any of the events discussed in the Risk Factors below occur, our business, financial condition, results of operations or prospects could be materially and adversely affected. In such case, the value and marketability of our common stock could decline.
Summary Risk Factors
Our business is subject to numerous risks and uncertainties that you should consider before investing in our common stock. Set forth below is a summary of the principal risks we face:
● | We need to raise capital through the sale of our common stock or securities convertible or exercisable into our common stock soon which will have a dilutive effect on our existing stockholders; | |
● | Our ability to continue as a going concern is in doubt unless we obtain adequate new debt or equity financing and achieve sufficient sales levels; | |
● | Because we require additional capital to execute our business plan and expand our operations, our inability to generate and obtain such capital on acceptable terms, or at all, could harm our business, operating results, financial condition and prospects; | |
● | We are highly dependent on our Chief Executive Officer, and the loss of her services or a conflict of interest arising from her loans to us and her other business endeavors would adversely affect us; | |
● | Our business and the CBD industry generally are subject to substantial regulation and governmental scrutiny characterized by high compliance costs and uncertainty, including the possibility that laws change in a manner adverse to us; | |
● | the impact of the COVID-19 pandemic on the U.S. and global economy, and the uncertainty relating to its continuation and the pace of economic recovery, could hinder our business plan or force us to change our production efforts; | |
● | Panacea’s operations and our new Chief Executive Officer were not previously subject to the Securities and Exchange Commission (“SEC”) reporting obligations, which could render us difficult to evaluate and expose us to risk; | |
● | If we are unable to keep up with rapid technological change, consumer preferences and economic developments in our industry or in general, our products may become obsolete. | |
● | We could become subject to data privacy and security claims or enforcement actions, particularly due to our digital marketing efforts; | |
● | We may become subject to product liability or related claims based on our production and sale of products containing chemical compounds designed to be ingested or applied topically; | |
● | Our Chief Executive Officer, directly and through entities she controls, owns a majority of our outstanding common stock and voting power on an as-converted basis, rendering other stockholders’ ability to influence matters before them limited in most cases; and | |
● | Operational risks such as material weaknesses and other deficiencies in internal control over financial reporting could result in errors, potentially requiring restatements of our historical financial data, leading investors to lose confidence in our reported results. |
6 |
Our ability to continue as a going concern is in doubt unless we obtain adequate new debt or equity financing and achieve sufficient sales levels.
Our auditors have issued their audit opinion which is qualified based upon our ability to continue as a going concern. We have incurred significant net losses to date. We anticipate that we will be forcedcontinue to ceaselose money for the foreseeable future. Additionally, we have negative cash flows from operations and we our activitiesrevenue may exceed our expenses in the next 12 months. Since our inception in 2017, we have generated losses from operations. As of December 31, 2021, our accumulated deficit was $16.8 million, and dissolve the Company. In such an event, we will need to satisfy various creditorshad $3.8 million in cash and other claimants, severance, lease terminationliquid stock. Our continued existence is dependent upon generating sufficient working capital and other dissolution-related obligations.
There are a number of factors that may notimpede our efforts to establish and maintain effective internal controls and a sound accounting infrastructure, including our lacking a Chief Financial Officer, our pace of growth, and general uncertainty regarding the operating effectiveness and sustainability of controls. Controls and procedures, no matter how well designed and operated, provide only reasonable assurance that material errors in our financial statements will be able to successfully implement our strategyprevented or detected on a timely basis or at all.
Risks Related to Our Business and the CBD Industry
Because we need to raise additional capital any financing based on our common stock or common stock equivalents will dilute our existing stockholders and the terms of any such financing could impose restrictions on our operations.
We have depended upon loans from our Chief Executive Officer and principal stockholder and prior to November 18, 2021, we have primarily financed our operations by borrowing funds from her. On November 18, 2021, we entered into an agreement with an institutional investor for a $1.1 million original issue discount convertible note. See Item 1, Business. We will require additional capital to execute our business plan and we do not know if investors will be interested in purchasing additional shares our common stock or common stock equivalents or, if any financing will be on terms that are less attractive to us. To the extent that we raise additional capital through the sale of common stock or common stock equivalents, our stockholders will be diluted. Further, the terms of such financings may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financings may involve an equity component, such as convertible notes and warrants, which could also result in dilution of our existing stockholders’ ownership. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our use of the proceeds, prohibitions on incurring additional debt or making subsequent dilutive issuances of securities, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, if we were to default on such indebtedness, we could lose any assets and intellectual property with which the indebtedness is secured. We received no additional cash proceeds from this transaction.
Because, we are highly dependent on the services of Leslie Buttorff, our Chief Executive Officer, the loss of her and our inability to expand our management team, could harm our business.
Our success is largely dependent on the continued services of Leslie Buttorff, our Chief Executive Officer and principal stockholder. The loss of the services of Ms. Buttorff would leave us without executive leadership, which could diminish our business and growth opportunities. Additionally, Ms. Buttorff has business interests outside our company, including as an owner and officer of a consulting company and of a real estate holding company each of which hold shares in us as a result of the recent share exchange under the Exchange Agreement. Accordingly, from time-to-time she may not devote her full time and attention to our affairs, which could have a material adverse effect on our operating results, and there can be no assurance that a conflict of interest will not arise from her other business ventures. Further, as of December 31, 2021, Ms. Buttorff holds demand promissory notes totaling $9,704,894 at various interest rates ranging from 0% to 12%. Thus, she has the power to call the notes and obtain all of our assets. As of this date of this Report, additional funds have been borrowed. Additionally, we have a line of credit with Ms. Buttorff through which it may borrow up to $1 million at a 10% annual interest rate. The fact that she continues to advance money and is our principal stockholder reflects her intent to support us.
We will also need to build an executive management team around Ms. Buttorff, including locating and hiring a Chief Financial Officer and other executive officers, which could be a time consuming and expensive process and divert management’s attention from other pressing matters concerning our operations or growth. The market for highly qualified personnel in this industry is very competitive and we may be unable to attract such personnel in a timely manner, on favorable terms or at all. If we are unable to attract and retain the required personnel, our business could be harmed.
7 |
The loss of Ms. Buttorff would have a material adverse effect on us. We do not have key man insurance on the life of Ms. Buttorff. Ms. Buttorff’s Employment Agreement with us (the “Employment Agreement”) permits her to resign for good reason which includes our material breach of the Employment Agreement including our failure to pay her. In the event Ms. Buttorff terminates her Employment Agreement for good reason, this would result in the us owing her approximately $760,000 in severance pay plus any earned bonuses and other benefits and would leave us without an executive officer which may have a material adverse effect upon us, your investment, and hamper our ability to continue operations. As of this date, the Company has not paid Ms. Buttorff a salary and continues to accrue this liability. If we fail to procure the services of additional executive management or implement and execute an effective contingency or succession plan for Ms. Buttorff, the loss of Ms. Buttorff would significantly disrupt our business from which we may not be able to recover.
If we are unable to develop and maintain our brand and reputation for our product offerings, our business and prospects could be materially harmed.
Our business and prospects depend, in part, on developing and then maintaining and strengthening our brand and reputation in the markets we serve. If problems with our products cause our customers to have a negative experience or failure or delay in the delivery of our products to our customers, our brand and reputation could be diminished. If we fail to develop, promote and maintain our brand and reputation successfully, our business and prospects could be materially harmed.
Because we face intense competition, we may not be able to increase our market share which would materially and adversely affect us.
Our industry is highly competitive. It is possible that future competitors could enter our market, thereby causing us to lose market share and revenues or fail to grow our operations and market presence as intended or at all. In addition, some of our current competitors have, or future competitors may have, significantly greater financial, technical, marketing and other resources than we do or may have more experience or advantages in the markets in which we will compete that will allow them to offer lower prices or higher quality products. If we do not successfully compete with these competitors, we could fail to develop a sufficient market share to achieve our goals and our future business prospects could be materially adversely affected.
The pet health and wellness industry is highly competitive. We compete on the basis of product and ingredient quality, product availability, palatability, brand awareness, loyalty and trust, product variety and innovation, product packaging and design, reputation, price and convenience and promotional efforts. The pet products and services retail industry has become increasingly competitive due to the expansion of pet-related product offerings by certain supermarkets, warehouse clubs, and other mass and general retail and online merchandisers and the entrance of other specialty retailers into the pet food and pet supply market.
We face direct competition from companies that sell various pet health and wellness products at a lower price point and distribute such products to traditional retailers, which are larger than we are and have greater financial resources. Price gaps between products may result in market share erosion and harm our business. Our current and potential competitors may also establish cooperative or strategic relationships amongst themselves or with third parties that may further enhance their resources and offerings. Further, it is possible that domestic or foreign companies, some with greater experience in the pet health and wellness industry or greater financial resources than we possess, will seek to provide products or services that compete directly or indirectly with ours in the future.
Many of our current competitors have, and potential competitors may have, longer operating histories, greater brand recognition, significantly greater financial, marketing and other resources and larger customer bases than we do. These factors may allow our competitors to derive greater net sales and profits from their existing customer base, acquire customers at lower costs or respond more quickly than we can to new or emerging technologies and changes in consumer preferences or habits. These competitors may engage in more extensive research and development efforts, undertake more far-reaching marketing campaigns and adopt more aggressive pricing policies (including but not limited to predatory pricing policies and the provision of substantial discounts), which may allow them to build larger customer bases or generate net sales from their customer bases more effectively than we do.
Our competitors may be able to identify and adapt to changes in consumer preferences more quickly than us due to their resources and scale. They may also be more successful in marketing and selling their products, better able to increase prices to reflect cost pressures and better able to increase their promotional activity, which may impact us and the entire pet health and wellness industry. Increased competition as to any of our products could result in price reduction, increased costs, reduced margins and loss of market share, which could negatively affect our profitability. While we believe we are better equipped to customize products for the pet health and wellness market generally as compared to other companies in the industry, there can be no assurance that we will be able to successfully compete against these other companies. Expansion into markets served by our competitors and entry of new competitors or expansion of existing competitors into our markets could materially adversely affect our business, financial condition and results of operations.
We may face difficulties as we expand our business and operations into jurisdictions in which we have no prior operating experience.
We plan in the future to expand our operations and business into jurisdictions outside of the jurisdictions where we currently carry on business. There can be no assurance that the hemp-based businessany market for our products will be successful, will occur timely ordevelop in a timeframe that is capable of prediction, or will generate enough revenue to recoup our investment.
We must accurately forecast demand for all of our products in order to ensure that we have enough products available to meet the needs of our customers. Our forecasts are based on multiple assumptions that may cause our estimates to be inaccurate and affect our ability to obtain adequate third-party contract manufacturing capacity in order to meet the demand for our products, which could prevent us from meeting increased customer demand and harm our brand and our business.products. If we do not accurately align our purchasingmanufacturing capabilities with customer demand, our business, financial condition and results of operations may be materially adversely affected.
In addition, we must continuously monitor our inventory and product mix against anticipatedforecasted demand. If we underestimate demand, we risk having inadequate supplies and damaging supplier relationships.supplies. We also face the risk of having too much inventory on hand that may reach its expiration date and become unsalable, and we may be forced to rely on markdowns or promotional sales to dispose of excess or slow-moving inventory. If we are unable to manage our supply chain effectively, our operating costs could increase and our profit margins could decrease.
Because the sale of our products involves the potential for product liability, we may incur significant losses and expenses in excess of our insurance coverage.
We face an inherent risk of exposure to competeproduct liability claims if the use of our products results in, or is believed to have resulted in, illness or injury. Our products are designed for ingestible or topical use and grow will be dependent on it having access, at a reasonable costcontain combinations of ingredients, and in a timely manner, to skilled labor, equipment, facilities, and raw materials. No assurances can be given that we will be successful in maintaining a required supply of skilled labor, equipment, facilitiesthere is little experience with or raw materials.
Although we believe all of our products contain hemp-derived CBD oil and isolate. Increases and unexpected decreaseswill be safe when taken as directed by us, there is little long-term research on the effects of human consumption of certain of the new product ingredients or combinations in concentrated form that we use or may in the costfuture use in developing our CBD products. Any instance of ingredients in ourillness or negative side effects of ingesting CBD products or applying them topically on the skin could have a material adverse effect on our business and operations by, among other things, exposing us to the risk of costly litigation and/or governmental sanctions and dramatically reducing the demand for some or all of our products.
Any product liability claim or related developments from our products or CBD in general may increase our costs and adversely affect our revenue, product demand and operating results. Significant price increases,Moreover, liability claims arising from a serious adverse event may increase our costs through higher insurance premiums and deductibles and may make it more difficult to secure adequate insurance coverage in the future. In addition, our product liability insurance may fail to cover future product liability claims, which, if adversely determined, could subject us to substantial monetary damages. Finally, we may sustain a judgment in excess of our insurance coverage.
8 |
The success of our business will depend upon our ability to create and expand our brand awareness.
The health and wellness and CBD markets we compete in are highly competitive, with many well-known brands leading the industry. Our competitors include CBD companies who have a longer history operating in these markets than we do. Our ability to compete effectively and generate revenue will be based upon our ability to create and expand awareness of our products distinct from those of our competitors. It is imperative that we are able to convey to consumers the benefits of our products both in general and as compared to competitive offerings. However, advertising, packaging and labeling of our products is limited by various regulations. Our success will be dependent upon our ability to convey to consumers that our products are superior to those of our competitors while complying with complex and varying regulations in the markets in which we attempt to market conditions, weather, acts of God and other disasters could materiallysell them.
If we fail to develop and introduce new products it will adversely affect our operating results. An increasefuture prospects.
Our industry is subject to rapid change. New products are constantly introduced to the market. Our ability to remain competitive depends in part on our ability to enhance existing products, to develop and manufacture new products in a timely and cost-effective manner, to adequately anticipate, prepare and execute strategies for market transitions, and to effectively market our products. Management believes that our future financial results will depend to a great extent on the successful expansion of our current product offerings and on the development and introduction of new products. We cannot be certain that we will be successful in selecting, developing, manufacturing and marketing new products or in improving upon or enhancing the market for existing products.
The success of new product introductions or expansions to new territories depends on various factors, including, without limitation, the following:
● | Successful sales and marketing efforts; |
● | Timely delivery of the products; |
● | Availability of raw materials and/or sufficient production facilities; |
● | Pricing of raw materials and labor; |
● | Regulatory allowance and restrictions of the products; and |
● | Market acceptance and consumer sentiment. |
If we fail to appropriately respond to changing consumer preferences and demand for new products, it could significantly harm our customer relationships and product sales and harm our operating costsresults and financial condition.
Our business is subject to changing consumer trends and preferences, especially with respect to targeted nutrition and natural wellness products. Our success will depend in part on our ability to anticipate and respond to these changes, and we may not respond in a timely or commercially appropriate manner to such changes. Furthermore, the health and wellness industry is characterized by rapid and frequent changes in demand for products and new product introductions and enhancements. Our failure to accurately predict these trends could negatively impact consumer opinion of our products, which in turn could harm our customer relationships and product demands and cause the loss of sales. The success of our product offerings depends upon a number of factors, including our ability to:
● | Accurately anticipate consumer needs; |
● | Successfully commercialize new products or product enhancements in a timely manner; |
● | Price our products competitively; |
● | Arrange for the production and delivery our products in sufficient volumes and in a timely manner; |
● | Differentiate our products from those of our competitors; and |
● | Innovate and develop new products or product enhancements that meet these trends. |
If we do not meet these challenges, some of our products could be rendered obsolete, which could negatively impact our operating results and financial condition.
9 |
Adverse publicity associated with our products or ingredients, or those of our competitors or similar businesses, could adversely affect our profitability. Factorssales and revenue.
Adverse publicity concerning any actual or purported failure by us or our competitors to comply with applicable laws and regulations or concerning any other aspect of our business or the CBD industry could have an adverse effect on the public perception of us and our products. This, in turn, could negatively affect our ability to obtain financing, endorsers and attract distributors, retailers or consumers for our products, which would have a material adverse effect
Our distributors’ and customers’ perception of the safety, utility and quality of our products or even similar products distributed by others can be significantly influenced by national media attention, publicized scientific research or findings, product liability claims and other publicity concerning our products or similar products distributed by others. Adverse publicity, whether or not accurate, that causes a perceived connection between consumption of our products or any similar products and illness or other adverse effects, will likely diminish the public’s perception of and in turn the demand for our products. Claims that any products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could have a material adverse effect on the market demand for our products, including reducing our sales and revenue, which would have a material adverse effect on our business.
If we are unable to manufacture our products in sufficient quantities or at defined quality specifications or are unable to maintain regulatory approvals for our production facility, we may be unable to develop or meet demand for our products and lose time to market and potential revenues.
Commercialization of our products require access to, or development of, facilities to manufacture a sufficient supply of our products. In the future we may face difficulties in the development, production or distribution of our products. We may need to outsource the testing or manufacturing process or other aspects of our commercialization efforts, and
We may face competition for access to any third-party supply sources, development or production partners and facilities such as inflation, increased laborhemp growers and employee benefitmay be subject to production delays if any of those third parties give their other business partners a higher priority than they give to us. Even if we are able to identify additional or replacement third-parties, the delays and costs associated with establishing and increased energy costsmaintaining a relationship with such third parties may have a material adverse effect on us. Further, a reduction in the control of our production efforts would be inherent in any such outsourcing, which exposes us to a greater risk of liability, including regulatory enforcement actions for alleged noncompliance with law and product liability claims. This could also result in lower product quality which could negatively impact demand for our offerings or our competitive advantage. Any of these challenges could prevent us from achieving our business objectives and harm your investment in us.
If the market opportunities for our current and potential future products are less lucrative than anticipated, our ability to generate revenues may be adversely affected and our business may suffer.
Our understanding, expectation and estimates of the market for our current and future products may prove to be incorrect, and new test results or studies, reports, legislative or regulatory developments or other factors beyond our control may result in the market for our products being lower than anticipated on a regional, national or global scale. The number of individuals in the U.S. who are willing to purchase our products may be lower than expected, or expectations for repetitive purchases and consumption may prove to be incorrect. These occurrences could materially adversely affect our operating costs. Decreasesprospects and operational results.
If we are unable to establish relationships with third parties to carry out sales, marketing, and distribution functions or to create effective marketing, sales, and distribution capabilities, we will be unable to market our products successfully.
Our business strategy includes using third parties to market and sell the products at the retail level. There can be no assurance that we will successfully be able to establish marketing, sales, or distribution relationships with a sufficient number of third parties to meet our goals, that such relationships, if established, will be successful, or that we will be successful in demandgaining market acceptance for current or excess availabilityfuture products. To the extent that we enter into any marketing, sales, or distribution arrangements with third parties, our product revenues per unit sold are expected to be lower than
10 |
if we marketed, sold, and distributed our products directly, and any revenues we receive will depend upon the efforts of biomass may cause unexpected decreases in raw materialssuch third parties.
If we are unable to establish such third-party marketing and corresponding decreasesales relationships, we would have to establish and grow in-house marketing and sales capabilities. To market any products directly, we would have to build a marketing, sales, and distribution force that has technical expertise and could support a distribution capability. Competition in the health and wellness and CBD industries for technically proficient marketing, sales, and distribution personnel is intense, and attracting and retaining such personnel may significantly increase our costs. There can be no assurance that we will be able to establish internal marketing, sales, or distribution capabilities or that these capabilities will be sufficient to meet our needs.
We face and may continue to face business disruption and related risks arising from the COVID-19 pandemic, which has had and could continue to have a material adverse effect on our business.
Our production and development and sale of our products has been and could continue to be materially adversely affected by the COVID-19 pandemic. In response to the pandemic, we began producing and selling personal protective equipment such as hand sanitizer and face masks in 2020. In 2021, sales levels declined as the pandemic began to be contained. We rely upon CBD sales in retail pricestores including convenience stores and have not created a material online sales presence. Sales of our CBD products.products declined as a result of the pandemic, due in part to decreased demand caused by economic hardship and uncertainty and production challenges caused by supply shortages and the lockdowns. While vaccinations beginning in 2021 allowed for the reopening of the economy, the recent “Delta” and “Omicron” variants of the virus, potential new variants of the virus, as well as reduced efficacy of vaccines over time and the possibility that a large number of people decline to get vaccinated or receive booster shots, creates inherent uncertainty as to the future of our business, our industry and the economy in general in light of the pandemic.
We are still assessing our business plans and the impact COVID-19 may have on our ability to commercialize our products, but there can be no assurance that this analysis will enable us to avoid or mitigate part or all of any impact from the spread of COVID-19 or its consequences, including macroeconomic downturns. The duration and extent of the impact from the COVID-19 pandemic depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus and its many variants, the extent and effectiveness of containment actions including vaccinations and the impact of these and other factors on our employees, customers, partners and vendors. If we are not able to respond to and manage the impact of such events effectively, our business will be harmed.
Because of the Russian invasion of Ukraine, the effect on the capital markets and the economy is uncertain, and we may have to deal with a recessionary economy and economic uncertainty including possible material adverse effects upon our business.
Because of the Russian Invasion of Ukraine, the effect on the capital markets and the economy is uncertain, and as a result we may have to deal with a recessionary economy and economic uncertainty, including possible adverse effects upon our ability to raise capital as and when needed. As a result of the Russian invasion of Ukraine, certain events are beginning to affect the global and U.S. economy including increased inflation, substantial increases in the prices of oil and gas, large Western companies ceasing to do business in Russia and uncertain capital markets with declines in leading market indexes. The duration of this war and its impact are at best uncertain. Ultimately the economy may turn into a recession with uncertain and potentially severe impacts upon public companies and us, including our ability to raise capital. We cannot predict how this will affect our operations or the industries in which we operate, however any such impact may be material and adverse.
If our information technology systems are compromised, the information we store and process, including our intellectual property, could be accessed, publicly disclosed, lost or stolen, which could harm our business, relationships with strategic partners and future results of operations.
Companies are increasingly suffering damage from attacks by hackers and there is a general risk that the Russia may adopt widespread Internet hacking as a weapon in the Ukrainian war, which hacking may ultimately affect us. In the ordinary course of business, we store sensitive information, such as our intellectual property, including trade secrets and results of our clinical and preclinical research, and that of our suppliers and business partners, on a central server, and such information is transmitted via email correspondence. The secure maintenance and processing of this information is critical to our research and development activities and future operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breaches due to employee error, malfeasance or other disruptions. Any such breach could compromise our information technology systems and the information stored there could be accessed by third parties, publicly disclosed, lost or stolen. Any such unauthorized access, disclosure, misappropriation or other loss of information could result in disruption of our operations, including our existing and future research collaborations, and damage our reputation, which in its turn could harm our business and future results of operations.
We have a limited operating history upon which investors can evaluate our future prospects.
Our subsidiary was founded and began operations in the CBD industry in 2017 and we therefore have a limited operating history upon which an evaluation of our business plan or performance and prospects can be made. Our business and prospects must be considered in the light of the potential problems, delays, uncertainties and complications encountered in connection with a business which is still in its early stages in a relatively new industry characterized by unexpected change. The risks include, but are not limited to, the possibility that we fail to develop functional and scalable products, or that although functional and scalable, our products will not be economical to market in order to become or remain profitable; that our competitors hold proprietary rights precluding us from marketing such products; that our competitors offer a superior or equivalent product or otherwise achieve or maintain greater market acceptance than us; that we are unable to upgrade or improve our processes and products to accommodate new features and expand our offerings; or that we fail to receive or maintain necessary regulatory clearances and compliance for our products and operations. In order to grow our revenue, we must develop and improve upon our brand name recognition and competitive advantages for our products and expand into new markets. Even if we accomplish such growth, resulting expenses may be greater than estimated, which could reduce or even eliminate any revenue gains for which such endeavors were made. There are no assurances that we can successfully address these challenges. If we are unsuccessful, our business, financial condition and operating results could be materially and adversely affected.
11 |
If the market for CBD products declines, it would materially and adversely affect our business.
Following the passage of the 2018 Farm Bill described below, our industry experienced during 2020,an influx of hemp farmers and producers which resulted in a saturated marketplace. As a result, the supply for CBD and related products has in the past exceeded demand. This trend has reduced prices and affected our gross margins and could force us to reduce our prices to remain competitive or could result in lower sales levels than we have experienced in the past, either of which would result in a decline in revenue or growth rate and could materially adversely affect our financial condition and prospects.
If we fail to attract new customers in a cost-effective manner, our business may be harmed.
A large part of our success depends on our ability to attract new customers in a cost-effective manner. We have made, and may continue to make, significant investments in attracting new customers through increased advertising spends on social media, radio, podcasts, and targeted email communications, other media and events, sponsorships, and influencer sponsorships. Marketing campaigns can be expensive and may not result in the cost-effective acquisition of customers. Further, as our brand becomes more widely known, future marketing campaigns may not attract new customers at the same rate as past campaigns and the cost of acquiring new customers may increase over time. Additionally, regulation, algorithms, or participants in the digital marketing ecosystem may change rules for our industry or access to available demographics which may result in significant changes in the ability to target key demographic pools, impacting our ability to target our customers effectively. If we are unable to attract new customers, or fail to do so in a cost-effective manner, our business may be harmed.
Even if we meet our growth objectives and our enter into new markets as intended, we may face difficulties evaluating our current and future business prospects, and we may be unable to effectively manage any growth associated with these achievements, which would increase the risk of your investment losing value and could harm our business, financial condition, and results of operations.
Our entry into new markets and/or growth in our product offering or consumer base may place a significant strain on our resources and increase demands on our executive management, personnel and operational systems, and our human, administrative and financial resources may be inadequate to meet these demands. We may also be unable to effectively manage any expanded operations or achieve planned growth on a timely or profitable basis, particularly if the number of customers using our products significantly increases within a short period of time. If we are unable to manage expanded operations effectively, we may experience situations whereoperating inefficiencies, the cost paid for inventory exceeds the current retail market. Manyquality of the factors affecting costs are beyond our control and we may not be able to pass along increased costs to our customers.
If we cannot manage our growth effectively, our results of operations would be materially and adversely affected.
We expect to experience growth as we raise additional capital. Businesses which grow rapidly often have difficulty managing their growth while maintaining their compliance and quality standards. If we grow as rapidly as anticipated, we will need to expand our management by recruiting and employing additional executive and key personnel capable of providing the necessary support. There can be no assurance that management, along with staff, will be able to effectively manage our growth nor can there be any assurance that growth in our product offerings, customer base or contracts will translate to an increase in revenue or profitability. Any failure to meet the challenges associated with rapid growth could materially and adversely affect our business and operating results.
Existing or future governmental regulations relating to CBD products may harm or prevent our ability to produce and/or sell our product offerings.
While a majority of state governments in the United States have legalized the growing, production, and use of CBD in some form and subject to certain restrictions, cannabis remains illegal under federal law. In addition, in July 2017, the United States Drug Enforcement Agency issued a statement that certain CBD extractions fall within the definition of marijuana and are therefore a Schedule I controlled substance under the Controlled Substances Act of 1970, as amended. Thus, the cannabis industry, including companies which sell products containing CBD, faces significant uncertainty surrounding regulation by the federal government, which could claim supremacy over state regulatory regimes including those with a “friendlier” view toward CBD products. While the federal government has for several years chosen to not intervene in the cannabis business conducted legally within the states that have legislated such activities, there is, nonetheless, potential that the federal government may at any time choose to begin enforcing its laws against the manufacture, possession, or use of cannabis-based products such as CBD. Similarly, there is the possibility that the federal government may enact legislation or rules that authorize the manufacturing, possession or use of those products under specific guidelines. Local, state and federal cannabis laws and regulations are broad in scope and subject to evolving interpretations. In the event the federal government was to tighten its regulation of the industry, we would likely suffer a material adverse effect on our business, including potentially substantial losses.
12 |
Because laws and regulations affecting our industry are evolving, changes to any regulation may materially affect our CBD products.
In conjunction with the enactment of the Agriculture Improvement Act of 2018 (the “Farm Bill”), the FDA released a statement about the status of CBD as a nutritional supplement, and the agency’s actions in the short term with regards to CBD will guide the industry. As a company whose products contain CBD, we intend to meet all FDA guidelines as the regulations evolve. Any difficulties in compliance with future government regulation could increase our operating costs and adversely impact our results of operations in future periods.
In addition, as a result of the Farm Bill’s passage, we expect that there will be a constant evolution of laws and regulations affecting the CBD industry which could affect our operations. Local, state and federal hemp laws and regulations may be broad in scope and subject to changing interpretations. These changes may require us to incur substantial costs associated with legal and compliance fees and ultimately require us to alter our business plan. Furthermore, violations of these laws, or alleged violations, could disrupt our business and result in a material adverse effect on our operations. In addition, we cannot predict the nature of any future laws, regulations, interpretations or applications, and it is possible that regulations may be enacted in the future that will be directly applicable to our business.
Unexpected changes in federal and state law could cause any of our current products, as well as products that we intend to develop and launch, containing hemp-derived CBD oil to be illegal, or could otherwise prohibit, limit or restrict any of our products containing CBD.
Our business is based on the production and distribution of products containing hemp-derived CBD. The Farm Bill, which amended various sections of the U.S. Code, and legalized the cultivation and sale of industrial hemp at the federal level, subject to compliance with certain federal requirements and state law. There can be no assurance that the Farm Bill will not be repealed or amended such that our products containing hemp-derived CBD would once again be deemed illegal under federal law.
The Farm Bill delegates the authority to the states to regulate and limit the production of hemp and hemp-derived products within their territories. Although many states have adopted laws and regulations that allow for the production and sale of hemp and hemp-derived products under certain circumstances, no assurance can be given that such state laws may not be repealed or amended such that our intended products containing hemp-derived CBD would once again be deemed illegal under the laws of one or more states now permitting such products, which in turn would render such intended products illegal in those states under federal law even if the federal law is unchanged. In the event of either repeal of federal or of state laws and regulations, or of amendments thereto that are adverse to our intended products, we may be restricted or limited with respect to those products that we may sell or distribute, which could adversely impact our intended business plan with respect to such intended products.
Additionally, the FDA has indicated that certain products containing CBD are not permissible under the Federal Food, Drug, and Cosmetic Act (the “FDCA”), notwithstanding the passage of the Farm Bill. On December 20, 2018, after the Farm Bill became law, then FDA Commissioner Scott Gottlieb issued a statement in which he reiterated the FDA’s position that CBD products that are marketed with a claim of therapeutic benefit must be approved by the FDA for their intended use before they may be distributed in interstate commerce and that the FDCA prohibits interstate distribution of food products containing CBD and marketing products containing CBD as a dietary supplement, regardless of whether the substances are hemp-derived. Although we believe our existing and planned CBD products comply with applicable federal and state laws and regulations, legal proceedings alleging violations of such laws could have a material adverse effect on our results of operations and financial condition, including expensive legal fees and other costs. Sources of hemp-derived CBD depend upon legality of cultivation, processing, marketing and sales of products derived from those plants under state law.
13 |
Hemp-derived CBD can only be legally produced in states that have laws and regulations that allow for such production and that comply with the Farm Bill, apart from state laws legalizing and regulating medical and recreational cannabis or marijuana, which remains illegal under federal law. This is one of the reasons why we are based in Colorado. Unexpected changes in federal and state law could cause our current CBD production methods or resulting products, as well as products that we intend to develop and launch, to be illegal or could otherwise prohibit, limit or restrict some or all of our products in the event of repeal or amendment of laws and regulations which are now comparatively favorable to the cannabis/hemp industry in certain states, we would be required to locate new suppliers in states with laws and regulations that qualify under the Farm Bill. If we were to be unsuccessful in arranging new sources of supply of our raw ingredients, or if our raw ingredients were to become legally unavailable, our intended business plan with respect to such products could be adversely impacted.
Because we and our distributors may only sell and ship our products containing hemp-derived CBD in states that have adopted laws and regulations qualifying under the Farm Bill, a reduction in the number of states having such qualifying laws and regulations could limit, restrict or otherwise preclude the sale of intended products containing hemp-derived CBD.
The interstate shipment of hemp-derived CBD from one state to another is legal only where both states have laws and regulations that allow for the production and sale of such products and that qualify under the Farm Bill. Therefore, the marketing and sale of our products is limited by such factors and is restricted to such states. Although we believe we may lawfully sell any of our finished products including those containing CBD in a majority of states, a repeal or adverse amendment of laws and regulations that are now favorable to the distribution, marketing and sale of finished products we intend to sell could significantly limit, restrict or prevent us from generating revenue related to our products that contain hemp-derived CBD. Additionally, any such adverse changes or existing legislation in new markets we target may stunt our growth and diminish our prospects. Any such repeal or adverse amendment of laws and regulations could have an adverse impact on our business plan with respect to such products.
Costs associated with compliance with numerous laws and regulations and quality standards could adversely impact our financial results.
The manufacture, labeling and distribution of CBD products is regulated by various federal, state and local government agencies. These governmental authorities regulate our products and processes to ensure that the products are not adulterated or misbranded. We buy ingredients fromare subject to regulation by the federal government and other manufacturers. If these materialsstate and local agencies as a result of our CBD products. In addition to the risks associated with the possibility of government enforcement or private litigation due to alleged noncompliance, our compliance costs associated with our day-to-day operations are alleged high and are expected to increase as we expand into new markets and/or provedevelop and market new products. For example, as a “seed to include contaminants that affectsale” CBD business, meaning a business which handles every step of a CBD product’s manufacture and sale in-house rather than relying on third parties for some or all the safety orproduction and distribution steps, we are responsible for the quality of our product, and the means by which it is produced and marketed, at every stage. Compliance with regulations imposed on our business model means we must deploy and maintain an advanced computer monitoring system which allows us to track our production and distribution process. We must train our employees and utilize and maintain security measures to ensure our facility functions properly. Compliance with these and other government requirements for product monitoring, quality, labelling and distribution are costly which may limit our profitability. Further, if we fail to properly comply with our obligations in the manufacturing process, we risk governmental enforcement actions which may be costly and adversely affect us.
Our products or third parties with whom we do business may not comply with health, safety and labelling standards.
We do not have control over all of the third parties involved in the sale of our products and their compliance with government health, safety and labelling standards. Even if our products meet these standards, they could otherwise become contaminated or fail, or the standards could be changed in a manner adverse to our operations or those of our business partners. A failure to meet these standards could occur in our operations or those of our distributors or suppliers. This could result in expensive production interruptions, recalls, regulatory investigations and enforcement actions and liability claims. Moreover, negative publicity could be generated from false, unfounded or nominal liability claims or limited recalls. Any of these failures or occurrences could negatively affect our business and financial performance.
14 |
If we fail to comply with U.S. laws related to privacy, data security, and data protection, it could adversely affect our operating results and financial condition.
We rely on a variety of marketing techniques, including email, radio, display advertising, and social media marketing, targeted online advertisements, and postal mailings, and we are otherwise rumoredor may become subject to various laws and regulations that govern such marketing and advertising practices. A variety of federal and state laws and regulations, including those enforced by various federal government agencies such as the Federal Trade Commission, Federal Communications Commission, and state and local agencies, govern the collection, use, retention, sharing, and security of personal data, particularly in the context of online advertising, which we utilize to attract new customers.
The legislative and regulatory bodies or self-regulatory organizations in various jurisdictions inside the United States may expand current laws or regulations, enact new laws or regulations, or issue revised rules or guidance regarding privacy, data protection, consumer protection, information security, and online advertising. California has enacted the California Consumer Privacy Act of 2018 (the “CCPA”), which became operative on January 1, 2020, and its implementing regulations took effect in August 2020. The CCPA requires companies that process personal information on California residents to make new disclosures to consumers about such companies’ data collection, use, and sharing practices and inform consumers of their personal information rights such as deletion rights, allows consumers to opt out of certain data sharing with third parties, and provides a new cause of action for data breaches. In November 2020, California enacted the California Privacy Rights Act of 2020 (the “CPRA”), which amends and expands the scope of the CCPA, while introducing new privacy protections that extend beyond those included in the CCPA and its implementing regulations. The CCPA, as amended and expanded by the CPRA, is one of the most prescriptive general privacy law in the United States and may lead to similar laws being enacted in other U.S. states or at the federal level. For example, the State of Nevada also passed a law effective on October 1, 2019 that amends the state’s online privacy law to allow consumers to submit requests to prevent websites and online service providers (“Operators”) from selling personally identifiable information that Operators collect through a website or online service. Further, on March 2, 2021, the Governor of Virginia signed into law the Virginia Consumer Data Protection Act (the “VCDPA”). The VCDPA creates consumer rights, similar to the CCPA, but also imposes security and assessment requirements for businesses. In addition, on July 7, 2021, Colorado, the state in which we are headquartered, enacted the Colorado Privacy Act (“CoCPA”), becoming the third comprehensive consumer privacy law to be passed in the United States (after the CCPA and VCDPA). Although the CoCPA closely resembles the VCDPA, both of which do not contain a private right of action and will instead be enforced by the respective states’ Attorney General and district attorneys, the two differ in many ways and once they become enforceable in 2023, we must comply with each if our operations fall within the scope of these newly enacted comprehensive mandates. Prior efforts undertaken to comply with other recent privacy-related laws have adverse effects,proven that these initiatives require time to carefully plan, assess gaps in current compliance mechanisms, and implement new policies, processes and remediation efforts. Additionally, the FTC and state attorneys general are interpreting federal and state consumer protection laws to impose standards for the online collection, use, dissemination, and security of data. Each of these privacy, security, and data protection laws and regulations, and any reason, weother such changes or new laws or regulations, could impose significant limitations, require changes to our business model or practices, or restrict our use or storage of personal information, which may sustain the costs ofincrease our compliance expenses and possible litigation resulting from a product recallmake our business more costly or less efficient to conduct. In addition, any such changes could compromise our ability to develop an adequate marketing strategy and need to find alternate ingredients, delay production, or discard or otherwise dispose of products,pursue our growth strategy effectively, which, in turn, could adversely affect our business, financial condition, and results of operations. In addition, if
While we intend to strive to comply with applicable laws and regulations relating to privacy, data security, and data protection, given that the scope, interpretation, and application of these laws and regulations are often uncertain and may be in conflict across jurisdictions, it is possible that these obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. Any failure or perceived failure by us or third-party service providers to comply with privacy or security policies or privacy-related legal obligations, or any compromise of our competitors experience similar events, our reputation could be damaged, including as a result of a loss of consumer confidencesecurity that results in the typesunauthorized release or transfer of products we sell.
15 |
Our planned expansion into international markets will be costly and time consuming to defend, and the outcomes of which are uncertain.
Our business plan includes the eventual marketing and sale of our efforts or intellectual property rights that are issued to us;
● | Economic conditions adversely affecting geographic areas in which we intend to do business; |
● | Foreign currency exchange rates; |
● | Political or social unrest or economic instability in a specific country or region; |
● | Higher costs of doing business in foreign countries; |
● | Infringement claims on foreign patents, copyrights or trademark rights; |
● | Difficulties in staffing and managing operations across disparate geographic areas; |
● | Difficulties associated with enforcing agreements and intellectual property rights through foreign legal systems; |
● | Trade protection measures and other regulatory requirements, which may affect our ability to import or export our products from or to various countries; |
● | Adverse tax consequences; |
● | Unexpected changes in legal and regulatory requirements and challenges in complying with varying requirements across jurisdictions; and |
● | Military conflict, terrorist activities, natural disasters and medical epidemics. |
If we are unable to overcome these or other challenges in executing our planned expansion into international markets, our prospects would be materially adversely affected.
Risks Related to Intellectual Property
We may become involved in litigation or other proceedings relating to patent and other intellectual property rights.
A third party may sue us or our strategic collaborators for infringing its intellectual property rights. Likewise, we may need to resort to litigation to enforce licensed rights or to determine the scope and validity of third-party intellectual property rights. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would divert our efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. If we do not prevail in this type of litigation, we or our strategic collaborators may be required to pay monetary damages; stop commercial activities relating to the affected products or services; obtain a license in order to continue manufacturing or marketing the affected products or services; or attempt to compete in the market or expand our product offerings, we will be unable to growwith a substantially similar product. Uncertainties resulting from the initiation and expand our business or implement our business strategy. Thiscontinuation of any litigation could materially impairlimit our ability to increase salescontinue some of our operations. In addition, a court may require that we pay expenses or damages, and revenuelitigation could distract management or disrupt our commercial activities.
If we become involved in intellectual property litigation, such litigation is likely to be expensive and time-consuming and could be unsuccessful.
Our commercial success will depend in part on our avoiding infringement on the patents and proprietary rights of third parties for products we license or sell. There is substantial litigation, both within and outside the United States, involving patent and other intellectual property rights in the health and wellness industry, including patent infringement lawsuits, interferences, oppositions, and reexaminations and other post-grant proceedings before the U.S. Patent and Trademark Office, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications which are owned by third parties may exist with products we may license and sell.
16 |
Parties making intellectual property claims against us may obtain injunctive or other equitable relief, which could block our ability to further develop and commercialize one or more products. Defense of these claims, regardless of their merit, involves substantial litigation expense and would be a substantial diversion of our management’s attention from our business. If a claim of infringement against us succeeds, we may have to pay substantial damages, possibly including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.
To counter infringement or unauthorized use claims against us, we may be required to file infringement claims in response, or we may be required to defend the validity or enforceability of any such intellectual property rights. In an infringement proceeding, a court may decide that either our or one or more of our licensors’ intellectual property rights are not valid or is unenforceable or may refuse to stop the other party from using the underlying concepts or technology at issue because our intellectual property rights do not cover those elements. In any event, intellectual property litigation is expensive and time consuming and we may be unsuccessful in defending or enforcing such claims, which would materially harm our business.
Any inability to protect our intellectual property rights could reduce the value of our products and brands, which could adversely affect our margins,financial condition, results of operations and business.
Our business is partly dependent upon our trademarks, trade secrets, copyrights and other intellectual property rights. Effective intellectual property rights protection, however, may not be available under the laws of every country in which we and our sub-licensees may operate. There is a risk of certain valuable trade secrets being exposed to potential infringers. Regardless of whether our compounds and technology are or becomes protected by patents or otherwise, there is a risk that other companies may employ such compounds or technology without authorization and without recompensing us.
The efforts we take to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual property rights could harm our business and cause our stock price to decline.
The intellectual property behind our products may include unpublished know-how, which is dependent on favorable terms, are unablecertain key individuals, as well as existing and pending intellectual property protection.
The commercialization of our products is partially dependent upon know-how and trade secrets held by certain individuals working with and for us. Because the expertise runs deep in these few individuals, if something were to achieve the desired results under these arrangements and programs, are unablehappen to maintain these relationships, fail to generate sufficient trafficany or generate sufficient revenue from purchases pursuant to these arrangements and programs, or properly manage the actionsall of these providers, ourindividuals, the ability to generate revenueproperly manufacture our products without compromising quality and performance could be diminished greatly. Further, while our abilityemployees and contractors are subject to attractnon-disclosure obligations, any misappropriation of confidential information including trade secrets and retainknow-how could allow our customers may be impacted, negatively affectingcompetitors and others to overcome any advantage we have and reduce our market share and viability.
17 |
Risks Related to Our Securities and Our Status as an SEC Reporting Company
Because our Chief Executive Officer, directly and through entities she controls, beneficially owns approximately 61% of our issued and outstanding common stock and voting power on an as-converted basis, she can exert significant control over our business and resultsaffairs which may be averse to those of operations.
Our Chief Executive Officer and currently one of our three directors, owns approximately 61% of our issued and outstanding shares of common stock and voting power on an as-converted basis. As of December 31, 2021 Ms. Buttorff and or product recall could materiallyher companies also hold $9,704,894 in demand notes which bear interest at a rate ranging from 0 to 12% per annum. As of the date of this Report, additional funds have been loaned to the Company. The interests of Ms. Buttorff may differ from the interests of our other stockholders, including by virtue of her other businesses operated through her entities and adversely affect our brand image, causing a decline in our sales and profitability, and could reduce or deplete our financial resources.
● | the election of our directors; |
● | charter or bylaw amendments; |
● | a merger, asset sale or other fundamental corporate transaction; and |
● | any other matter submitted to our stockholders for a vote, subject only to applicable law including the Nevada Revised Statutes. |
This concentration of ownership and the conflicts of interest may have the effect of impeding a significant product defectmerger, consolidation, takeover or product recall could cause a decline inother business combination or tender offer for our sales and profitability andcommon stock which other stockholders may deem desirable or could reduce our stock price or depleteprevent our financial resources.
The requirements of being a public company may strain our resources and distract our management, which could make it difficult to otherwise be in violation of governmental regulations. We may in the future havemanage our business.
The federal securities laws require us to recall, certain ofcomply with SEC reporting requirements relating to our products as a result of potential contaminationbusiness and quality assurance concerns. A product liability claim orsecurities. Complying with these reporting and other regulatory action against us couldobligations is time-consuming and will result in increased costs andto us which could adversely affecthave a negative effect on our reputation and goodwill withfinancial condition or business. These increased costs are not fully reflected in the financial statements contained in this Annual Report on Form 10-K because until June 30, 2021, our patients and consumers generally. We dosubsidiary was a private company not carry product liability insurance. subject to SEC reporting obligations.
As a result,public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”) and the requirements of the Sarbanes-Oxley Act. These requirements may place a successful product liability claim brought againststrain on our systems and resources. We are required to file annual, quarterly and current reports with the SEC disclosing certain aspects and developments of our business and financial condition. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls over financial reporting which we currently lack. To maintain and improve the effectiveness of our disclosure controls and procedures, we will need to commit significant resources, hire additional executive officers and personnel and provide for additional management oversight. We intend to implement additional procedures and processes for the purpose of addressing the standards and requirements applicable to SEC reporting companies. Sustaining our growth will also require us wouldto commit additional managerial, operational and financial resources to identifying competent professionals to join us and to maintain appropriate operational and financial systems to adequately support our intended expansion. These activities may divert management’s attention from other business concerns, which could have a material adverse effect on our business and results of operations. Although we are seeking to acquire product liability insurance, there can be no assurance that we will be able to obtain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could result in us becoming subject to significant liabilities that are uninsured and could adversely affect our commercial arrangements with third parties.
18 |
Due to factors beyond our control, our stock price may be adversely affected by instability, disruption or destruction in a geographic region in which it operates, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest, and natural or manmade disasters, including famine, food, fire, earthquake, storm or pandemic events and spread of disease (including the recent outbreakvolatile.
Any of the coronavirus commonly referred to as "COVID- 19") which has dramatically impacted the adoption of cannabinoid products due to store closures and restrictions on in-person sales. Such events may cause customers to suspend their decisions on using products and services, make it impossible to attend or sponsor trade shows or other conferences in which our products and services are presented to distributors, customers and potential customers, extraction facilities, manufacturing locations or other physical locations, cause restrictions, postponements and cancellations of events that attract large crowds and public gatherings such as trade shows at which we have historically presented our products, and give rise to sudden significant changes in regional and global economic conditions and cycles thatfollowing factors could interfere with purchases of goods or services, commitments to develop new brands and white label products, or agriculture and farming. These events also pose significant risks to our personnel and to physical facilities, transportation and operations, which could materially adversely affect the Company's financial results.
● | Our failure to generate increasing material revenues from our CBD products; |
● | Our failure to enhance our product offerings or expand into new markets; |
● | A decline in our revenue or growth rate; |
● | Our public disclosure of the terms of any financing which we consummate in the future; |
● | A decline in the economy which impacts the demand for our products and our ability to generate revenue and achieve growth metrics; |
● | Announcements by us or our competitors of significant contracts, new products, acquisitions, commercial relationships, joint ventures or capital commitments; |
● | Changes in laws, regulations or government actions affecting the CBD industry in general or our products in particular; |
● | Our ability to list our common stock on a national securities exchange; |
● | Our ability to attract analyst coverage; |
● | The sale of large numbers of shares of common stock by our shareholders; |
● | Short selling activities; or |
● | Changes in market valuations of similar companies. |
In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert our management’s time and attention, which would otherwise be used to benefit our business.
These broad market and industry in which we operate or sales of our common stock. This situation is attributable tofactors may have a number of factors, including the fact that we are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable.
We are subject to the operating performance of the specific companies. These broad market fluctuations may“penny stock” rules which will adversely affect the market priceliquidity of our common stock.
The future issuance of additional shares of our common stock or preferred stock or debt convertible into common stock would cause immediate, and potentially substantial, dilution to our existing stockholders, which could also have a material effect on the market value of the shares. During 2020 and early 2021, we issued approximately 40 million additional shares of common stock in settlements, cancellations and conversions.
Broker-dealers are increasingly reluctant to permit investors to buy or downturns in the industries that we serve;
Potential Impacts of the COVID-19 Pandemic on Our Business Operations
As disclosed in Note 2 to our consolidated financial statements, the market priceCOVID-19 pandemic has had a notable impact on general economic conditions, including but not limited to the temporary closures of many businesses, “shelter in place” and other governmental regulations, reduced business and consumer spending due to both job losses and reduced investing activity, among many other effects attributable to the COVID-19 pandemic, and there continue to be many unknowns. During 2020, COVID-19 had a significant impact on our stockCBD operations. Recognizing the sudden need for personal protective equipment, we shifted our business to importing and selling PPE hand sanitizers and masks.
The Omicron variant which had a significant impact in the future.
19 |
Potential Impacts of Certain Current and Proposed Regulations on our trademarks, trade names,Our Business and brand namesOperations
Recently, a bill titled the Cannabis Administration and Opportunity Act, put forward by Senate Majority leader Chuck Schumer, D-NY, would amend the definition of a dietary supplement to distinguish ourremove the prohibition on marketing CBD as a dietary supplement. Management sees the bill, if enacted, as an opportunity for the FDA to accelerate their decision to classify CBD products as a dietary supplement. This would be a significant step for hemp/CBD companies as it would open the door to new selling opportunities, such as getting into retail stores, who have largely been hesitant to welcome CBD in their doors without a clear position from the FDA.
Many people are increasingly turning to CBD products for several reasons: CBD is non-psychoactive, so it does not produce a “high” like THC, there are few known contraindications, the properties of our competitors,different cannabinoids can positively affect a wide range of ailments, and have registered or appliedcannabinoids work directly and indirectly with the body’s endocannabinoid system to register many of these trademarks. We cannot assure you that our trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use ofcreate balance known as homeostasis. As demand increases, we believe the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition,FDA must provide more clarity about CBD’s legalization, and could requirethis bill is a promising first step.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
Our contract with XXII provides us to devote resources advertising and marketing new brands. Further, we cannot assure you that competitors will not infringe our trademarks, or that we will have adequate resources to enforce our trademarks.
Item 3. LegalLegal Proceedings
From time to time,time–to-time, we may become involved in legal proceedings arising in the ordinary course of business. We are unable to predict the outcome of any such matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or range of loss and accordingly have not accrued a related liability.
We filed suit in District Court in and obligations to Dr. Krassen Dimitrov. Previously, we had recordedfor Osage, County, Oklahoma on December 19, 2019. We have sued Defendants, Mike Fisher, in his official capacity as Osage County District Attorney ex rel. State of Oklahoma as an obligation on our balance sheet of $575,000 for claims asserted against us. The termsinvestigating and/or prosecuting body, Eddie Virden in his official capacity as the Sheriff of the settlement are confidential, other than no cash was paid in connection withCity of Osage as holder of the settlement. As a result,property, and the City of Pawhuska as the property seizing body, (collectively the “Government Defendants”) for the return of approximately 17,000 pounds of industrial hemp (the “Property”). We believe we expectwere entitled to eliminate $575,000possession of indebtedness from our financial statements during the quarter ended March 31, 2021.
20 |
Item 4. Mine
Not applicable.
Item 5. MarketMarket for Registrant’sRegistrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our Common Stock is quoted on the OTCQB over-the-counter market under the symbol “EXDI.“PLSH.” Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not necessarily represent actual transactions. On March 31, 202115, 2022 the closing bid price on the OTC MarketsOTCQB for our Common Stock was $0.17.$0.50.
21 |
Holders of Our Common Stock
As of March 31, 2021,15, 2022, we had 99,632,71014,762,342 shares of our common stock issued and outstanding, and approximately 166186 shareholders of record.
Dividends
There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:
1. weWe would not be able to pay our debts as they become due in the usual course of business, or;
2. ourOur total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.
We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.
Item 6. SelectedSelected Financial Data
A smaller reporting company is not required to provide the information required by this Item.
Item 7. Man
The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes to those statements that are included elsewhere in this Report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements because of several factors, including those set forth under the Part I, Item 1A, Risk Factors and Business sections in this Report, and our other filings with the Securities and Exchange Commission. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Such statements are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this Report.
General
We are a Master Product DevelopmentNevada corporation organized in 2008. Exactus, Inc. was our former name. We have pursued opportunities in hemp-based businesses, which we refer to as “cannabinoids or CBD”. On June 30, 2021 Exactus acquired Panacea Life Sciences, Inc. (“Panacea” or “PLS”), our subsidiary, and Supply Agreement (the “Development Agreement”)as a result became a seed-to-sale Cannabinoid company. The former Panacea stockholders have assumed majority control of us and Managementall our operations are now operated through Panacea which because of the share exchange became our wholly owned subsidiary. Leslie Buttorff, became our Chief Executive Officer and Services Agreementa director upon the closing of the share exchange, also became our principal stockholder through common stock and Convertible Preferred Stock issued to her and entities she controls.
Panacea was founded by Leslie Buttorff in 2017 as a woman-owned business with Ceed2Med, LLC (“C2M”) entereda focus on CBD products and technology. Through Panacea, we are dedicated to developing and producing the highest-quality, most medically relevant, legal, hemp-derived cannabinoid products for consumers and pets. Beginning at a farm, XXII owns and of which we have the right to own a 10-acre parcel, located in 2018Needle Rock, Colorado and leases laboratory space located within a 51,000 square foot, state-of-the-art, cGMP, extraction, manufacturing, testing and fulfillment center located in order rapidly enter intoGolden, Colorado, Panacea operates in every aspect of the CBD business. C2M agreedproduct value chain. From cultivation to provide the Company access to expertise, resources, skills and experience suitable for producingfinished goods, Panacea ensures its products with active phyto-cannabinoid (CBD) rich ingredients including isolates, distillates, water soluble,stringent testing protocols employed at every stage of the supply chain. Panacea endeavors to offer pure natural remedies within product lines for every aspect of life: PANA Life®, PANA Beauty®, PANA Sport™, PANA Pet®, PANA PURE™ and proprietary formulations. Under the Development Agreement,PANA Health™.
22 |
We believe we had been allotted a minimum of 50arewell positioned to develop novel hemp extracts as dietary supplements and up to 300 kilograms per month, and up to 2,500 kilograms annually, of active phyto-cannabinoid (CBD) rich ingredients for resale, and offered tinctures, edibles, capsules, topical solutions and animal health products manufactured, directly or indirectly, under this arrangement. C2M was also responsible for overseeingapplications. Our biotechnology plans focus on our farming and manufacturing activities.
Results of Operations
Comparison of the Years Ended December 31, 2021 and 2020
The following table sets forth our results of operations for the years ended December 31, 20202021 and 2019:
Years Ended December 31, | Period to | |||||||||||
2021 | 2020 | Period Change | ||||||||||
Revenues from cannabinoid sales | $ | 1,933,627 | $ | 4,224,720 | $ | (2,231,092 | ) | |||||
Revenues from PPE sales | $ | 66,000 | $ | 4,793,000 | (4,727,000 | ) | ||||||
Cost of sales | $ | 1,519,049 | $ | 7,020,223 | $ | (5,501,174 | ) | |||||
Operating expenses | $ | 4,959,059 | $ | 4,449,313 | $ | 509,746 | ||||||
General and administrative | $ | 1,518,687 | $ | 2,806,026 | $ | (1,287,339 | ) | |||||
Interest expense | $ | (1,105,243 | ) | $ | (1,511,579 | ) | $ | 406,336 | ||||
Unrealized gain on marketable securities | $ | 1,008,046 | $ | 1,426,798 | $ | (418,672 | ) | |||||
Realized gain on sale of securities | $ | 160,296 | $ | - | $ | 160,296 | ||||||
Other loss | $ | - | $ | (20,180 | ) | $ | 20,180 | |||||
Employer retention credit | $ | 396,679 | $ | - | $ | 396,679 | ||||||
Rental income | $ | 236,560 | $ | 271,767 | $ | (35,207 | ) | |||||
Loss on sale of assets | $ | (297,351 | ) | $ | (140,714 | ) | $ | (156,637 | ) | |||
Gain on extinguishment of debt | $ | 755,782 | $ | - | $ | 755,782 |
Year Ended December 31, 2021 and 2020
Net Revenues
We are principally engaged in the business of producing and selling products made from industrial hemp. DuringRevenue consists of sales of our six category of brand products, white label and contract manufacturing sales to other CBD companies, raw material sales (distillate and isolate), and tolling arrangements. We have also engaged in the sale of personal protective equipment (PPE).
23 |
Our revenues for the year ended December 31, 2020, we generated total revenues of $2.1 million from the sale of CBD products, including revenues of $0.3 million from a related party, C2M,2021 decreased by $6,958,093, or 77%, to $2,059,627 as compared to $9,017,720 for the year ended December 31, 2020.
Cost of Sales
Cost of sales for the year ended December 31, 2021 decreased by $5,501,174, or 78%, to $1,519,049 as compared to $7,020,223 for the year ended December 31, 2020. The decrease in cost of sales was due primarily to decrease in sales as well as the effect of COVID-19 on the materials supply chain. The primary components of cost of sales include the cost of manufacturing the CBD product. For the year ended December 31, 2020, the Company’s cost of sales amounted to $2.7 million which includes cost of sales with a related party of $0.4 million. Cost of sales primarily increased related to increaseproducts and PPE. The decrease in volume.
Operating Expenses
Operating expenses as more of our revenue was generated from product distribution requiring less sales and marketing efforts, and $0.4 million decrease in general and administrative costs mainly related to a reduction in head count costs ..
The decrease in general and administrative expenses of $1,087,339 or 39% to $1,718,687 for the year ended December 31, 2021 as compared to $2,806,026 for the year ended December 31, 2020, was primarily due to decreases in sales commissions, sales and marketing activities as well as general activities, partially offset by an increase in professional fees relating the changevarious transactions relating to the merger.
The increase in valueproduction related operating expenses of the underlying derivative liability and conversion of notes in 2020.
Within the conversiontotal G&A category of notesexpenses, sales and interest into common and preferred shares duringmarketing expenses decreased from $1.505 million to $0.378 million for the year12 months ended December 31, 2019. We did not have comparable gains or losses during2021 when compared to the year12 months ended December 31, 2020, as there was less conversion activity inprimarily due to sales commissions paid for PPE sales, the Panacea brand development, advertising fees for the Facebook program and the new Panacea website.
Also, within the total G&A category of expenses, professional, legal, and consulting fees were $0.779 million for the 12 months ended December 31, 2021 when compared to $0.312 million the 12 months ended December 31, 2020. In 2020, bylegal expenses were attributed to the note holders.
Other income (expense)
Other income for the year ended December 31, 20192021 increased by $1,361,823, or 5,235%, to $1.01,387,835 as compared to $26,012 for the year ended December 31, 2020.
24 |
Summary of Cash Flows
Years ended December 31, | ||||||||
2021 | 2020 | |||||||
Cash (used in) / provided by | ||||||||
Operating activities | $ | (3,922,090 | ) | $ | (7,646,723 | ) | ||
Investing activities | 522,533 | (3,080,388 | ) | |||||
Financing activities | 3,334,953 | 2,295,981 | ||||||
Net decrease in cash and cash equivalents | $ | (64,605 | ) | $ | (8,431,130 | ) |
Cash flows from operating activities
Net cash used in operating activities was $3,922,090 for the year ended December 31, 2021 as compared to $7,646,723 for the year ended December 31, 2020. The decrease in 2021 was due primarily to decreases in revenues as well as cost of sales and operating expenses as well as favorable changes to working capital. The largest source of operating cash is from our customers. A large majority of our customers purchase CBD on-line, so credit card payments are collected and paid within 1-2 business days. Other white label and contract manufacturing customers pay before the products are released. Some larger customers have either net 10-, 2%- or 30-day net terms. Net cash used in operating activities was $3.922 million and $7.647 million for 12 months ended December 31, for 2021 and 2020, respectively.
Cash flows from investing activities
Net cash provided by investing activities was $522,533 for the year ended December 31, 2021 as compared to net cash used in investing activities of $3,080,388 for the year ended December 31, 2020. The increase of cash provided in interest expense is2021 was due primarily to a significant decrease in fixed asset acquisitions as well as increases in proceeds from sales of fixed assets and marketable securities. Machinery and building retrofitting expenses and cash received in the acquisition were the investing activities for the 12 months ended December 31, 2021 and totaled $0.522 million and $3.08 million for December 31, 2020.
Cash flows from financing activities
During the year ended December 31, 2021, cash provided by financing activities totaled $3,334,953 which includes proceeds of $2,302,468 from related to increasepart notes, $1,000,000 from convertible notes, and $243,042 from a related party payroll protection loan partially offset by repayments of notes payable in principle balance outstanding, amortizationthe amount of debt discount$210,556.
During the year ended December 31, 2020, cash provided by financing activities totaled $2,295,981 which includes of $5,984,226 from related party notes payable and debt issuance cost related to our convertible note payable issued during 2019.
Liquidity and Capital Resources
On December 31, 2021, we had approximately $3.8 million of liquid marketable securities and $20,000 in cash. There have been no material changes as of the date of this Report. Our Chief Executive Officer holds the XXII shares pursuant to the pledge agreement and has the power at any time to permit us to sell the shares to provide working capital. We have borrowed substantial sums from Leslie Buttorff, our inception in 2008,Chief Executive Officer, to meet its working capital obligations. On June 30, 2021 Panacea issued an affiliate of Ms. Buttorff a 12% demand promissory note for $4.063 million and issued Ms. Buttorff a 10% demand promissory note for $1.624 million secured by a pledge of certain XXII common stock owned by Panacea. Additionally, we have generated lossesa line of credit with Ms. Buttorff through which it may borrow up to $1 million at a 10% annual interest rate.
We do not have sufficient cash resources to sustain our operations for the next 12 months. This raises substantial doubt about our ability to continue as a going concern as we are dependent on obtaining financing from operations. Asone or more debt or equity offerings or further loans from Ms. Buttorff assuming she agrees to advance further funds.
25 |
These consolidated financial statements are presented on the basis that we will continue as a going concern. The going concern concept contemplates the realization of December 31, 2020,assets and satisfaction of liabilities in the normal course of business. No adjustment has been made to the carrying amount and classification of our accumulated deficit was $30.4 million. Asassets and the carrying amount of December 31, 2020,our liabilities based on the going concern uncertainty. These factors raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the date of this Report. Management cannot provide assurance that we had $25,139 ofwill ultimately achieve profitable operations or become cash and working capital deficit of $4.9 million. Accordingly,flow positive or raise additional debt and/or equity capital. In addition, due to insufficient revenue, we will need to obtain further funding through public or private equity offerings, debt financing, collaboration arrangements or other sources.sources in order to maintain active business operations. We currently do not have sufficient cash flow to pay our ongoing financial obligations on a consistent basis. The issuance of any additional shares of common stock, preferred stock or convertible securities could be substantially dilutive to our shareholders.stockholders. In addition, adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, we will be forced to borrow additional sums from our Chief Executive Officer or delay, reduce or eliminate our operationsresearch and development programs, we may not be able to continue as a going concern.
Off Balance Sheet Arrangements
As of December 31, 2020,2021, we had no material off-balance sheet arrangements.
Critical Accounting Estimates and New Accounting Pronouncements
Critical Accounting Estimates
The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with US GAAP. The preparation of our consolidated financial statements in accordance with accounting principles generally accepted in the United States requires its management to make estimates and assumptionsjudgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosuresdisclosures. Our management bases its estimates, assumptions and judgments on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements. Managementstatements which, in turn, could change the results from those reported. In addition, actual results may differ from these estimates and such differences could be material to our financial position and results of operations.
Critical accounting estimates are those that our management considers anthe most important to the portrayal of our financial condition and results of operations because they require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting estimateestimates in relation to be critical if it requires assumptionsits consolidated financial statements include those related to:
● | Goodwill and intangible assets | |
● | Fair value of marketable securities | |
● | Incremental Borrowing Rate used Right of Use Asset Calculations | |
● | Business combinations |
Goodwill and Indefinite-Lived Intangibles
We allocate the cost of acquired companies to be made that were uncertainthe identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the estimate wascompletion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, review of projected future operating results and changes in the estimate or different estimates that could have been selected could have a material impact on our resultsbusiness plans, economic projections, anticipated highest and best use of operations or financial condition.
26 |
Goodwill is not amortized but is tested for impairment annually and whenever events or circumstances change that indicate impairment may have occurred. We tested goodwill for impairment and determined there was no impairment and found not impairment charge based on the excess of a reporting unit’s carrying amount over our fair value.
Fair value of marketable securities
Marketable securities are recorded at fair value using the quoted market prices and changes in fair value are recorded as net realized gains or losses in comprehensive income. We monitor these investments for impairment and make appropriate reductions in carrying values as necessary.
Incremental Borrowing Rate used Right of Use Asset Calculations
We determine if a contract is a lease or contains a lease at the inception of the contract and reassess that conclusion if the contract is modified. All leases are assessed for classification as an operating lease or a finance lease. Operating lease right-of-use, or ROU, assets are included in non-current other assets on our consolidated balance sheet. Operating lease liabilities are separated into a current portion, included within other accrued liabilities on our consolidated balance sheet, and a non-current portion, included within other long-term liabilities on our consolidated balance sheet. We do not have any finance lease ROU assets or liabilities. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We do not obtain and control the right to use the Black-Scholes option-pricing formulaidentified asset until the lease commencement date.
Our lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to estimatebe paid over the lease term. Because the interest rate implicit in the lease is not readily determinable, we generally use our incremental borrowing rate to discount the lease payments to present value. The estimated incremental borrowing rate is derived from information available at the lease commencement date. We factor in publicly available data for instruments with similar characteristics when calculating our incremental borrowing rates. Our ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor. Variable lease payments are expensed as incurred and do not factor into the measurement of the applicable ROU asset or lease liability.
Business Combinations
We have applied significant estimates and judgments in order to determine the fair value of stock options. The Black-Scholes option-pricing formula uses complexthe identified assets acquired, liabilities assumed and subjective inputs, includinggoodwill recognized in connection with our business combinations to ensure the expected lifevalue of the options, stock price volatility, dividendsassets and liabilities acquired are recognized at fair value as of the pre-vesting option forfeiture rate. The assumptions used in calculatingacquisition date. In measuring the fair value, we utilize valuation techniques consistent with the market approach, income approach, or cost approach.
The valuation of stock-based awards representthe identifiable assets and liabilities includes assumptions made in performing the valuation, such as projected revenue, weighted average cost of capital, discount rates, estimated useful lives, and other relevant assessments. These assessments can be significantly affected by our best estimates, but thesejudgments, and assumptions. If actual results are not consistent with our estimates, involve inherent uncertainties and the application of management judgment. As a result,judgments, or assumptions, or if factors change and we use different assumptions, our stock-based compensation expense could be materially differentadditional or new information arises in the future.
A smaller reporting company is not required to provide the information required by this Item.item.
27 |
Index to Financial Statements Required by Article 8 of Regulation S-X:
Audited Financial Statements:
CONTENTS | ||
F-2 | ||
F-5 | ||
F-6 | ||
F-7 | ||
F-8 | ||
F-9 |
F-1 |
To the Boardshareholders and the board of Directors and Stockholdersdirectors of
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheetssheet of Exactus,Panacea Life Sciences Holdings, Inc. and Subsidiaries (the Company)“Company”) as of December 31, 2020 and 2019, and2021, the related consolidated statementsstatement of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year periodyear then ended, December 31, 2020, and the related notes (collectively referred to as the financial statements)“financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019,2021, and the results of its operations and its cash flows for each of the years in the two-year periodyear then ended, December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.
Substantial Doubt about the Company’s Ability to Continue as a Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has an accumulated deficit, recurringCompany’s significant operating losses and expects continuing future losses that raisesraise substantial doubt about the Company’sits ability to continue as a going concern. Management's evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits.audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)(“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our auditsaudit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our auditsaudit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our auditsaudit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provideaudit provides a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or are required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgments.
We determined that there are no critical audit matters.
/s/ BF Borgers CPA PC | |
BF Borgers CPA PC | |
We have served as the Company’s auditor since 2021 | |
Lakewood, CO | |
March 25, 2022 |
Firm ID is 5041.
F-2 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Panacea Life Sciences, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheet of Panacea Life Sciences, Inc. (the Company) as of December 31, 2020, and the related statements of operations, stockholders’ equity, and cash flows for the year ended December 31, 2020, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, and the results of its operations and its cash flows for the year ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.
The Company’s Ability to Continue as a Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and will require additional capital to continue as a going concern. This raises substantial doubt about the Company’s ability to continue as a going concern. Management’s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
F-3 |
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.
Goodwill
Description of the Matter
As described in Note 2 to the financial statements, the Company’s goodwill balance was $2,188,810 as of December 31, 2020. The Company performs goodwill impairment testing annually as of December 31 or more frequently if events or circumstances indicate the carrying value of a reporting unit that includes goodwill might exceed the fair value of that reporting unit. The Company estimates the fair value of each reporting unit based on a combination of an income approach that utilizes discounted cash flows specific to each reporting unit.
We identified the determination of the fair value of each reporting unit included in the Company’s annual goodwill impairment test as a critical audit matter. The key assumptions utilized by management in the determination of the fair value under the income approach include projected revenue growth rates, profit margins, operating expenses, terminal value and discount rates for the Company. Auditing management’s valuation methods and assumptions utilized in estimating the fair value involved especially challenging and subjective auditor since 2014.judgement due to the nature and extent of audit effort required to address this matter, including the extent of specialized skill or knowledge needed.
How we addressed the matter in our Audit
The primary procedures we performed to address this critical audit matter included:
● | Evaluating management’s review of key assumptions used in determining the valuation methodology for the measurement of the fair value of each reporting unit. | |
● | Evaluating management’s ability to forecast cash flows and the reasonableness of management assumptions used to develop cash flow forecasts and projections by comparing them to historical operating performance, internal and external communications made by the Company and forecasted information included in industry reports. | |
● | Testing the accuracy and completeness of the data used by management to develop its projections. | |
● | Utilizing personnel with specialized knowledge and skill of valuation techniques to assist in: (i) evaluating the methodologies used by management to determine the fair value of each reporting unit including the weighting of income and market approaches; (ii) assessing the underlying projections by comparing key assumptions to historical levels; (iii) evaluating the reasonableness of assumptions used in the income approach including discount rates, terminal values, present value factors; and (iv) testing the mathematical accuracy of the Company’s calculations. |
/s/ RBSM LLP | |
We have served as the Company’s auditor since 2021 | |
Las Vegas, Nevada | |
December 17, 2021 | |
Firm ID is 587. |
F-4 |
Panacea Life Sciences Holdings, Inc. and Subsidiaries
Consolidated BalanceBalance Sheets
December 31, | ||
2020 | 2019 | |
Restated | ||
ASSETS | ||
Current Assets: | ||
Cash and cash equivalents | $25,139 | $18,405 |
Accounts receivable, net | - | 55,725 |
Accounts receivable - related party | - | 18,860 |
Inventory, net | 10,712 | 1,337,809 |
Prepaid expenses and other current assets | 15,258 | 248,776 |
Prepaid expenses and other current assets - related party | - | 622,160 |
Due from related parties | - | 127,500 |
Total current assets | 51,109 | 2,429,235 |
Deposits | - | 80,000 |
Prepaid expenses and other assets - related party | - | 2,492,045 |
Property and equipment, net | 20,159 | 477,433 |
Intangible assets, net | - | 2,147,311 |
Operating lease right-of-use assets, net | - | 390,810 |
Total Assets | $71,268 | $8,016,834 |
LIABILITIES AND (DEFICIT) EQUITY | ||
Current Liabilities: | ||
Accounts payable | $2,027,507 | $1,442,409 |
Accounts payable - related parties | 506,585 | 454,511 |
Accrued expenses | 620,391 | 238,010 |
Unearned revenue - related party | - | 215,000 |
Notes payable - current portion | 130,344 | - |
Note payable - related parties | 115,517 | 55,556 |
Subscription payable | 250,000 | 250,000 |
Convertible notes, net of discounts | 646,036 | 85,906 |
Convertible notes – related party | 50,250 | - |
Derivative liability | 237,022 | 880,410 |
Interest payable | 52,051 | 16,677 |
Operating lease liabilities, current portion | 269,115 | 169,869 |
Total current liabilities | 4,904,818 | 3,808,348 |
Notes payable - long term | 205,166 | - |
Convertible notes payable - long-term portion | - | 100,000 |
Operating lease liabilities - long-term portion | - | 220,942 |
Total long-term liabilities | 205,166 | 320,942 |
Total Liabilities | 5,109,984 | 4,129,290 |
Commitment and contingencies (see Note 11) | ||
(Deficit) Equity: | ||
Exactus, Inc. Stockholders' (Deficit) Equity | ||
Preferred stock: 50,000,000 shares authorized; $0.0001 par value, 5,266,466 undesignated shares | ||
Preferred stock Series A: 1,000,000 shares designated; $0.0001 par value, 323,019 and 353,109 shares issued and outstanding, respectively | 32 | 35 |
Preferred stock Series B-1: 32,000,000 shares designated; $0.0001 par value, 1,650,000, shares issued and outstanding | 165 | 165 |
Preferred stock Series B-2: 10,000,000 shares designated; $0.0001 par value, 7,516,000 shares issued and outstanding | 752 | 752 |
Preferred stock Series C: 1,733,334 shares designated;$0.0001 par value, none shares issued and outstanding | - | - |
Preferred stock Series D: 200 shares designated; $0.0001 par value, 18 shares issued and outstanding | - | - |
Preferred stock Series E: 10,000 shares designated; $0.0001 par value, 10,000 shares issued and outstanding | 1 | 1 |
Common stock: 650,000,000 shares authorized; $0.0001 par value, 56,356,431 and 43,819,325 shares issued and outstanding, respectively | 5,636 | 4,382 |
Common stock to be issued (100,000 and 664,580 shares to be issued, respectively) | 10 | 66 |
Additional paid-in capital | 27,485,796 | 25,343,293 |
Due from related party | (128,489) | - |
Accumulated deficit | (30,384,380) | (20,923,681) |
Total Exactus Inc. Stockholders' (Deficit) Equity | (3,020,477) | 4,425,013 |
Non-controlling interest in subsidiary | (2,018,239) | (537,469) |
Total (Deficit) Equity | (5,038,716) | 3,887,544 |
Total Liabilities and (Deficit) Equity | $71,268 | $8,016,834 |
December 31, 2021 | December 31, 2020 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 19,774 | $ | 84,379 | ||||
Accounts receivable, net | 244,496 | 147,302 | ||||||
Other receivables, related party | 500,000 | - | ||||||
Inventory | 4,264,277 | 8,409,734 | ||||||
Marketable securities related party | 3,791,483 | 2,853,437 | ||||||
Prepaid expenses and other current assets | 278,328 | 27,375 | ||||||
TOTAL CURRENT ASSETS | 9,098,358 | 11,522,227 | ||||||
Operating lease right-of-use asset, net, related party | 3,595,100 | 3,937,706 | ||||||
Property and equipment, net | 8,839,982 | 13,590,286 | ||||||
Intangible assets, net | 61,401 | 122,801 | ||||||
Goodwill | 2,188,810 | 2,188,810 | ||||||
TOTAL ASSETS | $ | 23,783,651 | $ | 31,361,830 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable and accrued expenses | $ | 1,685,825 | $ | 1,765,267 | ||||
Operating lease liability, current portion, related party | 1,624,090 | 1,162,869 | ||||||
Note payable-current, related party | 6,441,866 | 15,061,044 | ||||||
Convertible note payable, net | 220,005 | - | ||||||
Paycheck protection loan, SBA Loan | 99,100 | 273,300 | ||||||
TOTAL CURRENT LIABILITIES: | 10,070,886 | 18,262,480 | ||||||
Operating lease liability, long-term portion, related party | 3,347,335 | 3,692,392 | ||||||
Other long-term liabilities, related party | 3,263,028 | 2,698,659 | ||||||
TOTAL LIABILITIES | 16,681,249 | 24,653,531 | ||||||
Commitments and contingencies | - | - | ||||||
STOCKHOLDERS’ EQUITY | ||||||||
Series A Preferred Stock: $ | Par Value, shares designated; and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.- | - | ||||||
Series B-1 Preferred: $ | Par Value, shares designated; and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.150 | - | ||||||
Series B-2 Preferred: $ and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively. | Par Value, shares designated;600 | - | ||||||
Series C Preferred: $ | Par Value, shares designated; and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.100 | 100 | ||||||
Series C-1 Preferred: $ | Par Value, shares designated and and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.1 | 1 | ||||||
Series C-2 Preferred: $ | Par Value, and shares designated and and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.1 | - | ||||||
Series D Preferred: $ | Par Value, shares designated and and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.1 | 1 | ||||||
Preferred Stock Value | ||||||||
Common Stock: $ | Par Value, shares authorized; and shares issued and outstanding on December 31, 2021 and December 31, 2020 respectively.1,407 | 1,692 | ||||||
Additional paid in capital | 23,865,155 | 18,689,119 | ||||||
Accumulated deficit | (16,765,013 | ) | (11,982,614 | ) | ||||
TOTAL STOCKHOLDERS’ EQUITY | 7,102,402 | 6,708,299 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 23,783,651 | $ | 31,361,830 |
The accompanying notes are an integral part of these consolidated financial statements.
F-5 |
Panacea Life Sciences Holdings, Inc. and Subsidiaries
Consolidated Statements of Operations
Years Ended December 31, | ||
2020 | 2019 | |
(Restated) | ||
Net revenues | $1,755,210 | $183,234 |
Net revenues - related party | 315,800 | 162,446 |
Total net revenues | 2,071,010 | 345,680 |
Cost of sales | 2,301,843 | 1,939,382 |
Cost of sales - related party | 417,783 | 106,752 |
Total cost of sales | 2,719,626 | 2,046,134 |
Gross loss | (648,616) | (1,700,454) |
Operating Expenses: | ||
General and administration | 2,679,337 | 2,816,308 |
Impairment | 4,577,406 | 250,192 |
Selling and marketing expenses | 638,632 | 948,296 |
Professional and consulting | 2,010,935 | 4,935,394 |
Research and development | - | 22,100 |
Total operating expenses | 9,906,310 | 8,972,290 |
Loss from operations | (10,554,926) | (10,672,744) |
Other (expenses) income | ||
Derivative gain (loss) | 513,674 | (1,871,583) |
Loss on stock settlement | (23,000) | - |
Gain on settlement of debt, net | 126,222 | 3,004,630 |
Interest expense | (1,003,439) | (479,111) |
Total other (expense) income, net | (386,543) | 653,936 |
Loss before provision for income taxes | (10,941,469) | (10,018,808) |
Provision for income taxes | - | - |
Net loss | (10,941,469) | (10,018,808) |
Net loss attributable to non-controlling interest | 1,480,770 | 537,469 |
Net loss attributable to Exactus, Inc. | (9,460,699) | (9,481,339) |
Deemed dividend on preferred stock | - | (904,450) |
Net loss available to Exactus, Inc. common stockholders | $(9,460,699) | $(10,385,789) |
Net loss per common share - basic and diluted | $(0.22) | $(0.30) |
Net loss attributable to non-controlling interest per common share – basic and diluted | $(0.03) | $(0.02) |
Net loss available to Exactus, Inc. common stockholders per common share - basic and diluted | $(0.19) | $(0.31) |
Weighted average number of common shares outstanding: | ||
basic and diluted | 49,688,543 | 33,899,585 |
for the year ending December 31, | ||||||||
2021 | 2020 | |||||||
REVENUE | $ | 2,059,627 | $ | 9,017,720 | ||||
COST OF SALES | 1,519,049 | 7,020,223 | ||||||
GROSS PROFIT | 540,578 | 1,997,497 | ||||||
OPERATING EXPENSES | ||||||||
Operating expenses | 4,959,059 | 4,449,313 | ||||||
General and administrative expenses | 1,518,687 | 2,806,026 | ||||||
TOTAL OPERATING EXPENSES | 6,477,746 | 7,255,339 | ||||||
LOSS FROM OPERATIONS | (5,937,168 | ) | (5,257,842 | ) | ||||
OTHER INCOME (EXPENSES) | ||||||||
Interest expense | (1,105,243 | ) | (1,511,579 | ) | ||||
Unrealized gain (loss) on marketable securities, net | 1,008,046 | 1,426,718 | ||||||
Realized gain on sale of securities | 160,296 | - | ||||||
Other income (loss) | - | (20,180 | ) | |||||
Employer retention credit | 396,679 | - | ||||||
Rental Income | 236,560 | 271,767 | ||||||
Loss on sale of assets | (297,351 | ) | (140,714 | ) | ||||
Gain on extinguishment of debt | 755,782 | - | ||||||
TOTAL OTHER INCOME (EXPENSE) | 1,154,769 | 26,012 | ||||||
INCOME (LOSS) BEFORE INCOME TAXES | (4,782,399 | ) | (5,231,830 | ) | ||||
TAXES | - | - | ||||||
NET INCOME (LOSS) | $ | (4,782,399 | ) | $ | (5,231,830 | ) | ||
Per-share data | ||||||||
Basic and diluted loss per share | $ | (0.27 | ) | $ | (0.31 | ) | ||
Weighted average number of common shares outstanding | 17,820,545 | 16,915,706 |
The accompanying notes are an integral part of these consolidated financial statements.
F-6 |
Panacea Life Sciences, Inc. and Subsidiaries
Statements of Stockholders' Equity (Deficit)
Preferred Stock | Common Stock | Additional Paid-in | Accumulated | Total Stockholder’s | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
Balance as of December 31, 2019 | 1,020,000 | $ | 102 | 16,915,706 | $ | 1,692 | $ | 18,689,119 | $ | (6,750,784 | ) | $ | 11,940,129 | |||||||||||||||
Shares issued for acquisition | ||||||||||||||||||||||||||||
Shares issued for acquisition , shares | ||||||||||||||||||||||||||||
Series A Preferred stock conversion to common stock | ||||||||||||||||||||||||||||
Series A Preferred stock conversion to common stock, shares | ||||||||||||||||||||||||||||
Issuance of common stock at split | ||||||||||||||||||||||||||||
Conversion of Common Stock to Series C-2 Preferred Stock to equity | ||||||||||||||||||||||||||||
Conversion of Common Stock to Series C-2 Preferred Stock to equity, shares | ||||||||||||||||||||||||||||
Issuance of convertible debt and warrants, net of issuance costs | ||||||||||||||||||||||||||||
Net Income (Loss) | - | - | - | - | - | (5,231,830 | ) | (5,231,830 | ) | |||||||||||||||||||
Balance as of December 31, 2020 | 1,020,000 | $ | 102 | 16,915,706 | $ | 1,692 | $ | 18,689,119 | $ | (11,982,614 | ) | $ | 6,708,299 | |||||||||||||||
Shares issued for acquisition | 7,500,450 | 750 | 4,408,002 | 440 | 4,377,802 | 4,378,992 | ||||||||||||||||||||||
Series A Preferred stock conversion to common stock | (100 | ) | - | 71,429 | 7 | (7 | ) | - | ||||||||||||||||||||
Issuance of common stock at split | - | - | - | - | - | |||||||||||||||||||||||
Conversion of Common Stock to Series C-2 Preferred Stock to equity | 10,000 | 1 | (7,321,429 | ) | (732 | ) | 731 | - | ||||||||||||||||||||
Issuance of convertible debt and warrants, net of issuance costs | - | - | - | - | 797,510 | 797,510 | ||||||||||||||||||||||
Net Income (Loss) | - | $ | - | - | $ | - | - | $ | (4,782,399 | ) | $ | (4,782,399 | ) | |||||||||||||||
Balance as of December 31, 2021 | 8,530,350 | $ | 853 | 14,073,708 | $ | 1,407 | $ | 23,865,155 | $ | (16,765,013 | ) | $ | 7,102,402 |
The accompanying notes are an integral part of these consolidated financial statements
F-7 |
Preferred Stock | Common Stock | ||||||||||||||||||||
Series A | Series B-1 | Series B-2 | Series C | Series D | Series E | Issued | Unissued | Paid in | Due from related | Accumulated Deficit (As | Non-controlling | Total (As | |||||||||
Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | party | restated) | Interest | restated) | |
Balance, December 31, 2018 | - | - | 2,800,000 | $280 | 8,684,000 | $868 | 1,733,334 | $173 | 45 | $1 | - | $- | 6,233,524 | $623 | - | $- | 7,111,445 | $(10,537,892) | $- | $(3,424,502) | |
Preferred stock issued upon conversion of convertible debt | - | 84 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 849,276 | - | - | 849,360 | |
Preferred stock issued for private placement | - | 6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55,084 | - | - | 55,090 | |
Preferred stock issued pursuant to Management and Services Agreement | - | - | - | - | - | - | - | - | - | - | 10,000 | 1 | - | - | - | - | 3,374,999 | - | - | 3,375,000 | |
Conversion of Series A Preferred Stock to Common Stock | (551,341) | (55) | - | - | - | - | - | - | - | - | - | - | 2,756,705 | 276 | - | - | (221) | - | - | - | |
Conversion of Series B-1 Preferred Stock to Common Stock | - | - | (1,150,000) | (115) | - | - | - | - | - | - | - | - | 143,750 | 14 | - | - | 101 | - | - | - | |
Conversion of Series B-2 Preferred Stock to Common Stock | - | - | - | - | (1,168,000) | (116) | - | - | - | - | - | - | 146,000 | 15 | - | - | 101 | - | - | - | |
Conversion of Series D Preferred Stock to Common Stock | - | - | - | - | - | - | - | - | (27) | (1) | - | - | 675,000 | 68 | - | - | (67) | - | - | - | |
Deemed dividend on Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 904,450 | (904,450) | - | - | |
Common stock issued for private placement | - | - | - | - | - | - | - | - | - | - | - | - | 22,187,007 | 2,219 | - | - | 7,213,161 | - | - | 7,215,380 | |
Common Stock issued for Master Supply | - | - | - | - | - | - | - | - | - | - | - | - | 8,385,691 | 839 | - | - | (839) | - | - | - | |
Common stock issued for debt settlement | - | - | - | - | - | - | - | - | - | - | - | - | 203,080 | 20 | - | - | 40,596 | - | - | 40,616 | |
Common stock issued for purchase of membership interest in subsidiary | - | - | - | - | - | - | - | - | - | - | - | - | 937,500 | 94 | - | - | 989,906 | - | - | 990,000 | |
Common stock issued for purchase of membership interest in subsidiary | - | - | - | - | - | - | - | - | - | - | - | - | 503,298 | 50 | - | - | 449,950 | - | - | 450,000 | |
Common stock unissued for pursuant to Asset Purchase Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100,000 | 10 | 69,990 | - | - | 70,000 | |
Common stock issued upon conversion of convertible debt | - | - | - | - | - | - | - | - | - | - | - | - | 250,000 | 25 | - | - | 195,975 | - | - | 196,000 | |
Common stock issued and unissued for prepaid services | - | - | - | - | - | - | - | - | - | - | - | - | 150,000 | 15 | 100,000 | 10 | 120,355 | - | - | 120,380 | |
Common stock issued and unissued for services | - | - | - | - | - | - | - | - | - | - | - | - | 1,312,490 | 131 | 20,830 | 2 | 925,714 | - | - | 925,847 | |
Stock-based compensation in connection with restricted common stock award grants | - | - | - | - | - | - | - | - | - | - | - | - | 115,280 | 11 | 68,750 | 7 | 143,896 | - | - | 143,914 | |
Common stock and preferred stock cancelled per Surrender and Release Agreement | - | - | - | (1,733,334) | (173) | - | - | - | - | (180,000) | (18) | - | - | 191 | - | - | - | ||||
Common stock issued for exercise of stock options | - | - | - | - | - | - | - | - | - | - | - | - | 375,000 | 37 | (37) | - | - | - | |||
Stock options granted for services | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,276,636 | - | - | 1,276,636 | |
Stock warrants granted for services | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,428,243 | - | - | 1,428,243 | |
Stock warrants granted as debt discount | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 194,388 | - | - | 194,388 | |
Net Loss | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | (9,481,339) | (537,469) | (10,224,506) | ||
Balance, December 31, 2019 | 353,109 | $35 | 1,650,000 | $165 | 7,516,000 | $752 | - | $- | 18 | $- | 10,000 | 43,819,325 | $4,382 | 664,580 | $66 | $25,343,293 | $(20,923,681) | $(537,469) | $3,887,544 | ||
Common stock issued for private placement | - | - | - | - | - | - | - | - | - | - | - | - | 3,700,000 | 370 | - | - | 384,630 | - | - | - | 385,000 |
Common stock issued for unissued common stock | - | - | - | - | - | - | - | - | - | - | - | - | 475,000 | 47 | (475,000) | (47) | - | - | - | - | - |
Conversion of Series A Preferred Stock to Common Stock | (30,090) | (3) | - | - | - | - | - | - | - | - | - | - | 150,450 | 15 | - | - | (12) | - | - | - | - |
Common stock issued for services | - | - | - | - | - | - | - | - | - | - | - | - | 765,000 | 77 | - | - | 378,446 | - | - | - | 378,523 |
Stock-based compensation in connection with restricted common stock award grants | - | - | - | - | - | - | - | - | - | - | - | - | 3,766,635 | 377 | (89,580) | (9) | 664,418 | - | - | - | 696,786 |
Stock options granted for services | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 276,736 | - | - | - | 276,736 |
Common stock issued upon conversion of convertible debt and accrued interest | - | - | - | - | - | - | - | - | - | - | - | - | 2,397,937 | 240 | - | - | 239,838 | - | - | - | 240,078 |
Common stock issued in connection with forbearance agreement | - | - | - | - | - | - | - | - | - | - | - | - | 500,000 | 50 | - | - | 89,950 | - | - | - | 90,000 |
Due from related parties reclassified to equity | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | (128,489) | - | - | (128,489) |
Common stock issued for private placement in fiscal 2019 | - | - | - | - | - | - | - | - | - | - | - | - | 12,084 | 1 | - | - | (1) | - | - | - | - |
Common stock issued for services and accounts payable | - | - | - | - | - | - | - | - | - | - | - | - | 750,000 | 75 | - | - | 70,500 | - | - | - | 70,575 |
Common stock issued for exercise of stock options | - | - | - | - | - | - | - | - | - | - | - | - | 20,000 | 2 | - | - | 5,998 | - | - | - | 6,000 |
Net Loss for the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | (9,460,699) | (1,480,770) | (10,941,469) |
Balance, December 31, 2020 | 323,019 | $ 32 | 1,650,000 | $ 165 | 7,516,000 | $ 752 | - | $ - | 18 | $ - | 10,000 | 56,356,431 | $ 5,636 | 100,000 | $ 10 | $ 27,485,796 | $ (128,489) | $(30,384,380) | $(2,018,239) | $(5,038,716) |
Panacea Life Sciences, Inc.
Statements of Cash Flows
For the years ended December 31, | ||||||||
2021 | 2020 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (4,782,399 | ) | $ | (5,231,830 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
Depreciation | 1,675,786 | 1,630,602 | ||||||
Realized gain on sale of securities | (160,296 | ) | - | |||||
Unrealized gain on marketable securities | (1,008,046 | ) | (1,426,718 | ) | ||||
Fixed Asset Disposal Loss | 297,351 | 140,714 | ||||||
Amortization of intangible assets | 61,400 | 61,400 | ||||||
Noncash settlement of convertible note and accrued interest | (755,782 | ) | - | |||||
Amortization of debt discount and non-cash interest expense | 117,515 | - | ||||||
Changes in operating assets and liabilities | ||||||||
Accounts receivable | (97,194 | ) | 151,676 | |||||
Inventory | (547,910 | ) | (5,049,759 | ) | ||||
Prepaid expense and other assets | (250,953 | ) | 963,525 | |||||
Accounts payable and accrued expenses | 1,069,668 | 654,888 | ||||||
Operating lease liability, net | 458,770 | 458,779 | ||||||
Net cash used in operating activities | (3,922,090 | ) | (7,646,723 | ) | ||||
Cash flows from investing activities | ||||||||
Net cash received from acquisitions | 9,157 | - | ||||||
Proceeds from sale of marketable securities | 230,296 | - | ||||||
Proceeds from sale of fixed assets | 446,026 | 119,623 | ||||||
Net fixed asset acquisitions | (162,946 | ) | (3,200,011 | ) | ||||
Net Cash provided by (used in) investing activities | 522,533 | (3,080,388 | ) | |||||
Cash flows from financing activities | ||||||||
Repayment of notes payable | (75,556 | ) | - | |||||
Proceeds from payroll protection loan, SBA loan | - | 273,300 | ||||||
Proceeds from payroll protection loan - related party | 243,041 | - | ||||||
Payments of principal on notes payable | (135,000 | ) | (3,961,545 | ) | ||||
Proceeds from Note payable-related party | 2,302,468 | 5,984,226 | ||||||
Proceeds from issuance of convertible notes, net of discount | 1,000,000 | - | ||||||
Cash provided by financing activities | 3,334,953 | 2,295,981 | ||||||
Net increase (decrease) in Cash and Cash Equivalents | (64,605 | ) | (8,431,130 | ) | ||||
Cash and Cash Equivalents, Beginning of Period | 84,379 | 8,515,509 | ||||||
Cash and Cash Equivalents, End of Period | $ | 19,774 | $ | 84,379 | ||||
Supplemental Disclosure of Cash Flow Information | ||||||||
Cash paid for income taxes during the year | $ | - | $ | - | ||||
Interest payments during the year | $ | - | $ | 583,333 | ||||
Noncash investing and financing activity | ||||||||
Non-cash Receivable - related party | $ | 500,000 | $ | - | ||||
Related party loan repayment with inventory | $ | 4,693,367 | $ | - | ||||
Non-cash fixed asset disposal as part of the reverse acquisition | $ | 3,058,457 | $ | - | ||||
Capitalized assets purchased on account - related party | $ | 564,369 | $ | 1,696,348 | ||||
Liabilities from acquisition | $ | 1,096,782 | $ | - | ||||
Debt retired in merger, related party | $ | 12,718,441 | $ | - | ||||
Preferred Series B-1 Issuance in Acquisition | $ | 150 | $ | - | ||||
Preferred Series B-2 Issuance in Acquisition | $ | 600 | $ | - | ||||
Common stock issued for the reverse merger with Exactus | $ | 4,369,085 | $ | - | ||||
Discounts related to issuance of convertible debt and warrants | $ | 997,510 | $ | - |
The accompanying notes are an integral part of these consolidated financial statements.
F-8 |
Years Ended December 31, | ||
2020 | 2019 | |
Cash Flows From Operating Activities: | ||
Net loss | $(10,941,469) | $(10,018,808) |
Adjustments to reconcile net loss to cash used in operating activities: | ||
Depreciation | 85,233 | 63,770 |
Derivative (gain) loss | (513,674) | 1,871,583 |
Gain on extinguishment of debt | (126,222) | - |
Stock-based compensation | 1,352,045 | 3,774,640 |
Bad debt expense | 149,907 | 32,577 |
Impairment expense | 4,577,406 | 250,192 |
Inventory reserve | 678,870 | 1,560,545 |
Amortization of prepaid stock-based expenses | 771,405 | 285,494 |
Amortization of discount and debt issuance costs for convertible notes | 836,316 | 425,712 |
Amortization of intangible assets | 734,584 | 828,526 |
Non-cash interest expense | 92,042 | - |
Amortization of operating lease right-of-use assets | 121,695 | - |
Loss (gain) on settlement of debt | 23,000 | (3,004,630) |
Changes in operating assets and liabilities: | ||
(Increase) decrease in operating assets: | ||
Accounts receivable | (94,182) | (88,302) |
Accounts receivable - related party | 18,860 | (18,860) |
Inventory | 648,227 | (2,864,383) |
Prepaid expenses and other assets | 163,370 | (140,765) |
Deposit | 40,000 | (80,000) |
Accounts payable | 614,004 | 518,979 |
Accounts payable - related party | (25,842) | 454,511 |
Accrued expenses | 382,381 | 201,136 |
Unearned revenues | (215,000) | 215,000 |
Settlement payable | - | (20,000) |
Interest payable | 49,054 | 6,793 |
Operating lease liabilities | (121,696) | - |
Net Cash Used In Operating Activities | (699,686) | (5,746,290) |
Cash Flows From Investing Activities: | ||
Purchase of membership interest in subsidiary | - | (1,500,000) |
Purchase of property and equipment | - | (541,203) |
Net Cash Used in Investing Activities | - | (2,041,203) |
Cash Flows From Financing Activities: | ||
Increase in due to related party classified as equity | (989) | - |
Proceeds from exercise of stock options | 6,000 | - |
Advances from related party | 97,000 | 242,500 |
Repayments on related party advances | (19,084) | (370,000) |
Proceeds from sale of common stock | 385,000 | 7,215,380 |
Payments of principal on notes payable | - | (59,500) |
Proceeds from issuance of notes payable | 335,510 | 97,156 |
Proceeds from issuance of notes payable - related party | 57,919 | - |
Payments of principal on convertible notes | (205,186) | (186,443) |
Proceeds from issuance of convertible notes, net of issuance cost | 50,250 | 864,845 |
Net Cash Provided By Financing Activities | 706,420 | 7,803,938 |
Net increase in cash and cash equivalents | 6,734 | 16,445 |
Cash and cash equivalents at beginning of year | 18,405 | 1,960 |
Cash and cash equivalents at end of year | $25,139 | $18,405 |
Supplemental Cash Flow Information: | ||
Cash paid for interest and finance charges | $46,025 | $40,116 |
Cash paid for taxes | $- | $- |
Non-Cash investing and financing activities: | ||
Forgiveness of debt by officers and directors | $- | $- |
Proceeds from sale of Series D preferred stock paid directly to settle amounts | ||
due to officers and directors | $- | $- |
Proceeds from sale of Series A preferred stock paid directly to settle debts | $- | $55,090 |
Convertible notes and interest payable settled by Series A preferred stock issued | $- | $849,360 |
Note payable, accrued expense and interest payable settled by common stock issued | $- | $40,616 |
Convertible notes settled by common stock issued | $184,680 | $196,000 |
Accounts payable and accrued liabilities settled by common stock issued | $70,575 | $- |
Common stock issued for purchase of membership interest in subsidiary | $- | $1,440,000 |
Common stock and preferred stock issued for prepaid services | $- | $3,495,380 |
Common stock issued pursuant to asset purchase agreement | $- | $70,000 |
Increase in intangible assets for subscription payable | $- | $250,000 |
Initial beneficial conversion feature and debt discount on convertible notes | $- | $670,467 |
Stock warrants granted as debt discount | $- | $194,388 |
Initial derivative liability on convertible notes | $- | $- |
Fair value of common stock issued on conversion of notes | $- | $- |
Fair value of common stock issued for settlement of accounts payable | $- | $- |
Preferred deemed dividend | $- | $904,450 |
Operating lease right-of-use assets and operating lease liabilities | ||
recorded upon adoption of ASC 842 | $- | $506,506 |
Reduction of operating lease right-of-use asset and operating lease liabilities | $- | $115,694 |
Prepaid expenses directly paid by a related party | $- | $35,000 |
PANACEA LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARIES
DECEMBER 31, 2020
NOTE 1 -
NATURE OF ORGANIZATIONOrganization and Business Description
Panacea Life Sciences Holdings, Inc. (the(the “Company”, “Panacea Holdings”, “Exactus”, “we”, “us”, “our”) was incorporated on January 18, 2008 as an alternative energy research and development company. During muchin the State of its history the Company had designed solar monitoring and charging systems which were discontinued in 2016 to focus on developing point-of-care diagnostic devices.Nevada. In January 2019, the Company added to the scope of its business activities, efforts to produce, market and sell products made from industrial hemp containing cannabidiol (“CBD”).
The Company believes manufacturing, testingoperates in one segment with a focus on developing and quality akin to pharmaceuticalproducing high-quality, medically relevant, legal, hemp-derived cannabinoid products is important when distributing hemp-based products. The Company’s products originated from farms at which the Company or C2M oversaw all stages of plant growthfor consumers and are manufactured under contract arrangements with third-parties.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation and principles of consolidation
On June 30, 2021 the Company merged with Panacea. The Company’s consolidated financial statements include the financial statements of its 50.1% subsidiary, EOWmerger is accounted for as a reverse acquisition and 51% subsidiary, Paradise Medlife.
The consolidated financial statements represent the accounts and balances for Panacea through June 30, 2021, and the consolidated balances and activities of the Company and its majority-owned subsidiaries as of December 31, 2020.wholly owned subsidiary, Panacea, from that date forward. All significant intercompanyconsolidated transactions and balances have been eliminated. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, stockholders’ (deficit) equityeliminated in consolidation.
All share and cash flows as of December 31, 2020 and 2019, and for the years then ended,per share numbers have been made. Those adjustments consist of normal and recurring adjustments.retroactively adjusted to give effect to a 1-for-28 reverse stock split effective October 25, 2021.
F-9 |
Going concern
These audited consolidated financial statements are presented on the basis that the Company will continue as a going concern. Panacea has merged with Exactus, so the below items reflect stand-alone historical results of Panacea through June 30, 2021 and the combined financial information thereafter. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. No adjustment has been made to the carrying amount and classification of the Company’s assets and the carrying amount of its liabilities based on the going concern uncertainty.Since our inception in later 2017, we have generated losses from operations, except for some slight profits in a few quarters. As reflected in the accompanying consolidated financial statements, the Company had a net loss attributable to Exactus Inc. common stockholders of $9.5 million for the year ended December 31, 2020. The net cash used in operating activities was $0.7 million for the year ended December 31, 2020. Additionally, the Company had an accumulated deficit of $30.4 million and working capital deficit of $4.8 million as of December 31, 2020. 2021, our accumulated deficit was $16.8 million, and we had $3.8 million in cash and liquid stock. As of December 31, 2021 the shares of common stock we hold in 22nd Century Group, Inc. (NASDAQ:XXII) (“XXII”) were valued at approximately $3.8 million. The XXII stock is pledged to secure a $4,062,713 promissory note in favor of Quintel-MC, Incorporated (“Quintel”) and a $1,685,685 promissory note in favor of Leslie Buttorff, CEO of the Company, but can be used in operations as the CEO determines. Quintel-MC, Inc. is wholly owned Company of the CEO. These items are shown on the balance sheet as related party loans. The current plan with respect to the XXII stock is to hold this stock during the short-term pending XXII’s application for MRTP FDA approval. We also currently do not have sufficient cash flow to pay our ongoing financial obligations on a consistent basis.
These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve12 months from the issuance date of this report.these financial statements. Management plans to raise additional capital to fund operations, until the Company achieves and maintains profitable operations and cash flows. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raiseissuance of any additional debt and/or equity capital. The Company is seeking to raise capital through additional debt and/or equity financings to fund its operations in the future. Although the Company has historically raised capital from salesshares of common andstock, preferred shares and from the issuance ofstock or convertible promissory notes, there is no assurance that it willsecurities could be ablesubstantially dilutive to continueour shareholders. In addition, adequate additional funding may not be available to do so. If the Company is unable to raise additional capitalus on acceptable terms, or secure additional lending in the near future, management expects that the Company will need to curtail its operations. The accompanyingat all. These audited consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
COVID-19
The COVID-19 pandemic has resulted in a global slowdown of economic activity which is likely to continue to reduce the future demand for a broad variety of goods and services, while also disrupting sales channels, marketing activities and supply chains for an unknown period of time until the virus is fully contained. The Company’s business operations have been negatively impacted by the COVID-19 pandemic and related events and the Company expects this disruption to continue to have a negative impact on its revenue and results of operations, the size and duration of which is currently difficult to predict. However, adverse consequences from COVID-19 and recent supply chain disruptions and delays may hinder our ability to continue our operations and generate revenue. The impact to date has included a decline in CBD product and sales demand. Further, in 2020, the Company (Panacea) invested in personal protective equipment (PPE) materials to sell. Hand sanitizers, testing kits and masks, and sales of PPE products, which constituted a significant portion of our revenue during the fiscal year ended December 31, 2021 and prior periods during the pandemic, have declined as vaccines continue to be administered and mask mandates and similar requirements have been lifted or reduced in many places. Although the Company is unable to predict the full impact and duration of COVID-19 on its business, the Company is actively managing its financial expenditures in response to the current uncertainty.
The impact of the COVID-19 pandemic and related events, including actions taken by various government authorities in response, have increased market volatility and make the estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes more difficult. As of the date of issuance of the financial statements, the Company is not aware of any specific event or circumstance that would require it to update its estimates, judgments or revise the carrying value of its assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known.
Use of Estimates
The Company prepares itsaudited consolidated financial statements have been prepared in conformity with US GAAP which requiresand required management of the Company to make estimates and assumptions that affect the reported amountsin preparation of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. In preparing the consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated balance sheet, and revenues and expenses for the period then ended.these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the fair value of derivative liabilities, useful life of property and equipment, fair valueincremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, income taxes, contingent liabilities,assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.
F-10 |
Cash and Cash Equivalents
For purposes of balance sheet presentation and reporting of cash flows, the Company considers all unrestricted demand deposits, money market funds and highly liquid debt instruments with an original maturity of less than 90 days to be cash and cash equivalents. There were no cash equivalents. The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. On December 31, 2021 and 2020, the Company’s cash balances did not exceed the FDIC limit.
Accounts Receivable
Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. As of December 31, 2021 and December 31, 2020, we did not believe we needed to reserve for any doubtful accounts, respectively. The Company’s accounts receivable policy changed in 2020 to only provide larger, well-established companies with Net 30 payment terms. For all other sales they are paid by credit card or wires received before the product is shipped to the customer.
Inventory
Inventories are stated at lower of cost or net realizable value. Inventories of purchased materials are valuated using a moving average method and managed by first in first out basis (FIFO). Inventories of internally manufactured materials are valuated using a standard costing method and are also managed on a FIFO basis. Production related costs that are capitalized as inventory as part of the standard cost valuation include the direct materials consumed, direct labor used, indirect labor used, and manufacturing overhead. Overhead is calculated based on specific manufacturing process and allocated on an order-by-order basis. Production variances that occur between standard cost valuation and actual costs are expensed as incurred in the income statement as part of cost of goods sold.
Marketable securities
The Company’s marketable securities consist of and shares of XXII at December 31, 2021 and 2020, respectively, which are classified as available-for-sale and included in current assets. (See Note 2 – Going Concern). Securities are valued based on market prices for identical assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized and realized gains and losses reported as a component of income (loss). Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the consolidated statements of operations.
Fair Value Measurements
The Company adopted the provisions of Accounting Standard Codification (“ASC”) Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value, and expands disclosure of fair value measurements. The guidance prioritizes the inputs used in measuring fair value and establishes a three-tier value hierarchy that distinguishes among the following:
● | Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. |
● | Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. |
● | Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
F-11 |
The Company measures certain financial instruments atfollowing table shows, by level within the fair value on a recurring basis. Assetshierarchy, the Company’s assets and liabilities measured at fair value on a recurring basis are as follows atof December 31, 20202021 and 2019:
At December 31, 2020 | At December 31, 2019 | |||||
Description | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 |
Derivative liabilities | — | — | $237,022 | — | — | $880,410 |
FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS
December 31, 2021 | December 31, 2020 | |||||||||||||||||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||||||
Marketable securities | $ | 3,791,483 | $ | 3,791,483 | $ | - | $ | - | $ | 2,853,437 | $ | 2,853,437 | $ | - | $ | - | ||||||||||||||||
Total | $ | 3,791,483 | $ | 3,791,483 | $ | - | $ | - | $ | 2,853,437 | $ | 2,853,437 | $ | - | $ | - |
There were no transfers of marketable securities into or out of Level 1 during the level 3 valuation financial instruments is as follows:
SCHEDULE OF MARKETABLE SECURITIES
December 31, 2021 | ||||
Balance at beginning of year | $ | 2,853,437 | ||
Sale of securities | (230,296 | ) | ||
Realized gain on sale of securities | 160,296 | |||
Unrealized gain on marketable securities, net | 1,008,046 | |||
Balance at end of period | $ | 3,791,483 |
As of December 31, 2020 and 2019,2021, the Company has no assetsliabilities that are re-measured at fair value.
December 31, 2020 | December 31, 2019 | |
Prepaid services | $- | $248,767 |
Prepaid insurance | 9,288 | - |
Other assets | 6,000 | - |
$15,258 | $248,776 |
Property and Equipment
Property and equipment are carriedstated at cost less accumulated depreciation. Depreciation is computedcalculated using the straight-linestraight–line method on the various asset classes over thetheir estimated useful lives, of the assets rangingwhich range from 3three to 10 years.ten years when placed in service. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the consolidated statementyear of operations.
Intangible Assets and Goodwill
The Company has intangible assets. Goodwill is comprised of long-livedthe purchase price of business combinations in excess of the fair market value assigned at acquisition to the tangible and intangible assets
SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL
Estimated Life | ||
Goodwill from Phoenix Acquisition | Tested Yearly for Impairment | |
Intangibles – Formulations | 5 Years |
December 31, 2021 | December 31, 2020 | |||||||
Goodwill | $ | 2,188,810 | $ | 2,188,810 | ||||
Intangibles – Formulations | 307,001 | 307,001 | ||||||
Less accumulated amortization | (245,600 | ) | (184,200 | ) | ||||
Net intangible assets | $ | 61,401 | $ | 122,801 |
F-12 |
Leases
The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease. In determining the leases classification, the Company assesses among other criteria: (i) 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities and long-term operating lease liabilities in the Company’s consolidated balance sheets. Finance leases are included in property, plant and equipment, net, other current liabilities, and long-term finance lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the right to use an underlying asset for impairment whenever eventsthe lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For leases with terms greater than 12 months, the Company records the ROU asset and liability at commencement date based on the present value of lease payments according to their term.
The Company uses incremental borrowing rates based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or changes in circumstances indicateterminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses are recognized on a straight-line basis over the lease term or the useful life of the leased asset.
In addition, the carrying amount of the assets may not be fully recoverable,ROU and lease liabilities are remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or at least annually. a change in the assessment to purchase the underlying asset.
Convertible Notes Payable
The Company recognizes an impairment loss whenhas issued convertible notes, which contain variable conversion features, whereby the sumoutstanding principal and accrued interest automatically convert into common shares at a fixed price which may be a discount to the common stock at the time of expected undiscounted future cash flows is less than the carrying amountconversion. Some of the asset. The amountconversion features of impairment is measured asthese notes are contingent upon future events, whereby, the difference betweenholder agreed not to convert until the asset’s estimated fair value and its book value. contingent future event has occurred.
Revenue Recognition
The Company recorded impairment expense of $4,577,406 and $250,192 as follows:
December 31, 2020 | December 31, 2019 | |
Prepaid expenses and other assets – related party | $2,483,523 | $ |
Deposit | 40,000 | |
Property and equipment | 372,041 | |
Intangible assets | 1,412,727 | 250,192 |
Operating lease – right of use asset | 269,115 | |
Total | $4,577,406 | $250,192 |
The Company accounts for a contract when it has been approved and committed to, be recognized in a manner that depictseach party’s rights regarding the transfer of goods or services to be transferred have been identified, the payment terms have been identified, the contract has commercial substance, and collectability is probable. Revenue is generally recognized net of allowances for returns and any taxes collected from customers and subsequently remitted to governmental authorities. However, the Company’s sales are primarily through retail stores, purchase orders or ecommerce; thus, currently contract liabilities are negligible. The Company does not have any multiple-element arrangements.
Some of the Company’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized. The Company recorded $24,585 and $121,300 in advanced customer payments as of December 31, 2021 and December 31, 2020, respectively and these amounts are included in the balance sheet line item of accounts payable and accrued expenses.
SCHEDULE OF REVENUE FROM CONTRACT WITH CUSTOMER
December 31, 2021 | December 31, 2020 | |||||||
Balance, beginning of period | $ | 121,300 | $ | 254,786 | ||||
Payments received for unearned revenue | 41,465 | 463,454 | ||||||
Revenue earned | 138,180 | 596,940 | ||||||
Balance, end of period | $ | 24,585 | $ | 121,300 |
F-13 |
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflectreflects the consideration to which thethat an entity expects to be entitledreceive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company recognizes revenue by applyingapplies the following steps:
Revenue related to the point in time whensale of products are shipped or deliveredis recognized once goods have been sold to the customer whichand the performance obligation has been completed. In both contracted purchase and retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or, to the customer directly. Revenue from tolling services is recognized when the customerperformance obligation, such as processing of the material, has titlebeen completed and output material has been transferred to the significant riskscustomer.
Revenue is generally recognized net of allowances for returns and rewardsany taxes collected from customers and subsequently remitted to governmental authorities. Some of ownership. Therefore, the Company’s contractscontract liabilities consist of advance customer payments. A contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have a single performance obligation (shipment of product).not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized. However, the Company’s sales are primarily through retail stores, purchase orders or ecommerce; thus, currently contract liabilities are negligible. The Company primarily receives fixed consideration for salesdoes not have any multiple-element arrangements.
Some of product. Payments receivedthe Company’s contract liabilities consist of advance customer payments. Contract liability results from customers that are related to unshipped or undelivered products are recorded as unearned revenue until the shipment of product. As of December 31, 2020 and 2019,transactions in which the Company had $0 and $215,000, respectively, of unearned revenue recorded from the Company’s related party customer, C2M.
Shipping and Handling Costs
The Company accounts for shipping and handling fees in accordance with ASC 606. The amounts charged to customers for shipping products are recognized as revenues and the related freight costs of shipping products are classified in sellinggeneral and marketing expensesadministrative costs as incurred. Shipping costs are included as a component of sellinggeneral and marketing expensesadministrative and were $24,68716,564 and $11,835$63,942 for December 31, 2021 and December 31, 2020, respectively. The decrease is due to less PPE items being shipped out.
Advertising & Marketing
Advertising costs are expensed when incurred. Included in this category are expenses related to public relations, investor relations, new package design, website design, design of promotional materials, cost of trade shows, cost of products given away as promotional samples, and paid advertising. The Company recorded advertising costs included in general and administrative costs of $377,916 and $1,504,592 for the yearyears ended December 31, 2021 and 2020, respectively.
Segment Information
The Company follows the provisions of ASC 280-10 Segment Reporting. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. Segment identification and 2019, respectively.
F-14 |
The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, “Earnings“Earnings per Share”Share”. Basic earnings per share is computed by dividing net income (loss) available to common shareholdersstockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if preferred stock converted to Common Stockcommon stock and warrants are exercised. Preferred stock and warrants are excluded from the diluted earnings per share calculation if their effect is anti-dilutive.
December 31, | ||
2020 | 2019 | |
Stock options | 3,751,749 | 4,671,280 |
Stock warrants | 1,578,549 | 2,014,299 |
Restricted stock to be issued upon vesting | 2,960,810 | 3,583,328 |
Convertible preferred stock | 9,460,845 | 9,611,295 |
Convertible debt | 14,145,825 | 3,027,778 |
Total | 31,897,778 | 22,907,980 |
Years ended December 31, | ||||||||
2021 | 2020 | |||||||
Convertible note payable | - | - | ||||||
Restricted Stock | - | - | ||||||
Options to purchase common stock | - | - | ||||||
Warrants to purchase common stock | - | - | ||||||
Series A Convertible Preferred | 250,000 | - | ||||||
Series B-1 Convertible Preferred | 6,679 | - | ||||||
Series B-2 Convertible Preferred | 26,786 | - | ||||||
Series C Convertible Preferred | 2,289,220 | 2,289,220 | ||||||
Series C-1 Convertible Preferred | 1,064,908 | 1,064,908 | ||||||
Series C-2 Convertible Preferred | 2,050,000 | - | ||||||
Series D Convertible Preferred | 1,628,126 | 1,628,126 | ||||||
Total | - | - |
Income Taxes
The Company accounts for income taxes pursuant to the provision ofin accordance with ASC 740-10, “Accounting for Income740, “Income Taxes” (“. ASC 740-10”), which740 requires among other things, an asset and liability approach for financial accounting and reporting for income taxes and established for all the entities a minimum threshold for financial statement recognition of the benefit of tax positions and requires certain expanded disclosures. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to calculating deferred income taxes.reverse. The asset and liability approach requireCompany evaluates the recognitionrecoverability of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Aestablishes a valuation allowance is provided to offset any net deferred tax assets for which management believeswhen it is more likely than not that some portion or all the net deferred assettax assets will not be realized.
Recently Issued Accounting Standards
In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):815- 40) Issuer’s Accounting for Convertible InstrumentsCertain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” which clarifies and Contractsreduces diversity in an Entity’s Own Equity”issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: i) for a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), to reduce complexityas the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged; ii) for all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. The amendments in applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 isthis Update are effective for interim and annual periodsall entities for fiscal years beginning after December 15, 2023, with early adoption permitted. We are2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company is currently evaluating the impact of this guidance.
F-15 |
The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective beginning on March 12, 2020 and may be applied prospectively through December 31, 2022. TheCompany does not expectdiscuss recent pronouncements that the adoption of the standard willare not anticipated to have a materialan impact on or are unrelated to its consolidated financial statements.
NOTE 3 – ACQUISITIONPROPERTY, EQUIPMENT, NET OF ASSETS AND OWNERSHIP
Property and equipment, net including any major improvements, are recorded at historical cost. The cost of repairs and maintenance is charged against operations as incurred. Depreciation is calculated using the Company acquired a 50.1% limited liability membership interest in Exactus One World, LLC, an Oregon limited liability company, formed on January 25, 2019 which since inception, had no operations.
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT USEFUL LIVES
Estimated Life | ||
Computers and technological assets | 3 – 5 Years | |
Furniture and fixtures | 3 – 5 Years | |
Machinery and equipment | 5 – 10 Years | |
Leasehold improvement | 10 Years |
Property and an additional 20.1% was acquired from existing members pursuant to the termsequipment, net consists of the Purchase Agreement. following:
SCHEDULE OF PROPERTY AND EQUIPMENT
December 31, 2021 | December 31, 2020 | |||||||
Computers and technological assets | $ | 3,514,421 | $ | 2,993,626 | ||||
Furniture and fixtures | 55,950 | 55,950 | ||||||
Machinery and equipment | 7,530,787 | 8,494,298 | ||||||
Land | 92,222 | 2,293,472 | ||||||
Assets Under Construction | - | 743,377 | ||||||
Leasehold Improvements | 1,508,915 | 1,508,915 | ||||||
Total | 12,702,295 | 16,089,638 | ||||||
Less accumulated depreciation | (3,862,313 | ) | (2,499,352 | ) | ||||
Total Property and equipment, net | $ | 8,839,982 | $ | 13,590,286 |
The existing members are considered third parties. The Company has the right to appoint a manager of the limited liability company. Under the Operating Agreement for EOW, as amended, the Company has the right to appoint,land and remove and replace, if desired, one of three managers of EOW, with each manager having the full rights to control the business and affairs of EOW.
Depreciation expenses in the post combination period under Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and services received in exchange for an award based on the grant-date fair value of the award.
December 31, | ||
2020 | 2019 | |
Finished goods – CBD | $10,712 | $- |
Finished goods – hemp flowers and hemp cuttings | - | 1,337,809 |
$10,712 | $1,337,809 |
As of December 31, | |||
Estimated life | 2020 | 2019 | |
Greenhouse | 10 years | $34,465 | $34,465 |
Fencing and storage | 5 years | 44,543 | 44,543 |
Irrigation | 5 years | 387,975 | 387,975 |
Office and computer equipment | 3 years | 40,834 | 40,834 |
Farming Equipment | 5 years | 11,500 | 11,500 |
Leasehold improvement | 5 years | 21,886 | 21,886 |
Total | 541,203 | 541,203 | |
Less: Accumulated depreciation | (149,003) | (63,770) | |
Less: Impairment expense | (372,041) | - | |
$20,159 | $477,433 |
The asset under construction in 2020 the Company recorded impairment expense of $372,041 which was equivalent to the remaining net book values of the greenhouse, fencing and storage, irrigation, farming equipment and leasehold improvement related to a commercial leasedeposit the Company made on an XL Novasep chromatography unit. The Company decided it did not have the proper equipment needed to house the unit, so it negotiated a settlement with Skybar Holding, LLC.
F-16 |
Useful life | December 31, 2020 | December 31, 2019 | |
Participation rights - EOW | 3 year | $2,930,000 | $2,930,000 |
Hemp operating license - EOW | 1 year | 10,000 | 10,000 |
Trademark – Green Goddess | 3 year | - | 3,500 |
Customer list – Green Goddess | 3 year | - | 212,529 |
Brand - Levor | 3 year | - | 70,000 |
Total | 2,940,000 | 3,226,029 | |
Less: accumulated amortization | (1,527,273) | (828,526) | |
Less: Impairment expenses | (1,412,727) | (250,192) | |
Intangible assets, net | $- | $2,147,311 |
NOTE 4 – INVENTORY
Inventory consists of the related EOW farm leases. Accordingly, the Company fully impaired the remaining carrying value of the intangible assets related to EOW farm leases and recorded an impairment expense of $1,412,727 for the year ended December 31, 2020.
SCHEDULE OF INVENTORY
December 31, 2021 | December 31, 2020 | |||||||
Raw Materials | $ | 970,393 | $ | 991,523 | ||||
Semi-Finished | 1,466,763 | 1,372,950 | ||||||
Finished Goods | 1,805,779 | 6,018,530 | ||||||
Packaging | 15,549 | 20,938 | ||||||
Trading | 5,793 | 5,793 | ||||||
Total | $ | 4,264,277 | $ | 8,409,734 |
NOTE 7 - 5 –OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES
Right of Use
The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, “Leases” (“ASC 842”) on January 1, 2019, the start of our 2019 fiscal year. The Company through its majority-owned subsidiary, EOW,has one lease arrangement with a related party entered into a farm lease agreementon December 22, 2018 for a 3-year term commencing January 1, 2019 for certain laboratory facilities with a nine-year extension option. This lease term of one year. The lease premise, located in Cave Junction, Oregon, consisted of approximately 100 acres. The lease required the Company to pay 5% of the net income realized by the Company from the operation of the lease farm. Accordingly,was extended and now expires on December 31, 2030. At inception, the Company recognized $0 Right-of-use asset (“ROU”)a Right of Use Asset and a corresponding lease liabilities on this farmliability in the amount of $4,595,509. The Company’s lease as the Company had not determined when net income would be generated from this lease. Thearrangements may contain both lease was to continue in effect year-to-year except for at least a 30-day written notice of termination.and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there is such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not paidto apply the recognition requirements of ASC 842 to Short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as Short-Term Leases.
The Company, as of January 1, 2019, leases a portion of the property (formerly the Environmental Protection Agency building) in Golden, CO from J&N Real Estate, owned by the CEO, a related party with a term expiring on December 31, 2030. The lease consists of all laboratory space including testing facilities, water treatment, extraction and production. The lease of the property is based on the fair market rent and triple net lease (NNN) values competitive in the marketplace for a cGMP facility. The Company also subleases some of its laboratory space to other CBD companies. This income is presented under this agreement for the Other Income line items of the income statement. The leases vary from short-term monthly leases to 3-year leases but are all month to month.
SCHEDULE OF RIGHT OF USE ASSET AND LIABILITY
December 31, 2021 | December 31, 2020 | |||||||
Right-of-use assets | $ | 3,595,100 | $ | 3,937,706 | ||||
Present value of operating lease liabilities | $ | 3,692,392 | $ | 4,022,870 | ||||
Less: Long-term portion of operating lease liability | (3,347,335 | ) | (3,692,392 | ) | ||||
Short-term portion of operating lease liability | 345,057 | 330,478 | ||||||
Unpaid balances | 1,279,033 | 832,391 | ||||||
Total short-term lease liability obligations | $ | 1,624,090 | $ | 1,162,869 | ||||
Weighted-average remaining lease term (Ends December 31, 2030) | 9 years | 10 years | ||||||
Weighted-average discount rate | 3.0 | % |
During years ended December 31, 2021 and 2020, we recognized approximately $458,772and 2019.$458,772, respectively in operating lease costs. Operating lease costs are included in operating expenses in our consolidated statement of operations.
F-17 |
Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of December 31, 2021, are as follows:
Maturity of operating lease liabilities for the following years ended:
SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES
2022 | $ | 451,110 | ||
2023 | $ | 455,622 | ||
2024 | $ | 460,178 | ||
2025 | $ | 464,780 | ||
2026 | $ | 469,427 | ||
Thereafter | $ | 1,925,123 | ||
Total undiscounted operating lease payments | $ | 4,226,240 | ||
Less: Imputed interest | $ | (533,848 | ) | |
Present value of operating lease liabilities | $ | 3,692,392 |
NOTE 6 – NOTES PAYABLE
Convertible Note Payable
On March 1, 2019,November 18, 2021, the Company through its majority-owned subsidiary, EOW, entered into a farm lease agreementSecurities Purchase Agreement (“SPA”) with Lincoln Park Capital Fund, LLC (the “Purchaser”) pursuant to which the Company agreed to sell a 10% original issue discount senior convertible promissory note in the principal amount of $1,100,000 (the “Convertible Note”) and five-year warrants to purchase 785,715 shares of the Company’s common stock, par value $ per share at an exercise price of $1.40 per share (the “Warrants”) pursuant to the terms and conditions of the SPA for a lease termtotal purchase price of $1,000,000.
The Note will be due November 18, 2022, which is one year.year from the issuance date. The lease premise, located in Glendale, Oregon, consistedNote initially does not bear any interest, however upon and during any event of approximately 100 acres. The leasedefault by the Company, the Note will accrue interest at a rate of 18% per annum. Events of default include the failure to file all required reports and other documents with the SEC pursuant to Exchange Act by January 2022, suspension of trading or quotation of the Company’s common stock on the OTCQB or a national securities exchange, and failure to reserve a sufficient number of shares for the conversion or exercise of all securities sold under the SPA. Further, upon an event of default, the holder will have the right to cause the Company to pay $120,000redeem the outstanding principal and accrued interest on the Note at a 125% premium.
The principal and accrued interest on the Note is convertible into common stock at a conversion price of $1.40 per year, whereby $50,000 was payable upon execution and $70,000 payableshare, subject to certain adjustments summarized as follows: (i) if an event of default has occurred prior to planting for agricultural use or related purposes. The lease wasthe maturity date, a reduction to continue80% of the conversion price then in effect, from year-to-year except(iii) anti-dilution adjustment upon certain issuances of common stock or derivative securities at a price per share that is lower than the conversion price, (iii) customary adjustments for stock splits, stock dividends and similar corporate events, and (iv) adjustment upon a public offering by the Company meeting certain delineated criteria, as summarized below.
Under the terms of the Note, upon a public offering by the Company of common stock, either alone or in units or with other securities pursuant to an effective registration statement resulting in gross proceeds to the Company of at least $10,000,000, and in connection with which the common stock is approved for listing listed on a 30-daynational securities exchange (a “Qualified Offering”), the conversion price will be reduced to 90% of the offering price per share in the Qualified Offering, if that price is lower than the conversion price then in effect. Additionally, immediately prior to a Qualified Offering, the Company may redeem all or part of the outstanding principal and accrued interest on the Note at a 115% premium.
The Note also contains customary negative covenants prohibiting the Company from certain actions while the Note remains outstanding.
The Warrants will be exercisable for a five-year term beginning on May 18, 2022, at an exercise price of $1.40 per share, subject to certain adjustments which are substantially similar to those contained in the Note, including the Qualified Offering adjustment.
Each of the Note and the Warrants contain a 4.99% beneficial ownership limitation pursuant to which neither may be converted or exercised, as applicable, if and to the extent that following such conversion or exercise the holder would beneficially own more than 4.99% of the Company’s outstanding common stock, subject to increase to 9.99% upon 61 days’ prior written notice by the holder.
F-18 |
The SPA provides that the Purchaser may purchase an additional note and additional warrants on substantially the same terms as the Note and the Warrants on any business day prior to the 91st business day immediately following the closing of termination. the SPA.
Pursuant to the SPA, the Company entered into a Registration Rights Agreement dated November 18, 2021, by and between the Company and the Purchaser, in which the Company has agreed to file a Registration Statement on Form S-1 with the SEC following request by the Purchaser at any time following the 180-day period after the initial closing.
The Company recognized lease expensecalculated the fair value of $100,000the Warrants using the Black Scholes method as $877,261 and recorded their fair value along with the $100,000 original issue discount and relates issuance costs of $20,249 as a debt discount which will be amortized using the straight-line method over the one year note period. Amortization of the debt discount for the year ended December 31, 2019 and2021 amounted to $117,515. The loan balance, net of discount was included in cost$220,005 as of sales on the accompanying consolidated statements of operations.
December 31, | ||
2020 | 2019 | |
Restated | ||
Farm lease ROU | $506,506 | $506,506 |
Less accumulated amortization | (237,391) | (115,695) |
Less impairment expense | (269,115) | - |
Balance of ROU asset | $- | $390,811 |
December 31, | ||
2020 | 2019 | |
Restated | ||
Farm lease ROU | $506,506 | $506,506 |
Reduction of lease liability | (237,391) | (115,695) |
Total | $269,115 | 390,811 |
Less: current portion | (269,115) | (168,869) |
Long term portion of lease liability | - | $220,942 |
Paycheck Protection Program Funding U.S. Small Business Administration Loan
On May 28, 2020, the Company received a Securedsecured, 30-year, Economic Injury Disaster Loan in the amount of $99,100 $99,100 from the U.S. Small Business Administration. The loan carries interest at a rate of 3.75%3.75% per year, requires monthly payments of principal and interest, and matures in thirty (30)30 years. Installment payments, including principal and interest, of $483 $483 monthly, will begin twelve (12)12 months from the date of the promissory Note. The SBA loan is secured by a security interest in the Company'sCompany’s tangible and intangible assets. The loan proceeds are to be used as working capital to alleviate economic injury caused by the Covid-19 disaster occurring in the month of January 31, 2020 and continuing thereafter. As of December 31, 2020,2021 the current principal balance of this note amounted to $99,100.
In April 2021, the Exactus Company borrowed a “second draw” loan of $236,410 under the PPP, as expanded pursuant to subsequent legislation. The loan was officially forgiven by the Small Business Administration (SBA) and lending bank, West Town Bank & Trust, on September 23, 2021.
Regarding Panacea Life Sciences, Inc.’s (PLS) Small Business Administration (SBA) loans, PLS received federal fundingthe PPP first draw loan in the amount of $236,410 through$273,300.00 on April 29, 2020. All funds were used to cover payroll expenses. The first draw loan, including any accrued interest, was officially forgiven by the Paycheck Protection Program (the “PPP”).SBA and the respective lending bank, FirstBank, on March 3, 2021. On January 28, 2021, PLS received the PPP funds have certain restrictionssecond draw loan in the amount of $243,041.00; the second draw loan was forgiven on useJune 28, 2021.
PLS’s accounting treatment of the funding proceeds,PPP loans and generally must be repaid within two (2) years at 1% interest.forgiveness follows best practice from the AICPA and accounted for the loan as a financial liability in accordance with FASB ASC 470 and accrue interest in accordance with the interest method under FASB ASC 835-30. The full amount of the PPP loan may, under circumstances, be forgiven. There shall be no payment due byand accrued interest was forgiven on June 28, 2021 and written off.
The aforementioned forgiveness of the Company duringvarious PPP loans was recorded in the six months period beginningCompany’s consolidated statement of operations as gain on extinguishment of debt
F-19 |
Employer Retention Credit
Panacea received an employer retention credit from the datefederal government of $190,388. On December 2, 2021, Panacea received an additional employer retention credit from the federal government of $206,341.
Note payable-current, related party
As part of the agreement in the share agreement transaction, certain loan balances (“Quintel Loans”) from Quintel-MC Incorporated, an affiliate of the Company’s CEO, (“Quintel”) and historical interest owed of $1,932,358 were combined into a new promissory note with the principal amount of $4.062 million (“Quintel Note”). In May, 2021, prior to the exchange agreement, Panacea also transferred $4.7 million in PPE inventory to Quintel to facilitate a transaction. The net effect of this transaction was a credit to revenue, debit to finished goods inventory and a credit to the Quintel Loans. The Quintel Note bears annual interest at 12% and was secured by a pledge of certain XXII common stock owned by Panacea (See Note 2 Going concern).
On June 30, 2021, Panacea issued the Company’s CEO, Ms. Buttorff, a 10% promissory note (“Deferral Period”in the amount of $1,624,000 (the “Buttorff Note”). Commencing one month afterThe Buttorff Note was secured by a pledge of certain XXII common stock owned by Panacea (See Note 2 Going concern). This demand note replaced a prior working capital note that Panacea had issued on January 1, 2021. The Company has an additional line of credit note from Ms. Buttorff of $1,000,000 on July 1, 2021. The terms include an annual interest rate of 10% and a maturity date in 2022.
On June 30, 2021 the expiration$7 million of the Deferral Period, the Company shall pay the lender monthly payments of principal and interest, eachconvertible debt (“XXII Debt”)was retired in equal amount required to fully amortize by the maturity date. Ifexchange for a payment on this note is more than ten days late, the lender shall charge a late fee of up to 5% of the unpaid portion of the regularly scheduled payment. As of December 31, 2020, the principal balance of this note amountedNeedle Rock Farm ($2.2 million), $500,000 was converted to $236,410. Thecommon stock and J&N Real Estate Company has formally applied for forgiveness of this PPPassumed a $4.3 million loan.
As of December 31, | ||
2020 | 2019 | |
Principal amount | $335,510 | $- |
Less: current portion | (130,344) | - |
Notes payable - long term portion | $205,166 | $- |
During October 2019, the Company entered into twoissued a short-term promissory notes (the “Notes”)note to an officer of Exactus, for an aggregate principal amount of $94,056 and gross cash proceeds of $85,000 (original issue discount of $9,056)$55,556. AThe note with principal amount of $55,556 was subscribed by Andrew Johnson, an officer of the Company. The Notesoriginally became due and payable between October 18, 2019 and December 16, 2019 and bearbore interest at a rate of twelve (12%) percent12% per annum prior to the maturity date, and eighteen (18%)18% per annum if unpaid following the maturity date. The Notes arecurrent interest rate is 18%. The note is an unsecured obligationsobligation of the Company. In addition, the NotesThe notes carry a 10%10% original issue discount of $9,056$5,556 which havehas been amortized and recorded in interest expense on the accompanying consolidated statements of operations. In December 2019, the Company repaid one of the notes with principal amount of $38,500 and accrued interest of $770. As of December 31, 2020, and 2019,2021, the principal balance under the notesthis note was $55,556. The Company is currently negotiating on extending the maturity date of the related party note.
During the year ended December 31, 2019, the Company had borrowed $14,229 under the promissory notes. Between February 2019 and March 2019, the Company paid $11,129 under the promissory notes. Additionally, in March 2019, the Company issued 153,080 shares of its Common Stock to a former executive officer upon the conversion of $27,000 of principal amount and accrued interest of $3,267 under a promissory note. In August 2019, the Company repaid principal amount of $21,000 and accrued interest of $1,769. The remaining principal balance of $6,500 and accrued interest of $2,107 were deemed paid pursuant to the respective severance arrangements. During the year ended December 31, 2019, the Company recognized $1,214 of interest expense. As of December 31, 2019, the notes had an accrued interest balance of $0. As of December 31, 2019, the principal balance under the notes was $0.
SCHEDULE OF NOTES PAYABLE
December 31, 2021 | December 31, 2020 | |||||||
Quintel Note | $ | 4,062,713 | $ | 7,911,044 | ||||
CEO Note | 2,379,153 | 150,000 | ||||||
XXII Debt | - | 7,000,000 | ||||||
Total related party notes | $ | 6,441,866 | $ | 15,061,044 |
On January 22, 2021 the notes principal and interest were converted into 2,070,300 shares1, 2019 Panacea received a loan from Quintel-MC Incorporated for up to $8,058,580, an affiliate of the company’s common stockCompany’s CEO, in full satisfactionexchange for a 12% demand promissory note for (the “Quintel Note”). The loan amount as of the note and accrued interest.
The Company’s convertible notes consist of the following as of December 31, 2020 and 2019: | 2020 | 2019 |
Convertible Notes in the aggregate amount of $100,000, issued on March 22, 2018. The Notes bear interest at a rate of 5% per annum and mature on February 1, 2023. If a qualified financing from which at least $5 million of gross proceeds are raised occurs prior to the maturity date, then the outstanding principal balance of the notes, together with all accrued and unpaid interest thereon, shall be automatically converted into a number of shares of the Company’s Common Stock at $0.40 per Share. The Notes offers registration rights wherein the Company agrees that within 45 days of a Qualified Offering, prior to the Maturity Date, the Company shall file a registration statement with the SEC registering for resale of the shares of Company’s Common Stock into which the Notes are convertible. The Company shall send a written conversion notice to the lender pursuant to the note agreement and as such the principal balance of the convertible note remains outstanding as of December 31, 2020 and 2019. The Company reclassed the principal balance to current portion as of December 31, 2020. | $100,000 | $100,000 |
Convertible Note in the amount of $833,333, issued on November 27, 2019. The Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company agreed to sell to Purchaser in a series of 3 closings up to $1,944,444 in aggregate principal amount of the Company’s senior secured convertible promissory notes (the “Notes”) and warrants to purchase shares of the Company’s Common Stock (the “Warrants”). On November 27, 2019 (the “Initial Closing Date”), the Company issued a Note in the principal amount of $833,333, and a two-year Warrant to purchase 275,612 shares of Common Stock at an exercise price of $0.756 per share (see Note 10). The Notes will be issued at a 10% original issue discount and bear an interest rate of 8%. The Notes mature one year after their issuance unless accelerated due to an event of default. The Notes are redeemable, in whole or in part, at any time at the discretion of the Company. At the Initial Closing Date, the Company received net proceeds, after the original issue discount and the Purchaser’s counsel fees, of $730,000. Each note is convertible at the option of the note holder at any time into shares of our common stock at the fixed conversion rate of $0.50 per share. However, the conversion rate is subject to adjustment in the event of default, redemption and upon the occurrence of certain events affecting stockholders generally, such as stock splits and recapitalizations. The Company must pay amortization redemption payments equaling one-ninth of the original principal amount due on each note commencing 90 days after issuance and continuing during the following eight months (each an “Amortization Redemption”). The note holder may at its option accelerate up to six future amortization redemption payments, in which case the note holder may demand the accelerated amortization amounts be paid in shares of the Company’s common stock at the lesser of i) the fixed conversion rate of $0.50 per share of common stock, or (ii) the rate equal to 80% of the lowest volume weighted average price, or VWAP, during the 10 trading days immediately before the applicable date of the amortization redemption payment (“Amortization Conversion Rate”). Amortization redemption payment amount is equivalent to 110% of the sum of (i) one-ninth (1/9th) of the Original Principal Amount of this Note, (ii) 100% of all accrued and unpaid interest on the principal amount of this Note that is subject to such Amortization Redemption, (iii) 100% of the Make-Whole Amount payable in respect of the principal amount of this Note that is subject to such Amortization Redemption (as applicable), and (iv) all liquidated damages, costs of collection and other amounts payable in respect of this Note as of the applicable amortization redemption payment Date for such Amortization Redemption. If the Company fails to make a redemption payment, the note holder may demand the amortization amounts be paid in shares of the Company’s common stock at the lesser of fixed conversion rate of $0.50 per share of common stock or the Amortization Conversion Rate. In addition, in the event of a subsequent issuance of the Company’s common stock or debt, the Company is subject to mandatory redemption provisions as defined in the note agreement. The Company may not issue shares of the Company’s common stock to third parties at a price lower than the fixed conversion rate of $0.50 per share of common stock without the consent of the note holder. At this time, the Company is delinquent in its payments under the initial convertible note, with the May 1, 2020, April 1, 2020, and a portion of the February 25, 2020 payments currently in arrears. The Company intends to make these payments and the upcoming monthly payments with receipts from product sales and/or the proceeds of additional equity funding. The Company paid original issuance cost of $83,333, cash commission and loan fees of $92,055, and recorded redemption premium of $88,889 related to the amortization redemption payment in connection with this note payable and are being amortized over the term of the note. On the Initial Closing Date, certain FINRA broker-dealers who acted on behalf of the Company were paid aggregate cash commissions of approximately $72,055 and were granted a four-year warrant to acquire an aggregate of 84,187 shares of Common Stock at an exercise price of $0.792 per share of common stock at any time before the close of business four years after their issuance, subject to adjustment in the event of stock dividends, splits, fundamental transactions, or other changes in our capital structure. | 546,036 | 85,906 |
Carrying Amount of Convertible Debt | $646,036 | $185,906 |
Less: Current Portion | (646,036) | (85,906) |
Convertible Notes, Long Term | $- | $100,000 |
On December 3, 2019, we entered into securities purchase agreement with an investor pursuant to which we sold a convertible note bearing interest at 10% per year in the principal amount of $7,000,000 due on December 3, 2024. The principal and interest payments on the note shall be secured by a line on all the assets of the Company. Subject to certain ownership limitations, the note will be convertible at the option of the holder at any time into shares of Series B Preferred Stock common stock at conversion price equal to $1.875 per share (the “Convertible Note”). The balance of the convertible note issued to XXII was $7,000,000 as of December 31, 2020.
Other long-term liabilities, related party
The Company has recorded a related party liability (“Fixed Asset Loan”) in the amounts of $2,749,638 and $2,185,269, as of December 31, 2021 and 2020, respectively, relating to building leasehold improvements and 2019:
2020 | 2019 | |
Principal Amount | $933,333 | $933,333 |
Add: additional principal | 50,250 | - |
Add: amortization of redemption premium | 88,889 | 8,280 |
Less: redemption premium payments | (20,800) | - |
Less: principle payments and conversions | (356,186) | - |
Less: unamortized debt discount and debt issuance costs | - | (755,707) |
Total convertible debt less unamortized debt discount and debt issuance costs | $696,286 | $185,906 |
In 2020, the Company made cash repayments towardsrecorded an additional related party liability in the principalamount of $185,186$513,390 in respect of certain building improvements ,due to J&N Real Estate Company (a company owned by the CEO) (“J&N Building Loan”). The balance bears no interest, and accrued interest of $14,814.the maturity date has not yet been determined.
F-20 |
Notes into payable is summarized as follows.
December 31, 2021 | December 31, 2020 | |||||||
Other long-term liabilities, related party | ||||||||
Fixed Asset Loan | $ | 2,749,638 | $ | 2,185,269 | ||||
J&N Building Loan | 513,390 | 513,390 | ||||||
Total | $ | 3,263,028 | $ | 2,698,659 |
NOTE 7 - STOCKHOLDERS’ EQUITY
Common Stock
The Company’s authorized common stock atconsists of shares with a contractual conversion price of $0.13, as a result of the conversion of principal of $30,000 and interest of $2,400 of the convertible note.
2020 | 2019 | |
Expected Volatility | 213.48% to 216.44% | 239.97% to 567.11% |
Expected Term | 0.16 to 0.66 Years | 0.25 to 1.0 Years |
Risk Free Rate | 0.08% to 0.18% | 1.59% to 2.54% |
Dividend Rate | 0.00% | 0.00% |
During the year ended December 31, 2019, the Company issued an aggregate2021, shares of 849,360 Series A preferred stock to various note holders and also sold an aggregate of 55,090Preferred Shares were converted into shares of preferredcommon stock.
Common stock for $55,090 which were used to repay and convert a total of $842,791 of principal amount (includes penalty fees of $149,313, included in derivative expenses) during the year ended December 31, 2019 and accrued interest of $61,569 pursuant to the Exchange Agreements (the “Exchange Agreements”). During the year ended December 31, 2019, the Company issued 250,000 shares of Common options
Stock to a note holder upon the conversion of $4,000 of accrued interest. In March 2019, the Company paid off the principal notes of $186,443 (includes penalty fees of $48,337, included in derivative expenses) during the year ended December 31, 2019 and accrued interest of $20,467. During the years ended December 31, 2020 and 2019, the Company recorded a gain on settlement of debt of $3,004,630 in connection with the exchange and repayments of various convertible notes.
On January 11, 2019, the Board of Directors of the Company approved a reverse stock split ofJune 30, 2021 the Company’s Common Stock at a ratio of 1-for-8 (the “Reverse Stock Split”) including shares issuable upon conversion of the Company’s outstanding convertible securities. All share and per share values of the Company’s Common Stock for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the Reverse Stock Split.
Number of Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | |
Balance at December 31, 2018 | 644,083 | $ 1.77 | 1.38 |
Granted | 1,578,549 | 0.45 | 5.00 |
Cancelled | — | — | — |
Exercised | — | — | — |
Forfeited | (208,333) | 4.80 | — |
Balance at December 31, 2019 | 2,014,299 | 0.45 | 3.31 |
Granted | 50,000 | 0.50 | 0.17 |
Cancelled | (485,750) | 0.49 | |
Exercised | - | - | |
Forfeited | - | - | |
Balance at December 31, 2020 | 1,578,549 | 0.49 | 3.01 |
Warrants exercisable at December 31, 2020 | 1,578,549 | $0.49 | 2.50 |
Weighted average fair value of warrants granted during the period | $0.50 |
As part of the warrantsmerger of $140,243 usingExactus, Panacea assumed the Binomial Lattice method and is being amortized over the term of the note. Additionally, the Company issued 84,187 warrants to purchase shares of the Company’s common stock to a certain FINRA broker-dealer who acted on behalf of the Company in connection with the issuance of this convertible note. The warrants had a term of 4 years from the date of grant and was exercisable at an exercise price of approximately $0.08. The 84,187 warrants were valued on the grant date at approximately $0.64 per warrant for a total of $54,145 using a Binomial Lattice method with the following assumptions: stock price of $0.65 per share (based on the quoted trading price on the date of grant), volatility of 270%, expected term of 4 years, and a risk free interest rate of 1.63%. The Company recorded these warrants as debt discount which is being amortized over the term of the note. The Company assessed the classification of its common stock purchase warrants as of the date of each equity offering and determined that such instruments met the criteria for equity classification under the guidance in ASU 2017-11 “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Feature”. The Company has no warrants that contain a ‘round down’ feature under Topic 815 of ASU 2017-11.
Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life(Years) | |
Balance at December 31, 2018 | 959,375 | $0.41 | 8.79 |
Granted | 4,753,572 | 0.21 | 8.54 |
Exercise | (375,000) | 0.01 | 9.12 |
Forfeited | (666,667) | 0.05 | 8.56 |
Balance at December 31, 2019 | 4,671,280 | 0.29 | 7.29 |
Granted | 1,000,000 | 0.30 | 9.75 |
Exercise | (20,000) | 0.30 | 9.18 |
Forfeited | (1,899,531) | 0.41 | - |
Balance at December 31, 2020 | 3,751,749 | $0.23 | 8.0 |
Options exercisable at December 31, 2020 | 3,470,499 | $0.24 | 8.0 |
On January 22, 2021, Exactus had granted historical volatilityJanuary grants to three of the Company’sinsiders and sought to negate their option awards in order to achieve two stated goals: to allow the directors to vote a sufficient number of shares required to approve a matter purportedly requiring additional votes to achieve a majority under Nevada law, and to correct an alleged mistake in the January action which was claimed to have unintentionally awarded options instead of shares of common stock. The expected term assumption for stock options granted isdirectors present thereupon purported to grant four directors a total of shares and directed the contractual termCompany’s transfer agent to issue such shares. The effectiveness of the option award. The Company has never declared or paid dividends on its common stockMarch 31, 2021 board action is currently under review and has no plansmay ultimately be determined to do so in the foreseeable future. Forfeitures are recognizedhave been ineffective as a reductionmatter of stock-based compensation expenselaw. All related shares and options outstanding have been reported as they occur. if legally transacted. -year options exercisable at $ per share to certain officers and directors, including options to Larry Wert who remains a director. Subsequently, at a meeting on March 31, 2021 several directors reviewed the
F-21 |
Stock Options
SCHEDULE OF STOCK OPTIONS
Options Outstanding as of December 31, 2021 | ||||||||||||||||
Number of Shares Subject to Options | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (in years) | Aggregate Intrinsic Value | |||||||||||||
Balance at December 31, 2020 | - | - | - | |||||||||||||
Options assumed in merger | 196,486 | $ | 3.51 | 2,500 | ||||||||||||
Options granted | - | - | - | - | ||||||||||||
Options exercised | - | - | - | - | ||||||||||||
Options canceled / expired | - | - | - | - | ||||||||||||
Balance at December 31, 2021 | 196,486 | $ | 3.51 | $ | 2,500 | |||||||||||
Vested and exercisable at December 31, 2021 | 196,486 | $ | 3.51 | $ | 2,500 |
Stock to various membersWarrants
As a result of the Board of Directors of the company and consultants with vesting terms pursuant to their respective sock option agreements. The options have a term of 10 years from the date of grant and were exercisable at an exercise price ranging from $0.01 to $0.96. The Company recognized $1,276,637 of compensation expense related to the vesting of stock options for the year ended December 31, 2019. These amounts are included in general and administrative expenses on the accompanying consolidated statement of operations.
Name | Number of Shares | Average Exercise Price | ||||||
Balance at December 31, 2020 | - | - | ||||||
Assumed in Merger | 56,337 | $ | 13.64 | |||||
Issued with convertible debt | 785,715 | 1.40 | ||||||
Total as of December 31, 2021 | 56,337 | $ | 2.22 |
As of December 31, 2019, aggregate2021, the outstanding warrants have no intrinsic value in connection with exercisable options amounted to $726,371. value.
Restricted Stock
SUMMARY OF RESTRICTED STOCK
Restricted Stock Common Stock | ||||
Balance at December 31, 2020 | - | |||
Assumed in merger | 107,993 | |||
Balance at December 31, 2021 | 107,993 |
As of December 31, 2019, 872,392 outstanding options are unvested and2021, there was $337,863 unrecognized compensation expense in connection with unvested stock options (see Note 11).
Restricted Stock Common Stock | Weighted Average Grant-Date Fair Value Per Share | |
Balance at December 31, 2018 | - | $- |
Granted | 3,727,778 | 0.69 |
Vested and issued | (144,450) | (0.84) |
Forfeited | - | - |
Balance at December 31, 2019 | 3,583,328 | $0.68 |
Granted | 4,871,022 | 0.08 |
Vested and issued | (1,727,394) | 0.39 |
Forfeited | (3,766,153) | 0.36 |
Balance at December 31, 2020 | 2,960,803 | $0.41 |
F-22 |
Preferred Stock
The Company’s authorized preferred stock consists of weighted average periodpar value of 0.75 years. shares with a
In connection with his appointmentour acquisition of Panacea on December 31, 2021, we issued convertible preferred stock to the Boardour new principal shareholder and Chief Executive Officer (and her affiliates) as follows:
Directors, Alvaro Daniel Alberttis was awarded $100,000 worthSeries C Convertible Preferred Stock (the “Series C”) shares of restricted common stock, valued at the closing market priceSeries C-1 Convertible Preferred Stock (the “Series C-1”) and shares of Series D Convertible Preferred Stock (the “Series D”), which together convert into approximately % of the Company’s common stock outstanding as of that date. The Series C has a liquidation preference of $ per share, is convertible at the rate of shares of common stock per share and through December 31, 2023 has the option to participate in the recovery by the Company of certain assets. In order to avail herself of the rights, the holder can cause the Company to use the cash generated by the assets and repurchase Series C at a price equal to the liquidation preference per share, subject to the Company maintaining an agreed upon level of net assets. The Series C-1 has a liquidation preference of $ per share and is convertible at the rate of shares of common stock for each share of Series C-1. The Series D has a liquidation preference of $ per share and is convertible into common stock at the rate of shares of common stock per share. The Series C, C-1 and D also vote on an as converted basis. shares of
In addition, the Company entered into an exchange agreement with an investor and filed with the Secretary of State of the State of Nevada a Certificate of Designation of Preferences, Rights and Limitations for Series A Preferred stock under which the Note in the original principal amount of $750,000 would be exchanged for shares of a new series of our preferred stock designated 0% Series A Convertible Preferred Stock (the “Series A Preferred”) with a stated value of $ per share (the “Stated Value”).
The Company authorized the issuance of a total of 0.05 per share (the “Conversion Price”), subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications or similar transactions that proportionately decrease or increase the common stock. During the quarter ended December 31, 2021, the investor converted shares of Series A Preferred stock into shares of common stock shares of Series A Preferred for issuance. Each share of Series A Preferred is convertible at the option of the holder, into that number of shares of our common stock (subject to certain limitations on beneficial ownership) determined by dividing the Stated Value by $
The Company is prohibited from effecting the conversion of the Series A Preferred to the extent that, as a result of such conversion, the holder beneficially owns more than 4.99% (which may be increased to 9.99% upon 61 days’ written notice to the Company), in the aggregate, of the issued and outstanding shares of the common stock calculated immediately after giving effect to the issuance of shares of common stock upon the conversion of the Series A Preferred. Holders of the Series A Preferred are entitled to vote on all matters submitted to the Company’s stockholders and are entitled to the number of votes equal to the number of shares of common stock into which the shares of Series A Preferred stock are convertible, subject to applicable beneficial ownership limitations. The Series A Preferred stock provides a liquidation preference equal to the Stated Value, plus any accrued and unpaid dividends, fees or liquidated damages.
The Series A Preferred can be redeemed at the Company’s option upon payment of a redemption premium between 120% to 135% of the Stated Value of the outstanding Series A Preferred redeemed.
On February 16, 2021 the Company offered to our prior Series A Preferred stock holder enhanced conversion inducements to voluntarily convert the preferred shares into our common stock and filed a Certificate of Cancellation and Withdrawal with the Secretary of State of the State of Nevada cancelling our prior Certificate of Designation of Preferences, Rights and Limitations for Series A Preferred stock, all of which has been converted to common stock, in order to issue the new 0% Series A Preferred stock described herein.
On April 7, 2021 the Company filed a Certificate of Cancellation and Withdrawal with the Secretary of State of the State of Nevada cancelling our prior Certificate of Designation of Preferences, Rights and Limitations for the previous Series C Preferred Stock, all of which has been cancelled or converted into common stock.
On February 16, 2021, the Company offered to holders of our prior Series D Preferred Stockholder(s) enhanced inducements to voluntarily convert preferred shares into our common stock.
On April 7, 2021 the Company filed a Certificate of Cancellation and Withdrawal with the Secretary of State of the State of Nevada cancelling our prior Certificate of Designation of Preferences, Rights and Limitations for the previous Series D Preferred Stock, all of which has been cancelled or converted into common stock.
F-23 |
During the quarter ended December 31, 2021 the Company withdrew its prior Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock and issued shares of newly designated Series C, Series C-1 and Series D to former Panacea stockholders pursuant to the Exchange Agreement.
Common Stock for services
In October, 2021 the Company entered into a consulting agreement for investor relations services. The consultant shall receive compensation of the appointment. Thesethis agreement and common shares vest at a rate of 1/24th on the date of grant, and 1/24th per month thereafter, contingent upon his continued service. The Company valued the shares of restricted common stock at the fair value of $0.36 per common share or $100,000 based on the quoted trading price on the date of grant. shares of the Company’s Common Stock and shall vest over one year with common stock to vest on the date of
NOTE 118 - COMMITMENTS AND CONTINGENCIES
Legal Matters
In the ordinary course of business, the Company enters into agreements with third parties that include indemnification provisions which, in its judgment, are normal and customary for companies in the Company’s industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, the Company generally agrees to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to the Company’s product candidates,products, use of such product candidates,products, or other actions taken or omitted by us. The maximum potential amountnumber of future payments the Company could be required to make under these indemnification provisions is unlimited. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, the Company has no liabilities recorded for these provisions as of December 31, 2021.
As a result of our acquisition of Panacea, the Company is now involved in the following pending litigation:
On February 16, 2021, Henley Group, Inc. filed with the Superior Court of the State of California, San Bernardino County, a complaint (Case #: SIV SB 2105771) against Panacea for breach of contract and fraud related to Panacea’s non-delivery of product. While Panacea refunded the purchase price, the plaintiff seeks damages including lost profits and costs which plaintiff alleged to have incurred in the amount of approximately $45,000 as well as lost profits from expected future contracts with a prospective third-party buyer which plaintiff alleged to be $720,000. The plaintiff also seeks attorney’s fees and costs, consequential damages and punitive damages. Panacea attorney has submitted counterclaims and believes this complaint is frivolous as there are no contracts involved. We have not recorded any liabilities related to these claims, as we believe a liability is not probable.
On October 7, 2019, CMI Mechanical (“CMI”) agreed to procure, deliver, and install a dehumidification system (the “System”) at the Company’s facility located at 16194 W. 45th Drive, Golden, Colorado 80403 (the “Property”). The Company believes the System has failed to meet the requirements of the subject contract, and CMI has not remedied that failure for the Company. The Company withheld certain payments as permitted under the contract. On December 10, 2020, or 2019.
Concentrations
The Company has no concentration of vendors that would impact production costs in the longer term.
On the revenue side, in the 3rd Quarter of 2021 we signed a large contract with a convenience store chain. The revenues from the first shipment of CBD products are confidential,16% of the 2021 revenue. We also have a tolling contract and this contract is 18.8% of revenue in 2021. In 2020, there was one customer that accounted for 29% of our revenue.
In 2020, there were concentrations of purchases from two vendors: BSH (approximately 37%) and SAT Co (approximately 26%). Both of these vendors are PPE vendors; thus, they will not be future vendors for Panacea. The first purchase was for hand sanitizers and the second vendor sold Panacea KN95 and 3-ply masks.
The other thanconcentration is in the accounts receivable category, where three customer accounts for 62% of the accounts receivable in 2021. One of the three customer contracts is unique in that we produced all of the products for them to sell, and they pay Panacea as the items are sold in the ecommerce marketplace. Thus, until their inventory is depleted, we will have accounts receivable. This customer receivable is 31% of the 62%. In 2020, this same customer was 63% of our total receivables.
F-24 |
The Company has no cash was paid in connection with the settlement. As a result, we expect to eliminate $575,000 of indebtedness from our financial statements during the quarter ended Marchother contingencies, material commitments, or purchase obligations or sales obligations.
Executive Employment Agreement
On December 31, 2021.
Under her Employment Agreement, she is entitled to retainseverance payments under termination provisions which are intended to comply with Section 409A of the Internal Revenue Code of 1986, or the Code, and the Regulations thereunder.
In the event of termination by the Company without “cause” or resignation by Ms. Buttorff for “good reason,” Ms. Buttorff is entitled to receive two years’ base salary, or $780,000, all unreimbursed business expenses and other accrued but unpaid compensation, and any annual bonus earned but not yet paid for any fiscal year ending prior to the fiscal year in which the date of termination occurs. In addition, in the event of termination by the Company without “cause,” subject to execution of a general release Ms. Buttorff will be entitled to (i) a settlement amount equal to another two years’ base salary (or a total of $1,560,000) and (ii) an amount equal to the annual bonus which Ms. Buttorff would have been entitled to receive in respect of the year of termination based on the achievement of any performance objectives for the Company.
Generally, “good reason” is defined as (i) any material breach of the Employment Agreement by the Company, (ii) the Company’s assignment of Ms. Buttorff to a position that has materially less authority, status, or functional responsibility than the position with the Company as of the commencement date, or the assignment to her of duties that are not those of an executive at the management level, (iii) the reduction of Ms. Buttorff’s base salary, (iv) the requirement that Ms. Buttorff move her primary place of employment more than 30 miles from her initial place of employment, or (v) upon any change of control event as defined in Treasury Regulation Section 1.409A-3(i)(5) provided that within 12 months of the change of control event the Company terminates Ms. Buttorff or fails to obtain an agreement from any successor to perform the Employment Agreement.
Under the terms of her Employment Agreement, Ms. Buttorff is subject to non-competition and non-solicitation covenants during the term of her employment and following termination of employment with the Company. The Employment Agreement also contains customary confidentiality and non-disparagement covenants.
NOTE 9 - RELATED PARTY TRANSACTIONS
Notes Payable and Accrued Interest – Related Parties
On December 31, 2021 Panacea received a loan of $4,062,713 from Quintel-MC Incorporated, an affiliate of the Company’s CEO in exchange for the Quintel Note. (See Note 6 – Notes Payable — Quintel Note).
On December 31, 2021, Panacea issued the Company’s CEO, Ms. Buttorff, a 10% promissory note in the amount of $1,624,000 secured by a pledge of certain cancelled equity awardsXXII common stock owned by Panacea (see Note 6 – Notes Payable — Buttorff Note and seeks specific performance and damages. In FebruaryNote 2 Going concern).
F-25 |
On July 1, 2021, the Company issued Ms. Buttorff a $1 million line of credit note (see Note 5 – Notes Payable — Buttorff Note). To date $693,468 of the line of credit has been consumed.
During October 2019, the Company granted 1,000,000 optionsissued a short-term promissory notes to purchasean officer of Exactus, for an aggregate principal amount of $55,556. This note was carried forward from Exactus from the merger and he is a related party. This note was paid off in December, 2021.
J&N Real Estate related party owned by Ms. Buttorff—See Note 10 Exchange Agreement and Note 5 Operating lease.
Services Agreement dated January 1, 2019, by and between the Company and Quintel, with respect to IT, HR, accounting/periodic reporting, production planning, and employee reporting services. Master Agreement dated January 1, 2019, by and between the Company and Quintel/Canna Software, LLC for the provision of the ERPCannabis solution. As of December 31, 2021 the outstanding obligation under these two service contracts is $2,529,248. In 2021, $229,497 of the costs were capitalized and $91,482 of the costs were expensed. See Note 6.
The interest expense recorded for related party loans are shown below.
SCHEDULE OF RELATED PARTY TRANSACTIONS LOANS
December 31, 2021 | December 31, 2020 | |||||||
Accrued Interest | ||||||||
Related party loan-Quintel | $ | 249,939 | $ | 1,347,356 | ||||
Related party loan-CEO loan | 86,060 | 1,500 | ||||||
Related party loan-XXII | - | - | ||||||
Related party loan – Line of credit | 29,435 | - | ||||||
Accrued Interest | 29,435 | - |
Year ended December 31, 2021 | Year ended December 31, 2020 | |||||||
Interest Expense | ||||||||
Related party loan-Quintel | $ | 772,463 | $ | 913,063 | ||||
Related party loan-CEO loan | 146,245 | 1,500 | ||||||
Related party loan-XXII | - | 583,333 | ||||||
Related party loan – Line of Credit | 29,235 | - | ||||||
Interest Expense | 29,235 | - |
Other
The Company continues to hold shares of XXII stock which is available for trading. XXII recently moved from the NYSE to NASDAQ. As of December 31, 2021 XXII is a common shareholder of the Company. See Note 10 for additional details related to XXII resolution.
NOTE 10 – EXCHANGE AGREEMENT BETWEEN EXACTUS, INC. AND PANACEA LIFE SCIENCES, INC.
On June 30, 2021, Exactus legally acquired Panacea pursuant to the Exchange Agreement with the shareholders of Panacea including its founder Leslie Buttorff and 22nd Century Group, Inc., (“XXII”), a principal investor. Panacea, which was founded by Leslie Buttorff in 2017 as a woman-owned business, attracted $14 million in investment ($7M convertible debt, XXII shares of common stock and $5 million in cash) from XXII (NASDAQ) during 2019, a leading plant biotechnology company focused on technology to decrease nicotine in tobacco plants also uses its expertise for genetic engineering of hemp plants to modify cannabinoid levels used in manufacturing CBD, CBG and CBN. The transaction was accounted for as a reverse merger with Panacea the accounting acquirer. Following the closing, XXII owns approximately 15.19% stake in the Company on a fully diluted basis.
F-26 |
Shares Issuances
Pursuant to the Exchange Agreement, on June 30, 2021 the Company issued a total of 1,000,000 shares of Series C convertible into 2,289,220 shares of common stock, 10,000 shares of Series C-1 convertible into 1,064,907 shares of common stock and 10,000 shares of Series D convertible into 1,628,125 shares of common stock to the former Panacea stockholders, in exchange for one-hundred (100%) percent of the shares of capital stock of Panacea. On a fully diluted basis, Ms. Buttorff beneficially owns approximately 62% of outstanding Common Stock consisting of the Common Stock issuable upon conversion preferred shares and shares of Common Stock. The Company changed its name to Panacea Life Sciences Holdings, Inc., in October, 2021. shares of common stock,
On June 29, 2021 the Company filed with the Secretary of State of the State of Nevada three new series of preferred stock (“Preferred Stock”) designated as Series C Convertible Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock and authorized the filing of a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock, Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock in the State of Nevada. The Board designated for issuance 1,000,000, 10,000 and 10,000 shares, respectively, for issuance. Each share of Preferred Stock is convertible into shares of the Company’s Common Stock to a former directoras provided in the Certificate of Designation, therefore. These are reflected in the Equity sections of the Company, Jonathan Gilbert, with vestingbalance sheet for December 31, 2021.
Also, on December 31, 2021, Panacea and XXII agreed to dissolve their business relationship. In terms pursuant to the respective stock option agreement. The former director resigned as a director of the Companyagreement the following transactions occurred in August 2019.consideration for the XXII investment in Panacea of $14 million. The options have a term of 10 years frombelow four items explain how the date of grant and$14 million was exercisable at an exercise price at $0.01. The Company already recognized $320,000 of compensation expense which relatesaccounted for.
1. | Series B Preferred ($7,000,000) converted to Exactus common stock | |
2. | $500,000 of the $7,000,000 convertible debt converted to Exactus common stock. | |
3. | Panacea sold to XXII the real property and improvements located in Delta County, Colorado, and comprised of approximately 234.394 acres of land. Panacea has the right to acquire 10 acres of the land for its own use. The agreed upon amount was $2,200,000 for an allocated value as follows: (i) $1,770,000 for the real property and improvements which constitute a part of the Farm Parcel; and (ii) $430,000 for the equipment, machinery and other personal property owned by Panacea. As a part of the agreement XXII will deliver to Panacea $500,000 of hemp from the 2021 grow season. This is recorded as a receivable. As a part of this transaction XXII also returned 1,013,333 shares of Panacea stock which were converted to 719,404 Exactus shares in the Exchange Agreement. There was no gain or loss on this part of the transaction. | |
4. | J&N Real Estate Company LLC (J&N), owned by Leslie Buttorff, assumed a $4.3 million note payable to XXII. In consideration of J&N’s issuance of a $4.3 million mortgage note to XXII on real property owned by J&N, Panacea issued J&N shares of newly designated Series D. |
On December 31, 2021, the vesting of 500,000 stock options prior to his resignation. After Jonathan Gilbert’s resignation, he filed a complaint againstBoard authorized the Company disputing his rights to receivefile a certificate of amendment (the “Amendment”) to its Amended and Restated Articles of Incorporation with the Company’s commonSecretary of State of the State of Nevada in order to effectuate a reverse stock through the exercise of his stock options. In January 10, 2020, Mr. Gilbert and the Company entered into a Settlement and General Release Agreement and both parties agreed to such consideration. The Company will issue to Mr. Gilbert 375,000 sharessplit of the Company’s issued and outstanding common stock, whereby 187,500 shares of common stock shall be issued immediately (“First Tranche”) and another 187,500 shares of common stock shall be issued immediately and held by the transfer agent and deliveredpar value $ per share on the six month anniversary of this agreement (“Second Tranche”) (collectively the First and Second Tranche shall be called “Settlement Stock”a one (1) for twenty-eight (28) basis (the “Reverse Stock Split”). The SettlementReverse Stock is by virtue of the exercise of Mr. Gilbert’s stock optionsSplit was effective October 25, 2021.
As disclosed in Note 1 and any required payments from the exercise of the stock options have been credited or forgiven. The Settlement Stock which is issued under the Stock Option Plan based upon the exercise of the stock options registered pursuant to the Company’s registration statement on form S-8 (File no. 333-229025). The Company and Mr. Gilbert have released and discharged each other from all claims and demands. In January 2020, Mr. Gilbert dismissed the lawsuit against the Company. Pursuant to the Settlement and General Release Agreement dated in January 2020, the Company recorded the issuance of 375,000 shares at par value upon the exercise of the 375,000 stock options and cancelled the remaining 625,000 stock options during fiscal 2019.
NOTE 11 2020 Mr. Aloi resigned from his positions as Interim Chief Executive Officer and Director of the company and on January 21, 2021 the Company entered into a Settlement Agreement with Ceed2Med, LLC and its principals cancelling all agreements, obligations and claims and providing full mutual releases of the Company and such persons, although Mr Aloi was not released from any claims or obligations that could be asserted by the Company. In connection with the settlement, Ceed2Med, LLC agreed to assignment of all rights to convert its outstanding shares of Series E Preferred Stock at a price of $1.60 per share to third parties in connection with settlement and releases of third party claims, resulting in no further dilution from issuances of settlement shares other than the right for Ceed2Med to have received such shares upon conversion and thereupon the Series E Preferred Stock was simultaneously converted into shares of common stock.
The Company has incurred aggregate net operating losses of approximately $21.1$21.1 million for income tax purposes as of December 31, 2020. The net operating losses carry forward for United States income taxes, which may be available to reduce future years’ taxable income. Management believes that the realization of the benefits from these losses appears not more than likely due to the Company’s limited operating history and continuing losses for United States income tax purposes. Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset to reduce the asset to zero. Management will review this valuation allowance periodically and make adjustmentsadjust as necessary.
F-27 |
The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company’s effective tax rate for financial statement purposes for the yearsyear ended December 31, 2020 and 2019:
December 31, 2020 | December 31, 2019 | |
US Federal Statutory Tax Rate | 21.0% | 21.6% |
State taxes | 4.35% | 4.6% |
Bad debt | (1.62%) | - |
Derivative loss | 1.02 | - |
Stock-based compensation | (3.17%) | - |
Depreciation | 0.19% | - |
Amortization | 2.17% | - |
Impairment | (12.00%) | - |
Change in valuation allowance | (11.92%) | (25.6%) |
0.00% | 0.00% |
SCHEDULE OF EFFECTIVE TAX RATE
December 31, 2020 | ||||
U.S. federal statutory rate | 21.0 | % | ||
Increase (decrease) in taxes resulting from: | ||||
Increase in valuation allowance | (21.9 | )% | ||
ROU Assets/Liabilities | (2.7 | )% | ||
State taxes | 3.6 | % | ||
Income tax (expense) benefit | - | % |
The tax effects of temporary differences that give rise to deferred tax assets and liabilities as of December 31, 2020 and 2019 are summarized as follows:
Deferred Tax Asset: | December 31, 2020 | December 31, 2019 |
Net operating loss carryforward | $8,337,000 | $4,226,345 |
Valuation allowance | (8,337,000) | (4,226,345) |
Net deferred tax asset | $- | $- |
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES
December 31, 2020 | ||||
Deferred tax assets (liabilities) | ||||
Net Operating Loss Carryforwards | $ | 3,848,037 | ||
Marketable securities | (382,185 | ) | ||
ROU Assets/Liabilities | (207,389 | ) | ||
Depreciation and amortization | (618,501 | ) | ||
Total deferred tax assets (liabilities) | 2,639,962 | |||
Valuation Allowance | (2,639,962 | ) | ||
Net deferred tax assets (liabilities) | $ | - |
The Company provided a valuation allowance equal to the deferred income tax asset for the year ended December 31, 2020 because it was not known whether future taxable income will be sufficient to utilize the loss carryforward. The increase in the allowance was $4.0$4.137 million in fiscal 2020. Additionally, the future utilization of the net operating loss carryforward to offset future taxable income may be subject to an annual limitation, based upon IRC Section 382/383 Ownership change rules that may have or could occur in the future. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2017, 2018, 2019 and 2020 Corporate Income Tax Returns are subject to Internal Revenue Service examination.
As of March 31, 2020 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Balance Sheet | |||
Current assets | $1,661,211 | $- | $1,661,211 |
Current liabilities | $5,338,486 | $(564,628) | $4,773,858 |
Working capital (deficit) | $(3,677,275) | $564,628 | $(3,112,647) |
Total assets | $8,458,826 | $(1,705,115) | $6,753,711 |
Total liabilities | $6,985,191 | $(2,034,232) | $4,950,959 |
Total stockholders' equity | $1,473,635 | $329,117 | $1,802,752 |
As of December 31, 2019 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Balance Sheet | |||
Current assets | $2,429,235 | $- | $2,429,235 |
Current liabilities | $4,190,544 | $(382,196) | $3,808,348 |
Working capital (deficit) | $(1,761,309) | $382,196 | $(1,379,113) |
Total assets | $9,799,277 | $(1,782,443) | $8,016,834 |
Total liabilities | $6,117,431 | $(1,988,141) | $4,129,290 |
Total stockholders' equity | $3,681,846 | $205,698 | $3,887,544 |
As of September 30, 2019 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Balance Sheet | |||
Current assets | $3,255,169 | $- | $3,255,169 |
Current liabilities | $2,052,454 | $(302,196) | $1,750,258 |
Working capital (deficit) | $1,202,715 | $302,196 | $1,504,911 |
Total assets | $11,449,203 | $(1,858,284) | $9,590,919 |
Total liabilities | $4,054,527 | $(1,940,563) | $2,113,964 |
Total stockholders' equity | $7,394,676 | $82,279 | $7,476,955 |
For the Three Months Ended | |||
March 31, 2020 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Statements of Operations | |||
Revenues | $836,000 | $- | $836,000 |
Operating expenses | $2,192,767 | $(123,419) | $2,069,348 |
Loss from operations | $(2,757,023) | $123,419 | $(2,633,604) |
Other income (expenses) | $(188,480) | $- | $(188,480) |
Net loss | $(2,945,503) | $123,419 | $(2,822,084) |
Net Loss available to Exactus, Inc. common stockholders | $(2,789,684) | $123,419 | $(2,666,265) |
Basic & diluted EPS | $(0.06) | $0 | $(0.06) |
For the Year Ended | |||
December 31, 2019 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Statements of Operations | |||
Revenues | $345,680 | $- | $345,680 |
Operating expenses | $9,177,988 | $(205,698) | $8,972,290 |
Loss from operations | $(10,878,442) | $205,698 | $(10,672,744) |
Other income (expenses) | $653,936 | $- | $653,936 |
Net loss | $(10,224,506) | $205,698 | $(10,018,808) |
Net Loss available to Exactus, Inc. common stockholders | $(10,591,487) | $205,698 | $(10,385,789) |
Basic & diluted EPS | $(0.31) | $0 | $(0.31) |
For the Nine Months Ended | |||
September 30, 2019 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Statements of Operations | |||
Revenues | $215,816 | $- | $215,816 |
Operating expenses | $5,803,458 | $(82,279) | $5,721,179 |
Loss from operations | $(5,803,847) | $82,279 | $(5,721,568) |
Other income (expenses) | $1,178,363 | $- | $1,178,363 |
Net loss | $(4,625,484) | $82,279 | $(4,543,205) |
Net Loss available to Exactus, Inc. common stockholders | $(5,168,306) | $82,279 | $(5,086,027) |
Basic & diluted EPS | $(0.16) | $0 | $(0.15) |
For the Three Months Ended | |||
September 30, 2019 | |||
Previously Reported | Adjustments | As Corrected | |
Consolidated Statements of Operations | |||
Revenues | $60,153 | $- | $60,153 |
Operating expenses | $2,062,677 | $(82,279) | $1,980,398 |
Loss from operations | $(2,102,942) | $82,279 | $(2,020,663) |
Other income (expenses) | $(5,105) | $- | $(5,105) |
Net loss | $(2,108,047) | $82,279 | $(2,025,768) |
Net Loss available to Exactus, Inc. common stockholders | $(1,934,367) | $82,279 | $(1,852,088) |
Basic & diluted EPS | $(0.05) | $0 | $(0.05) |
NOTE 16 - 13 – SUBSEQUENT EVENTS
On October 7, 2019, CMI Mechanical (“CMI”) agreed to procure, deliver, and install a dehumidification system (the “System”) at the Company’s facility located at 16194 W. 45th Drive, Golden, Colorado 80403 (the “Property”). The Company believes the System has evaluated any events or transactions occurring afterfailed to meet the requirements of the subject contract, and CMI has not remedied that failure for the Company. The Company withheld certain payments as permitted under the contract. On December 31,10, 2020, CMI recorded a lien against the balance sheet date, through the date of filing of this report and note that there have been no such events or transactions that would require recognition or disclosureProperty in the consolidated financial statements asamount of and for the year ended December 31, 2020, except as disclosed below.
F-28 |
On February 16, 2021, the Company entered into a Securities Purchase Agreement with 3i, LP (“3i”) and an institutional investor (“Investor”) under which the Investor agreed to purchase and 3i agreed to sell that certain 8% senior secured convertible note dated November 27, 2019 (the “Note”) and all of our warrants previously issued to 3i and 3i agreed settle and release all claims asserted against us. As a result, 3i agreed to dismissal of all pending litigation against the Company.
The Note will be due March 3, 2023, which is one year from the issuance date. The Note initially does not bear any interest, however upon and during any event of default by the Company, the Note will accrue interest at a rate of 18% per annum. Events of default include suspension of trading or quotation of the Company’s common stock on the OTCQB or a national securities exchange, and failure to reserve a sufficient number of shares for the conversion or exercise of all securities issued pursuant to the Agreement. Further, upon an event of default, the holder will have the right to cause the Company to redeem the outstanding principal and accrued interest on the Note at a 125% premium.
The principal and accrued interest on the Note is convertible into common stock at a conversion price of $1.40 per share, subject to certain adjustments summarized as follows: (i) if an event of default has occurred prior to the maturity date, a reduction to 80% of the conversion price then in effect, (iii) anti-dilution adjustment upon certain issuances of common stock or derivative securities at a price per share that is lower than the conversion price, (iii) customary adjustments for stock splits, stock dividends and similar corporate events, and (iv) adjustment upon a public offering by the Company meeting certain delineated criteria, as summarized below.
Under the terms of the Note, upon a Qualified Offering, as defined in the Note, the conversion price will be reduced to 90% of the offering price per share in the Qualified Offering, if that price is lower than the conversion price then in effect. Additionally, immediately prior to a Qualified Offering, the Company may redeem all or part of the outstanding principal and accrued interest on the Note at a 115% premium.
The Note also contains customary negative covenants prohibiting the Company from certain actions while the Note remains outstanding. The Warrants will be exercisable for a five-year term beginning on May 18, 2022, at an exercise price of $1.40 per share, subject to certain adjustments which are substantially similar to those contained in the Note, including the Qualified Offering adjustment.
Each of the Note and the Warrants contain a 4.99% beneficial ownership limitation pursuant to which neither may be converted or exercised, as applicable, if and to the extent that as a result offollowing such conversion or exercise the holder would beneficially ownsown more than 4.99% (which may be increasedof the Company’s outstanding common stock, subject to 9.99%increase to 9.99% upon 61 days’ prior written notice by the holder.
Pursuant to the Company), in the aggregate, of the issued and outstanding shares of the Common Stock calculated immediately after giving effect to the issuance of shares of Common Stock upon the conversion of the Series A Preferred. Holders of the Series A Preferred shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to the number of votes equal to the number of shares of Common Stock into which the shares of Series A Preferred Stock are convertible, subject to applicable beneficial ownership limitations. The Series A Preferred Stock provides a liquidation preference equal to the Stated Value, plus any accrued and unpaid dividends, fees or liquidated damages.
The Company previously issued 10,000 shares of Series E Preferred Stock convertible into 6,250,000 shares of common stock to C2M. Pursuant toobtained the Agreement, C2M will permit the Company to transfer all outstanding shares of Series E Preferred stock to settle various third-party claims and obligations, avoiding dilution in furtherance of ongoing restructuring efforts. Under the Settlement and Release Agreement with Ceed2Med, all existing agreements, obligations and claims have been cancelled and rescinded, the parties exchanged full mutual releases. and the Company is to receive a cash payment of $200,000, a portion of which has been paid.
F-29 |
Item 9. ChangesChanges In and Disagreements with Accountants on Accounting and Financial Disclosure
As previously disclosed on the Company’s Current Report on Form 8-K filed on December 29, 2021, on December 28, 2021, the Company’s Board of Directors approved the change of the Company’s independent registered public accounting firm from RBSM LLP to BF Borgers CPA PC for the 2021 audit and 308 of Regulation S-K duringfor the fiscal year ending December 31, 2020.
Item 9A. ControlsControls and Procedures
Evaluation of 1934, we have carried out an evaluation of the effectiveness of our disclosure controlsDisclosure Controls and procedures as of the end of the fiscal year ended December 31, 2020. This evaluation was carried out under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Chief Financial Officer.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by us in ourthe reports filedthat we file or submittedsubmit under the Securities Exchange Act of 1934 (the “Exchange Act”) are recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosure.
Our Chief Executive Officer (principal executive officer), who is presently also serving as our principal financial officer, has conducted an evaluation of the design and effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of the end of the period covered by this Report. Our management’s evaluation of our internal control over financial reporting was based on the framework in Internal Control-Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission. In designing and evaluating the disclosure controls and procedures, management recognizes that because of inherent limitations, any controls and procedures, no matter how well designed and operated, may not prevent or detect misstatements and can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Our internal control over financial reporting includes those policies and procedures that:
● | pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; | |
● | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and | |
● | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. |
Our Chief Executive Officer has concluded that our disclosure controls and procedures were not effective to ensure that the information relating to us is required to be disclosed in our SEC reports (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’sSEC rules and forms. Disclosure controlsforms, and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934(ii) is accumulated and communicated to management, including our Interim Chief Executive Officer and Chief Financial Officer,management to allow timely decisions regarding required disclosure.
● | The Company does not have sufficient segregation of duties within accounting functions due to only having two officers and limited resources. | |
● | The Company does not have an audit committee; and | |
● | The Company does not have written documentation of our internal control policies and procedures. |
We plan to take stepsrectify these weaknesses by establishing written policies and procedures for our internal control of financial reporting and hiring additional accounting personnel at such time as we raise sufficient capital to enhancedo so.
Changes in Internal Controls over Financial Reporting
There have been no changes in the internal control over financial reporting (as such term is defined in Rules 13a-15(f) and improve15d-15(f) under the design ofExchange Act) during the quarter ended December 31, 2021 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we have appointed additional independent directors and we plan to appoint additional qualified personnel to address inadequate segregation of duties. Our ability to retain additional personnel is largely dependent upon our securing additional financing to cover the costs required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.
Item 9B. OtherOther Information
None.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
The information required by Item 10. Directors,10 (Directors, Executive Officers and Corporate Governance
Year | Salary | Option Award(s)(1) | Total | |
Emiliano Aloi(2) | 2020 | $62,308 | $— | $62,308 |
Former Interim CEO | 2019 | $108,036 | $32,000 | $140,036 |
Alvaro Alberttis(3) | 2020 | $— | $50,980 | $50,980 |
Chief Operating Officer | 2019 | $— | $— | $— |
Kenneth E. Puzder(4) | 2020 | $76,731 | $122,500 | $199,231 |
Former Chief Financial Officer | 2019 | $81,428 | $70,000 | $151,428 |
Andrew Johnson(5) | 2020 | $75,962 | $122,500 | $198,462 |
Chief Strategy Officer | 2019 | $92,977 | $174,500 | $267,477 |
Derek du Chesne(6) | 2020 | $76,730 | $500,000 | $575,000 |
Former President | 2019 | $— | $— | $— |
Number of Securities Underlying Unexercised Options (#) Exercisable | Equity Incentive Plan Award: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | ||
Emiliano Aloi * | 250,000 | (1) | — | $0.320 | 01/09/2029 |
Former Interim Chief Executive Officer | |||||
Kenneth E. Puzder * | 250,000 | (2) | 149,739 | $0.200 | 01/11/2029 |
Former Chief Financial Officer | |||||
Andrew Johnson | 12,500 | (3) | — | $0.320 | 01/15/2029 |
Chief Strategy Officer | 31,250 | (4) | 15,625 | $0.960 | 01/15/2029 |
125,000 | (5) | 20,832 | $0.560 | 03/12/2029 |
DIRECTOR COMPENSATION | ||||||||
Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | Non-Qualified Deferred Compensation Earnings ($) | All Other Compensation ($) | Total ($) | |
Lawrence J. Wert Executive Chairman | (a) | - | 100,000 | - | - | - | - | 100,000 |
John Price Board Member | (b) | - | 25,000 | - | - | - | - | - |
Alvaro Daniel Alberttis Board Member | (c) | - | 100,000 | - | - | - | - | 100,000 |
Julian Pittam Board Member | (d) | - | 100,000 | - | - | - | - | 100,000 |
Emiliano Aloi Former Board Member | (e) | - | 29,167 | - | - | - | - | 29,167 |
Justin A. Viles Former Board Member | (f) | - | 24,500 | - | - | - | - | 24,500 |
Title of class | Name and address of beneficial owner | Amount and Nature of Beneficial Ownership | Percent of Class(1) | |
Current Named Executive Officers & Directors: | ||||
Common Stock | Julian Pittam 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 3,914,791 | (2) | 13.75% |
Common Stock | John Price 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 2,672,111 | (3) | 2.70% |
Common Stock | Andrew Johnson 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 8,486,240 | (4) | 8.58% |
Common Stock | Alvaro Alberttis 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 4,770,726 | (5) | 4.81% |
Common Stock | Lawrence J. Wert 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 8,620,297 | (6) | 8.70% |
Common Stock Total of All Current Directors and Executive Officers: | 28,464,147 | 38.54% |
Title of class | Name and address of beneficial owner | Amount and Nature of Beneficial Ownership | Percent of Class(1) | |
Former Named Executive Officers & Directors: | ||||
Common Stock | Kevin Esval 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 817,000 | (2) | 0.82%* |
Common Stock | Jeffrey Thompson 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 350,000 | (3) | 0.35%* |
Common Stock | Vladislav Yampolsky 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 8,723,192 | (4) | 8.76% |
Common Stock | Justin Viles 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 631,577 | (5) | 0.63%* |
Common Stock | Emiliano Aloi 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 271,317 | (6) | 0.27%* |
Common Stock | Derek DuChesne 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 20,000 | (7) | 0.02%* |
Common Stock | Ken Puzder 80 NE 4th Avenue, Suite 28 Delray Beach, FL 33483 | 250,000 | (8) | 0.25%* |
Common Stock Total of All Former Directors and Former Executive Officers: | 11,043,106 | 11.08% |
Item 10. Directors, Executive Officers and 2019, $575,000 was included in accounts payable, respectively. During the year ended December 31, 2020Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and 2019, $0 was paid.
Item 13. Certain Relationships and its principals cancelling all agreements, obligationsRelated Transactions, and claims and providing full mutual releases of the Company and such persons. In connection with the settlement, Ceed2Med, LLC agreed to assignment of all rights to convert its outstanding shares of Series E Preferred Stock at a price of $1.60 per share to third parties in connection with settlement and releases of third party claims, resulting in no further dilution from issuances of settlement shares other than the right for Ceed2Med to have received such shares upon conversion and thereupon the Series E Preferred Stock was simultaneously converted into shares of common stock.
Item 14. Pr
PART IV
Item 15. Exhibits,Exhibits, Financial Statements Schedules
(a) Financial Statements and Schedules
The following financial statements and schedules listed below are included in this Form 10-K.
Financial Statements (See Item 8)
* Filed herewith.
** Exhibits and/or Schedules have been omitted. The Company hereby agrees to furnish to the Securities and Exchange Commission upon request any omitted information.
*** This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.
+Portions of this exhibit have been omitted as permitted by the rules of the SEC. The information excluded is both (i) not material and (ii) the type that the Company customarily and actually treats as private or confidential. The Company undertakes to submit a marked copy of this exhibit for review by the SEC Staff, to the extent it has not been previously provided, and provide supplemental materials to the SEC Staff promptly upon request.
Copies of this Report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our shareholders who make a written request to Panacea Life Sciences Holdings, Inc., at the address on the cover page of this Report, Attention: Corporate Secretary.
Item 16. Form 10-K Summary.
Not applicable.
29 |
Panacea Life Sciences Holdings, Inc. | |
March 31, 2022 | /s/ Leslie Buttorff |
Leslie Buttorff | |
Chief Executive Officer (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this reportReport has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:indicated.
SIGNATURE | TITLE | DATE | ||
/s/ Leslie Buttorff | Principal Executive Officer and Chairman | March 31, 2022 | ||
Leslie Buttorff | ||||
/s/ Nathan Berman | Principal Accounting Officer | March 31, 2022 | ||
Nathan Berman | ||||
/s/ Janice Nerger | Director | March 31, 2022 | ||
Janice Nerger | ||||
/s/ Lawrence J. Wert | Director | March 31, 2022 | ||
Lawrence J. Wert |
30 |